Primary immunodeficiencies - from genetic basis to therapeutic targets by Arts, P.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/175281
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Primary immunodeficiencies –
from genetic basis to therapeutic targets
Peer Arts
The work presented in this thesis was carried out within the Radboud Institute for 
Molecular Life Sciences
Printing of this thesis was financed by the Radboud University Medical Center, 
Nijmegen, The Netherlands
ISBN: 978-94-028-0705-9
Printed by Ipskamp Printing
Layout and cover design by Neelke Goossens-Arts and Peer Arts
Image design by Cycology Gear
Copyright © 2017 Peer Arts, Nijmegen, The Netherlands
Primary immunodeficiencies –  
from genetic basis to therapeutic targets
Proefschrift 
ter verkrijging van de graad van doctor  
 aan de Radboud Universiteit Nijmegen  
 op gezag van de rector magnificus prof. dr. J.H.J.M. van Krieken 
volgens besluit van het college van decanen  
in het openbaar te verdedigen op dinsdag 12 september 2017,  
om 14.30 uur precies
door 
 
Peer Arts 
geboren op 24 oktober 1982 
te Deurne
Promotoren:  
Prof. dr. J.A. Veltman 
Prof. dr. M.G. Netea 
Copromotoren: 
Dr. A. Hoischen 
Dr. F.L. van de Veerdonk
Manuscriptcommissie: 
Prof. dr. M.A.A.P. Willemsen  
Prof. dr. C.G. Figdor 
Prof. dr. S.M. van der Maarel (Universiteit Leiden) 


Table of contents
Chapter 1: General introduction 9
                    Aim of the thesis 17
Chapter 2: Diagnostic exome sequencing: a generic test for 254 
patients with primary immunodeficiencies 
19
Chapter 3: A missense mutation underlies defective SOCS4 function in 
a family with autoimmunity
39
Chapter 4: Progressive multifocal leukoencephalopathy in an 
immunocompetent patient
51
Chapter 5: MST1R mutation as a genetic cause of Lady Windermere 
syndrome
61
Chapter 6: Rare NOX3 variants confer susceptibility to Agranulocytosis 
during Thyrostatic Treatment of Graves’ Disease
69
Chapter 7: Quantification of differential gene expression by multiplexed 
targeted resequencing of cDNA
83
Chapter 8: Immunologic defects in severe mucocutaneous HSV-2 
infections: Response to -γ therapy
105
Chapter 9: General discussion 123
References 137
List of Abbreviations 161
Summary 165
Samenvatting 169
List of Publications 175
About the Author 181
Word of Thanks 183
RIMLS Portfolio 187
Ch
ap
te
r 
1
9Immunology
As humans, our bodies interact continuously with countless microorganisms, such 
as bacteria, viruses and fungi. Some of the bacteria colonizing our gastrointestinal 
tract are essential for digestion and absorption of nutrients. Other microorganisms 
of the commensal gut flora or mucocutaneous layers have less prominent roles on 
the individuals’ wellbeing and some can even be potentially pathogenic and cause 
disease1,2. 
During evolution, our immune system has developed a multi-layered defense 
mechanism constantly interacting with the microorganisms populating our bodies. 
The aim of this mechanism is to maintain equilibrium in the amount and type of 
harmless microorganisms, and counteract or eliminate potentially pathogenic 
microorganisms. 
The first layer of defense is the physical barrier, comprised of the skin and the mucous 
membranes that protect us from the microenvironments around us. Once these 
barriers are crossed, the microorganisms enter our body and multiply3.
Chapter 1
Chapter 1: 
General introduction 
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Cytotoxic cells recognize and destroy other cells
that have become infected
Several cell types have the capacity to kill other cells should
they become infected. Cytotoxic cells include CTLs, nat-
ural killer (NK) cells (large granular lymphocytes), and
eosinophils. Of these, the CTL is especially important,
but other cell types may be active against particular types
of infection.
All of these cell types damage their different targets by
releasing the contents of their intracellular granules close
to them. Cytokines secreted by the cytotoxic cells, but
not stored in granules, contribute to the damage.
Lymphocytes known as large granular lymphocytes
(LGLs) have the capacity to recognize the surface changes
that occur on a variety of tumor cells and virally infected
cells. LGLs damage these target cells, but use a different
recognition system to CTLs. This action is sometimes
called NK cell activity, so these cells are also described
as NK cells.
Eosinophils are a specialized group of leukocytes that
have the ability to engage and damage large extracellular
parasites, such as schistosomes.
Auxiliary cells control inflammation
The main purpose of inflammation is to attract leukocytes
and the soluble mediators of immunity towards a site of in-
fection. Inflammation is mediated by a variety of other cells
including basophils, mast cells and platelets.
Basophils and mast cells have granules that contain a va-
riety of mediators, which induce inflammation in surround-
ing tissues and are released when the cells are triggered.
Basophils and mast cells can also synthesize and secrete a
number of mediators that control the development of im-
mune reactions. Mast cells lie close to blood vessels in all tis-
sues, and some of their mediators act on cells in the vessel
walls. Basophils are functionally similar tomast cells, but are
mobile, circulating cells.
Platelets are small cellular fragments which are essential
in blood clotting, but they can also be activated during im-
mune responses to release mediators of inflammation.
Soluble mediators of immunity
A wide variety of molecules are involved in the develop-
ment of immune responses, including antibodies, opsonins
and complement system molecules. The serum concentra-
tion of a number of these proteins increases rapidly during
infection and they are therefore called acute phase
proteins.
One example of an acute phase protein is C reactive
protein (CRP), so-called because of its ability to bind to
the C protein of pneumococci; it promotes the uptake
of pneumococci by phagocytes. Molecules such as anti-
body and CRP that promote phagocytosis are said to act
as opsonins.
Another important group of molecules that can act as
opsonins are components of the complement system.
Complement proteins mediate phagocytosis,
control inflammation and interact with antibodies
in immune defense
The complement system, a key component of innate immu-
nity, is a group of about 20 serum proteins whose overall
function is the control of inflammation (Fig. 1.5). The com-
ponents interact with each other, and with other elements
of the immune system. For example:
• a number of microorganisms spontaneously activate the
complement system, via the so-called ‘alternative
pathway’, which is an innate immune defense – this
results in themicroorganism being opsonized (i.e. coated
by complement molecules, leading to its uptake by
phagocytes);
• the complement system can also be activated by
antibodies or by mannose binding lectin bound to the
pathogen surface via the ‘classical pathway’.
Complement activation is a cascade reaction, where one
component acts enzymatically on the next component
in the cascade to generate an enzyme, which mediates
the following step in the reaction sequence, and so on.
(The blood clotting system also works as an enzyme
cascade.)
Functions of different types of lymphocyte
antigen
presentation
activation
antigen
presentation
activation
macrophage
B
LGLTH1 TH2 CTL
antibody production
cytotoxicity
virally infected cell and
some tumor cells
Fig. 1.4 Macrophages present antigen to
TH1 cells, which then activate the
macrophages to destroy phagocytosed
pathogens. B cells present antigen to TH2
cells, which activate the B cells, causing them
to divide and differentiate. Cytotoxic
T lymphocytes (CTLs) and large granular
lymphocytes (LGLs) recognize and destroy
virally infected cells.
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Effector CTLs home to peripheral organs
and sites of inflammation
Naive CTLs circulate in the blood and lymphatic system,
but in order to kill specific target cells, they must be acti-
vated and become effector cells. This process is mediated
by APCs in the lymph nodes. Naive T cells in the lymph
nodes use their T cell receptor (TCR) to recognize specific
antigens being presented by MHC molecules on APCs.
Most CTLs are CD8þ and therefore recognize antigen pre-
sented on MHC class I molecules, although some CD4þ
cells are cytotoxic and so recognize antigen presented on
MHC class II molecules.
If, in addition to signaling through the TCR, the APC also
delivers a costimulatory signal through CD28, the CTL be-
comes activated and proliferates. Activated CTLs down-
regulate sphingosine phosphate receptor, allowing them to
exit the lymph node. They also downregulate molecules as-
sociated with homing to the lymph node, such as L-selectin
and CCR7, and upregulate molecules that allow them to
home to sites of inflammation, such as CD44 and LFA-1.
Effector T cells may also express adhesion molecules that
allow them to home to specific tissues. CD8þ memory T
cells appear to preferentially migrate to the tissue in which
they first encountered their antigen.
CTLs recognize antigen presented on MHC
class I molecules
The most important role of CTLs is the elimination of vi-
rally infected cells. CTLs recognize specific antigens (e.g.
viral peptides on infected cells) presented by MHC class
I molecules, which are expressed by nearly all nucleated
cells. Cellular molecules that have been partly degraded
by the proteasome are transported to the endoplasmic retic-
ulum, where they become associated withMHCclass I mol-
ecules and are transported to the cell surface. Normal cells
therefore present a sample of all the antigens they produce
to CD8þ T cells.
Q. How does a virus-infected cell know which molecules
are viral antigens and should therefore be presented
to CTLs?
A. It does not. Each cell samples its own molecules and
presents them for review by CD8þ T cells. Both the cell’s
own molecules and those of intracellular pathogens will be
presented in this way. It is the T cells that distinguish self
from non-self antigens, not the infected cell.
Additional interactions may be required to stabilize the
bond between a CTL and its target. Like CD4þ T cells,
CD8þ CTLs form an immunological synapse with their tar-
get. Signaling molecules including the TCR and CD3 are
found in the central zone of the supra-molecular activation
cluster (cSMAC), while adhesion molecules segregate in
the peripheral zone (pSMAC). In contrast to CD4þ T cells,
the cSMAC of CTLs and NK cells is divided into signaling
and secretory domains (Fig. 10.2). After signaling has oc-
curred, the microtubule organizing center polarizes towards
the synapse, directing cytotoxic granules to the secretory
domain of the cSMAC. Early CTL signaling occurs within
ten seconds of cell–cell contact and granule release follows
some two minutes later.
CTLs and NK cells are complementary in
the defense against virally infected and
cancerous cells
Natural killer (NK) cells were first identified as a subset of
immune cells that were able to kill tumor cells in vitrowith-
out prior immunization of the host, even in T cell deficient
mice. In 1981 Klas Ka¨rre made the seminal observation that
targets killed by NK cells tend to be spared by T cells and
vice versa. From this, he reasoned that NK cells must rec-
ognize targets that are not expressing a full complement
CTLs and NK cells mediate cytotoxicity
non-self
recognition
TCR
inhibitory
receptor
CD8
NKG2D
stress-
induced
activating
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NK
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tonic activating
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Fig. 10.1 CTLs recognize processed
antigen presented on the target cell by MHC
molecules, using their T cell receptor (TCR).
Most CTLs are CD8þ and recognize antig n
presented by MHC class I molecules, but a
minority are CD4þ and recognize antigen
presented on MHC class II molecules. In
contrast, NK cells have r ceptors that
recognize MHC class I on the target and
inhibit cytotoxicity. NK cells also express a
number of activating receptors to identify their
targets positively, including NKG2D and their
FC receptor (CD16).
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from the prima y lymphoid organs to function in the sec-
ondary lymphoid organs. These can be subdivided into:
• encapsulated organs – the spleen and lymph nodes;
• non-encapsulated tissues, e.g. mucosa-associated
lymphoid tissues (MALT).
In the secondary lymphoid organs and tissues, lymphocytes
undergo their final differentiation steps, which occur in the
presence of antigen. Effector B and T cells generated in the
secondary lymphoid tissues account for the two major cell
types participating in adaptive immune responses of hu-
moral and cellul r immunity, respectively.
As the cells of the immune syst m develop, they acquire
molecules that are important for their function. These spe-
cific functional molecules are referred to as ‘lineage
markers’ because they identify the cell lineage for example:
• myeloid cells – p lymorphs a d monocytes;
• lymphoid cells – T a d B ells.
Other marker molecules include those involved in regulat-
ing cell differentiation (maturation, development), prolifer-
ation and function and those involved in regulating the
number of cells participating in the immune response. Some
of these are called ‘death receptors’ and mediate the pro-
grammed cell death (apoptosis) that occurs as the cells
reach the end of their lifespan.
Myeloid cells
Mononuclear phagocytes and
polymorphonuclear granulocytes are
the two major phagocyte lineages
Phagocytic cells are found both in the circulation and in tis-
sues. Phagocytes belong to two major lin ages that differen-
tiate fro myeloid precursors:
• mononuclear phagocytes – monocytes/macrophages;
and
• polymorphonuclear granulocytes.
Themononuclear phagocytes consist of circulating cells (the
monocytes) and macrophages, that differentiate from
monocytes and reside in a variety of organs (e.g. spleen,
liver, lungs, kidneys) where they display distinctive mor-
phological features and perform diverse functions.
The other family of phagocytes, polymorphonucl ar gran-
ulocytes, have a lobed, irregularly shaped (polymorphic) nu-
cleus. On the basis of how their cytoplasmic granules stain
with acidic and basic dyes, they are classified into neutro-
phils, basophils and eosinophils, and have distinct effector
functions:
• the neutrophils, also called polymorphonuclear
neutrophils (PMNs), are most numerous and constitute
the majority of leukocytes (white blood cells) in the
blood stream (around 60–70% in adults);
• the primary actions of eosinophils and basophils, which
can both function as phagocytes, involve granule release
(exocytosis).
The mononuclear phagocytes and polymorphonuclear gran-
ulocytes evelop from a common precursor.
Mononuclear phagocytes are widely
distributed throughout the body
Cells of the mononuclear phagocytic system are found in
virtually all organs of the body where the local microenvi-
ronment determines heir morphology and functional char-
acteristics, e.g. in the lung as alveolar macrophages, in
kidney as glomerular mesangial cells, and in the liver as
Kupffer cells (Fig. 2.3 and see Fig. 1.2).
The main role of the mononuclear phagocytes is to re-
move particulate matter of ‘foreign’ origin (e.g. microbes)
or self origin (e.g. aged erythrocytes).
Myeloid progenitors in the bone marrow differentiate
into pro-monocytes and then into circulating monocytes,
which migrate through the blood vessel walls into organs
to become macrophages.
The human blood monocyte:
• is large (10–18 mm in diameter) relative to the
lymphocyte;
• has a horseshoe-shaped nucleus;
Antigen-presenting cells (APCs) in the immune system
microbe
antigens
cytokines cytokines
innate immunity adaptive immunity
phagocytes
cytokines
antigen presentation
T
B
NK 
Fig. 2.2 Specialized APCs are involved in both
innate and adaptive immunity to bacteria and
viruses by the production of cytokines and by
presentation of pr cessed antigens to T cells.
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B cause many pathogens have both intracellular and extra-
cellular phases of infection, different mech nisms are
usually effective at different ti es. For example, the polio
virus travels from the gut, through th blood stream to
infect nerve cells in the spinal cord. Antibody is particu-
larly effective at blocking the early phase of infection
while th virus is in the blood stream, but to clear an estab-
lished infection CTLs must kill any cell that has become
infected.
Consequ ntly, antibody is important in limiting the
spr ad of infecti n and preventing reinfectionwith the same
virus, while CTLs are essential to deal with infected cells
(Fig. 1.15). These factors play an important part in the de-
velopment of effective vaccines.
Vaccination
The study of immunology has had its most successful appli-
cation in vaccination (see Chapter 18), which is based on the
key elements of adaptive immunity, namely specificity and
memory. Memory cells allow the immune system to mount
amuch s ronger response on a second enco nterwith antigen.
Compared with the primary response, the secondary
response is:
• faster to appear;
• more effective.
The aim in vaccine development is to alter a pathogen or its
toxins in such a way that they become innocuous without
losing antigenicity. This is possible because antibodies and
T cells recognize particular parts of antigens (the epitopes),
and not the whole organism or toxin.
Take, for example, vaccination against tetanus. The teta-
nus bacterium produces a toxin that acts on receptors to
caus tetanic contractions of muscle. The toxin can be mod-
ified by formalin treatment so that it retains its epitopes,
but loses its toxicity. The resulting molecule (known as a
toxoid) is used as a vaccine (Fig. 1.16).
Whole infectious agents, such as the poliovirus, can be at-
tenuated so they retain their antigenicity, but lose their
pathogenicity.
Inflammation
Tissu damage caused by physical agents (e.g. trauma or
radiation) or by pathogens results in the tissue response of
inflammation, which has three principal components:
• increased blood supply to the infected area;
• increased capillary permeability due to retraction of the
endothelial cells lining the vessels, permitting larger
molecules than usual to escape from the capillaries;
• migration of leukocytes out of the venules into the
surrounding tissues – in the earliest stages of
inflammation, neutrophils are particularly prevalent, but
in later stages monocytes and lymphocytes als migrate
towards the site of infection or damage.
Q. What advantage could the inflammatory responses
have in the defense against infec ion?
A. The inflammatory responses allow leukocytes, antibodies,
and complement systemmolecules (all of which are required
for the phagocytosis and destruction of pathogens) to enter
the tissues at the site of infection. Lymphocytes are also
required for the recognition and destruction of infected
cells in the tissues.
Reaction to extracellular and intracellular pathogens
interferons
complement antibody
virus
infection
viral
replication
resistance
antiviral
killing
infected
cell
CTL
Fig. 1.15 Different immunological systems are effective against
different types of infection, here illustrated as a virus infection.
Antibodies and complement can block the extracellular phase of
the life cycle and promote phagocytosis of the virus. Interferons
produc d by infected cells signal to uninfected cells to induce a
state of antiviral resistance. Viruses can mu tiply only within living
cells; cytotoxic T lymphocytes (CTLs) recognize and destroy the
infected cells.
Principle of vaccination
vaccination
primary
antibody
response
natural
infection
secondary
antibody
response
acquired
immunity
toxintoxoid
time
antibody
response
mem ry cells formed
Fig. 1.16 Chemical modification of tetanus toxin produces a
toxoid, which has lost its toxicity but retains many of its epitopes.
A primary antibody response to these epitopes is produced
following vaccinatio with the t xoid. If a natural infection occurs,
the toxin restimulates m mory B cells, which produce a faster and
more intense secondary response against that epitope, so
neutralizing the toxin.
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too limits their effectiveness in activating naive T cells.
Macrophages:
• ingest mic bes and particulate antigens;
• digest them in phagolysosomes; and
• present fragments at the cell surface on MHC
molecules.
Q. A number of bacterial components enhance the ex-
pression of MHCmolecules and costimulatory molecule
on macrophages. What effect would you expect this to
hav on the immune response? Would it b advanta-
geou for the individual?
A. In the presence of infection, the ac ion of the microbial
compone ts would enhance t bility of macrophages to
present antigen to T cells. This would generally be
advantageous because it would allow the immune system
to respond more effectively to the infection. However, i
some circumstances it might be disadvantageous because
microbial components would also enhance unwanted
immun responses such as autoimmune reactions.
B cells can:
• bind to a specific antigen through surface IgM or IgD;
• internalize it; and
• then degrade it into peptides, which associate with
MHC class II molecules.
If antigen concentrations are very low, B cells with high-
affinity antigen receptors (IgM or IgD) are the most effec-
tive APC because other APCs si ply cannot capture
enough antigen. Therefore, for secondary responses, when
the number of antigen-specific B cells is high, B cells may
be a major APC.
Th properties and functions of some APCs are summa-
rized in Figures 8.3 and 8.4.
Localization of antigen-presenting cells (APCs) in lymph nodes
area antigen-presenting cells antigen persistenceof antigen
subcapsular
(marginal) sinus
follicles and
B cell areas
medulla
T cell areas
marginal zone macrophages
follicular dendritic cells
classic macrophages
interdigitating dendritic cell
polysaccharides Ficoll (Tind)
immune complexes that
fix complement
most antigens
most antigens
medulla
B
T
afferent
efferent
folliclemarginal sinus
Fig. 8.2 A lymph node represented schematically showing afferent and efferent lymphatics, follicles, the outer cortical B cell area, and the
paracortical T cell area. Different APCs predominate in these ar as and sel ctively t ke up diff re t types of antigen, which then persist on
the surface of the cells for variable periods. Polysaccharides are pr ferentially taken up by marginal zone acrophages and may persist
for months or years, whereas antigens on recirculating macrophag s in the medulla may last for only a few days or weeks. The recirculating
‘ iled’ cells (Langerhans’ cells and dermal d dritic cells), which originally me from the skin, chang their morphology to bec me
interdigit ting den ritic cells within the lymph no e. Both th se cells and the f llicular dendritic cells have lo g proces es, which are in intimate
contact with lymphocytes.
Antigen prese tation
mononuclear phagocytes
TH
phagolysosome
no -specific
receptor
MHC
class II
molecule
antigen
specific antigen uptake
surface
immunoglobulin
pinocytosis
B cells
dendritic cells
Fc receptor
antigen
TH
1
2
3
THB
Fig. 8.3 Mono uclear phagocytes (1), B cells (2), a d DCs
(3) c all present antig n to MHC class II r stricted TH cells.
Macrophages take up bacteria or particulate antigen via non-
specific receptors or as immune complexes, process it, and return
fragments to the cell surface in association with MHC clas II
molecules. Activated B ce ls can t ke up a tigen via their surface
immunoglobulin and present it to T cells associated with their MHC
class II molecules. DCs constitutively express MHC cl ss II
molecules and take up antigen by pinocytosis.
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The central, an igen-specific interaction is that between
theMHC class II–antigen compl x and the TCR. This inter-
acti n is augmented by interactions between LFA-3 and
CD2 and between ICAM-1 or ICAM-3 and LFA-1.
Q. Which costimulatory molecules, present on B cells
and other APCs, promote T cell proliferation? What
mechanisms are inv lv d?
A. B7–1 (CD80) and B7–2 (CD86) act on antigen-activated
T cells by ligating CD28, leading to expression of the high-
affinity IL-2 r ceptor (s e Fig. 8.1).
The interaction between B and T cells is a two-way event as
follows:
• CD40, a member of the TNF receptor family, delivers a
strong activating signal to B cells, more potent even than
signals trans itted via surface immunoglobul ;
• upon activation, T cells transiently express a ligand,
termed CD40L (a member of the TNF family), which
interacts with CD40;
• CD40–CD40L interaction helps to drive B cells int c ll
cycle;
• transductionofsignals throughCD40inducesupregulation
of CD80/CD86 and therefore helps to provide further
costimulatory signals to the responding T cells.
Signaling through CD40 is also essential for germinal center
development and antibody responses to TD antigens.
Q. Some individuals have amutation that produces a non-
functional variant of CD40L. In its homozygous for ,
what effect would you expect this mutation to have on
serum antibody levels?
A. The mutation produces hyper-IgM syndrome, with high
serum IgM and low IgG, IgA, and IgE levels, due to lack of
germinal centers and failure of the B cells to switch isotype.
Cytokine secretion is important in B-cell proliferation
and differentiati n
Recent work has shown that CD4þ T cells in bothmouse and
man can be divided into different subsets, depending on their
cytokine profile (see Fig. 11.4). During B-cell–T-cell
interaction, T cells can secrete a number of cytokines
hat have a powerful effect on B cells (Fig. 9.7). IL-2, for
example, is an inducer of proliferation for B cells as well as
T cells.
In particular, cytoki es produced by TH2 cells strongly
promote B c ll activation and the production of IgG1 and
IgE. These cytokines include IL-4, IL-5, IL-6, IL-10 and
IL-13:
• IL-4 acts on B cells to induce activation and
differentiation. It also acts on T cells as a growth factor
and promotes differentiation of TH2 cells, thus
reinforcing the antibody response; excess IL-4 plays a
part in all rgic disease, causing production of IgE;
• IL-5 in humans is chiefly a growth and activation factor
for eosinophils and is responsible for the eosinophilia of
parasitic disease. In the mouse it also acts on B cells to
induce growth and differentiation;
• IL-6 is produced by many cells including T cells,
macrophages, B cells, fibroblasts and endothelial cells
and acts onmany cell types, but is particularly important
in inducing B cells to differentiate into AFCs. IL-6 is
considered to be an important growth factor formultiple
myeloma, a malignancy of plasma cells;
• IL-10 acts as a growth and differentiation factor for
B cells in addition to modulating cytokine production by
TH1 cells;
• IL-13, which shares a receptor component and signaling
pathway with IL-4, act on B cells to produce IgE.
Additional TH subsets have been identified having distinct
developmental programs and cytokine profiles. TH17 cells
secrete IL-17 and are associated with immunity against
extracellular bacteria and fungi, chronic inflammatory dis-
ease, and autoimmunity. Another T cell subset that helps
B cells is the T follicular helper (TFH) cell, characterized
by the expression of the chemokine receptor CXCR5 and
localized to developing germinal centers. TFH cells help
provide instructive signals that lead to Ig class switching
and somatic mutation. TFH cells also produce high levels
of IL-21, a cytokine that is critical for germinal center
formation.
Cytokines and B cell development
TH0 TH1
IL-4
IL-1
IL-13
IL-2IL-4
IL-4
IL-5
IL-6
IL-10
activat on division differenti tion
IL-12, IFN
IFN
B B
APC
B
AFC
Fig. 9.7 B cell development is influenced by
cytokines from T cells andAPCs, and by direct
interactions with TH2 cells. IL-4 is most
important in promoting cell division, and a
variety of other cytokines including IL-4, IL-5,
IL-6, IL-10 and IFNg, influence development
into antibody-forming cells (AFCs) and affect
the isotype of antibody that will be produced.
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Cytotoxic cells recognize and destroy other cells
that have beco infected
Sev ral cell types have the capacity t kill other cells should
they become infect d. Cytotoxic cells include CTLs, nat-
ural killer (NK) cells (large granular lymphocytes), and
eosinophils. Of these, the CTL is especially important,
but other cell types ay be activ against p rticular types
of inf ction.
All of thes cell types damage their different targets by
releasing the conte ts of their intrac llular granules close
to them. Cytokines secreted by the cytotoxic cells, but
not stored in granules, contribute to the damage.
Lymphocytes known as large granular lymphocytes
(LGLs) hav the capacity to recognize the surface changes
that occur on a variety of tumor cel s and virally infected
cells. LGLs damage these target cells, but use ifferent
recognition system to CTLs. This ction is sometimes
called NK ell activity, so these cells are also d scribed
as NK cells.
Eo inophils are a specialized gr up of leukocytes that
have the ability to engage and d mage l rge extracellular
parasites, such as schistosomes.
Auxiliary cells control inflammation
The main purpose of inflammation is to attract leukocytes
and the soluble mediators of immunity towards a site of in-
fectio . Inflammation is mediated by a variety of other cells
including bas phils, mast cells and platelets.
Basop ils and mast cells hav granules that contain a va-
riety of mediators, which induc inf ammation in surround-
ing tissue are released when the cells are triggere .
Basophils and mast cells can also synthesize and secrete a
number of mediators that control the development of im-
mune reactions. Mast cells lie close to blood vessels in all tis-
sues, and some of their mediators act on cells in the vessel
walls. Basophils are functionally similar tomast cells, but are
mobile, circulating cells.
Platelets are small cellular fragments which are essential
in blood clotting, but they can also be activated during im-
mune responses to release mediators of inflammation.
Soluble mediators of immunity
A wide variety of molecules are involved in the develop-
ment of immune responses, including antibodies, opsonins
a d c mp eme t yst m molecul s. The serum concentra-
tion of a number of these proteins increases rapidly during
infection and they a e therefore called acute phase
pr t ins.
One exampl of an acute phase protein is C reactive
protein (CRP), so-call d because of its ability to bind to
the C protein of pneumococci; it promotes the uptake
of pneumococci by phagocytes. Molecules such as anti-
body and CRP that promote phagocytosis are said to act
as opsonins.
An ther important group of molecules that can act as
opsonins are components of the complement system.
Complement proteins mediate phagocytosis,
control inflam ation and interact with antibodies
in immune defense
The complement system, a key component of innate immu-
ni y, is a group of about 20 serum proteins whose overall
function is the control of inflammation (Fig. 1.5). The com-
ponents interact with each other, and with other elements
the immune system. For example:
• a number of microorganisms spontaneously activate the
complement sys em, via the so-called ‘alternative
pathway’, which is an innate immune defense – this
results i th microorganism being opsonized (i.e. coated
by complement molecules, leading to its uptake by
phagocytes);
• the complement system can also be activated by
antibodies or by mannose binding lectin bound to the
pathogen surface via the ‘classical pathway’.
Complement ctivation is a cascade reaction, where one
component acts enzymatically on the next component
in the cascade to generate an enzyme, which mediates
the following step in the reaction sequence, and so on.
(The blood clotting system also works as an enzyme
cascade.)
Functions of different types of lymphocyte
antigen
presentation
activation
antigen
presentation
activation
macrophage
B
LGLTH1 TH2 CTL
antibody prod c ion
cytotoxicity
virally infect  cell and
som  tum r cells
Fig. 1.4 Macrophages present antigen to
TH1 cells, which then activate the
macrophages to destroy phagocytosed
pathogens. B cells present antigen to TH2
cells, which activate the B cells, causing them
to divide and differentiate. Cytotoxic
T lymphocytes (CTLs) and large granular
lymphocytes (LGLs) recognize and destroy
virally infected cells.
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1 Introduction o the immune system
Natural killer  
(NK) cell 
M t cell 
Eosinophil 
B sophil 
requirescontrolsystemscapableofdownmodulatingmacro-
phageactivation.Oneofthesesystemsinvolvesthemolecule
CD200L,whichisaninhibitoryreceptorexpressedbymye-
loidcells.CD200Linhibitorysignalingistriggeredthrough
interactionwithCD200expressedbynon-hematopoietic
cellsaswellasmacrophages.TheCD200–CD200Linterac-
tionisimportantforthecontrolofmacrophageactivationby
othercellspresentintissues.
Phagocytosisadedocytosis
Solublecompoundseintrnalized
byendocytosis
Mcrophagesplayakeyroleintheclearanceofaltered
formsoflipoproteins(e.g.acetylatedlipoproteins)orglyco-
proteins(e.g.asialylatedmannosylatedproteinsorproteins
bearingadvancedglycanpoducts),damagedorapoptotic
cells,pollutantparticlesandmicrobes.Forthispurpose,
macrophageshaveahighlydevelopedendocyticcompart-
mntthatmediatestheuptakeofawiderangeofstimuli
andtargetsthmfordegradationinlysosomes.Soluble
Macrophagesinsecondarylymphoidtissues
12
34
Fig.7.4Hetrogeneitofmacrohagesinsecondrylymphoidorgansofmouseandhuman.(1)RedpulpofspleenstainedforF4/80.
Macrophagesstainstronglyositive.(2)Mousespleenstainedwithantibodytosialoadhesin.Themarginalmetallophilsofspleenarestrongly
sialoadhesin(CD169)positive.(3)HumanspleenstainedforCD68and(4)immunofluorescencestainingwithanti-CD68(green),andforthe
mannosereceptor(red)indicatesstaininglngsinuoidsbutmostCD68þmacrophageslackthemannosereceptor.Nucleiarestainedblue.
((1)CourtesyofDrDAHume.(2)CourtesyofDrPRCrocker.)
Comparisonofthefunctionsofmacrophages
anddendriticcells
macrophage
• Maintenance of tissue homeostasis
• Antigen presentation to activated T cells
• Effector cells during cell mediated immunity
 with enhanced microbicidal properties in the
 presenc of IFNγ
• Key role in restoring tissue hmeostasis
 after inflammation by clearing apoptotic
 neutrophils and promoting wound repair
• Antigen presentation to naïve T cells
• Modulation of T cell differentiation
• Poor lysosomal degradative capcity
mononuclear phagocytes
macophages vs dendritic lls
dendritic cell
Fig.7.5Coarisonofthefunctionsofmacrophagesand
dendriticcells.
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Dendritic cell 
Macrophage 
Neutrophil 
Antigen prese tation via MHC-II   
activates CD4+ helper T cells 
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Cyt toxic cells recognize and d str y other cells
th t have be ome infected
Several cell types have the capacity o kill other cells should
they ecome infected. Cytotoxic c lls include CTLs, na -
ural killer (NK) cells (large gra ular lymphocytes), and
eosinophils. Of these, the CTL is especially important,
but other cell types may e active against particular types
f infection.
All of th se c ll types damage their different targets by
releasing the contents of their intracellular granules close
to them. Cytokines secreted by the cytotoxic cells, but
not stored in gr nules, contribute to the damage.
Lymp ocytes known as large granular lymphocytes
(LGLs) ha the capaci y to ecognize the surfac chang s
that occur on a variety of tu or cells and virally infected
cells. LGLs damage th se t rge cells, but use a different
r cognition system to CTLs. This action is sometimes
called NK ell activity, s these cells are also described
as NK cells.
Eosinophils are a specialized gr up of leukocytes that
have t e ability to engage and dam ge large extracellular
paras tes, such as schistosomes.
Auxiliary cells control inflammation
Th main pu pose of inflammation is to attract leukocytes
and the soluble mediators of immunity towards a site of in-
fecti n. Inflammation is mediat by a variety of other cells
including basophils, mast cells and platelets.
Basop ils and m st cells have granules that contain a va-
riety of mediators, which induce inflammation in surround-
ing tissues and are released when the cells are triggered.
Basophils and mast cells can also synthesize and secrete a
number of mediators that control the development of im-
mune reactions. Mast cells lie close to blood v sel all tis-
sues, nd some of t eir mediators act on cells in the vessel
walls. Basophils are functionally similar tomast cells, but are
mobile, circulating cells.
Platele s are small cellular frag ents which are essential
in b ood cl tting, but they can also be activated during im-
mune responses to r lease mediators of inflammation.
Sol ble mediators of immunity
A wide variety of molecules are involved in the develop-
me t of i mune responses, including antibodies, opsonins
and complement system molecules. The serum concentra-
tion of a number of these proteins increases rapidly during
infection and they are therefore called acute phase
proteins.
One example of an acute phase protein is C reactive
protein (CRP), so-called because of its ability to bind to
the C protein of pneumococci; it promotes the uptak
of pneumococci by phagocytes. Molecules such as anti-
body and CRP that romote phagocytosis are said to act
as opsonins.
Another important group of molecules that can act as
op onin are components of the complement system.
Complement proteins mediate phagocytosis,
c ntrol inflammation and i t ract with ntibodies
in immune defen e
The complement system, a k y component of innate immu-
nity, is a group of about 20 serum proteins whose overall
function is the control of inflammation (Fig. 1.5). The com-
ponents int ract with each other, and with other elements
of the immune system. For example:
• a number of microo g nisms spontaneously activate the
co plement system, via the so-called ‘alternative
pathway’, which is an innate immune defense – this
results in themicroorganism being opsonized (i.e. coated
by complement molecules, leading to its uptake by
phagocytes);
• the complement system can also be activated by
anti odies or y mannose binding lectin bound to the
pathogen surface via the ‘classical pathway’.
Complement activation is a cascade reaction, where one
component acts enzymatically on the next component
in the cascade to generate an enzyme, which mediates
the following step in the reaction sequence, and so on.
(The blood clotting system also works as an enzyme
cas de.)
Functions of different types of lymph cyte
antigen
presentation
activation
antigen
presentation
activation
macrophage
B
LGLTH1 TH2 CTL
antibody production
cytotoxicity
virally infe ted cell and
some tumor cell
Fig. 1.4 Macrophages present antigen to
TH1 cells, which then activate the
macrophages to destroy phagocytosed
pathogens. B cells present antigen to TH2
cells, which a tiv te the B cells, cau ing them
to divide and differentiate. Cytotoxic
T lymphocytes (CTLs) and large ranular
lymphocytes (LGLs) recognize and destroy
virally infected cells.
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Induces cytokine 
production 
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Antigen presentation via MHC-I   
activates CD8+ cytotoxic T cells (CTL) 
Phagoc tes 
 
 
 
 
 
 
 
 
 
 
 
 
Ctotoxicellsrecognizeanddestroyohercells
thathavebcomeinfected
Severalcelltypeshavethecapacitytokillothercellsshould
theybecomeinfected.CytotoxiccellsincludeCTLs,nat-
uralkiller(NK)cells(largeganularlymphocytes),and
eosinophils.Ofthse,theCTLisespeciallyimportant,
butothercelltypesmaybeactiveagainstparticulartyps
ofinfection.
Allofthesecelltypesdamageheirdiffernttargetsby
releasigthecontentsoftheiintracellulargranulesclose
tothem.Cytokinessecretedbythecytotoxiccells,but
ntstoredingranules,contributetothedamage.
Lymphoctesknownslargegranularlymphocytes
(LGLs)havethecapacitytorecognizehsurfacchanges
thatoccuronavarietoftumrcellsandvirallyinfected
cells.LGLsdamagehesetargetcell,butuseadifferent
recognitionsystemtoCTLs.Thisactionissmemes
calledNKcellactivity,sothesecellsarealsodescribed
asNKcells.
Eosinophilsaraspecializedgoupofleukocytesthat
havetheabilitytoengageanddamagelargeextracellular
parasites,suchasschistosomes.
Auxiliarycellscontrolinflammation
Themainpurposeofinflammationistoattracleukocyte
adthesolublemediatrsofimmunitytwardsasiteofin-
fection.Inflammationismediatebyavarietyofthercells
includingbasophils,mastcellsandplatelets.
Basophilsandmastcellshavegranulesthatcontainava-
rietyofmeiators,whichinduceinflammationinsurround-
ingtissuesandarereleasedwhenthecellsaretriggered.
Basophilsandmastcellscanalsosynthesizeandsecretea
numberofmediatorsthacontrlthedevelopmentofim-
munereactions.Mastcllsliecloseobloodvesselsinalltis-
sues,andsomeoftheirmediatorsactoncellsinthevessl
walls.Basophilsarefunctionallysimilartomastcells,butare
mobile,circulatingcells.
Plateletsaresmallcellularfragmetswhichareessential
inbloodclotting,buttheycanalsobeactivatedduringim-
muneresponsestoreleasemdiatosofinflammation.
Slublemediatorofiuity
Awidevarietyofmoleculesareinvolvedinthedevelop-
mentofimmuneresponses,incudingantibodies,opsonins
andcomplementsystmmolcules.Theserumconcentra-
tionofanumberoftheseproteinsincreasesrapidlyduring
infectionandtheyrethereforecalledacutephase
proteins
Onexampleofanacutephaseproteinisreactive
prtein(CRP),so-calledbecauseofitsabilitytobindto
theCproteinofpneumococci;itpromotestheuptake
ofpneumococcibyphagocytes.Moleculessuchasanti-
bodyandCRPthatpromotephagocytsisaresaidtoact
aspsonins.
Anotherimportatgroupofmolculesthtcanactas
opsoninsarecompoentsofthecomplementsystem.
Complementproteinsmediatephagocytosis,
controlinflammationandinteractwithantibodies
inimmunedefense
Thecomplementsystem,akeycomponentofinnateimmu-
nity,isagroupofabout20seruproteinswhoseoverall
functionistecontrolofinflammation(Fig.1.5).Thecom-
ponentsinteractwitheahother,andwithotherelements
oftheimmunesystem.Forexample:
•anumbrofmicroorganismsspontaneouslyactivatethe
complementsystem,viatheso-called‘alternative
pathway’,whichisaninnateimmunedefense–this
resultsinthemicroorganismbeingopsonized(i.e.coated
bycomplementmolecules,leadingtoitsuptakeby
phagocytes);
•thecomplementsystemanalsobeactivatedby
anibodiesorbymannosebindinglectinboundtothe
patogensurfacviathe‘classicalpathway’.
Compleentactivationisacascadereaction,whereone
componentactsenzymaticallyonthenextcomponent
intecascdetogenerateaenzyme,whichmediates
thefollowingstepinthreactionsequence,andsoon.
(Thebloodclottingsystemalsoworksasanenzyme
cascade.)
Functionsofdifferenttypesoflymphocyte
atgen
presention
activation
antien
presentatin
activation
macrophage
B
LGL TH1T2CTL
antibody production
cytotoxicity
virally infected cell and
some tumor cells
Fig.1.4Macrophagespresentatieto
TH1cells,whichthenactivatethe
macrophagestodestroyphagoytosed
pathogens.BcellspresentantigentoTH2
cells,whichactivatetheBclls,causingthem
todivideanddifferentiat.Cytotoxic
Tlymphocytes(CTLs)andlargegranular
lymphocytes(LGLs)recognizeanddestroy
virallyinfectedcell.
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B-lymphocyte activation 
Becaus many p thogens have both intrac llular and extra-
cellular phases of infection, different mechanisms are
usually effective at different times. For example, the polio
virus travels from the gut, through the blood stream to
infect nerve cells in the spin l cord. Antibody is particu-
larly effective at blocking the early phase of infectio
while the virus is in the b ood tream, but to clear an estab-
lish d infection CTLs must kill any cell that has bec me
inf cted.
Co sequently, antibody is important in limiting the
spread of infection and preventing rei fectionwith the same
virus, while CTLs are essential to deal wit infected cells
(Fig. 1.15). These factors play an important part i the de-
velopme t of effective vaccines.
Vaccination
The study of im unology has ad i s most successful appli-
cati n in vaccinati n (see Chapter 18), which is based on the
key ele ents of adaptive immunity, nam ly specificity and
memory. Me ory cells allow the immune system to mount
amuch stronger respon e on a second encounterwith antigen.
Compared with he primary respon , the seco dary
response is:
• faster to appear;
• more effective.
The aim in vaccine development is to alter a pathogen r its
toxins in such a way that they become innocuous without
losing antige icity. This is possible because antibodies and
T cells recognize particular parts of antigens (the epitopes),
and not the whole or anism or toxin.
Take, for example, vaccination against tetanus. The teta-
nus bacterium pro uces a oxi that acts on receptors to
cause t tanic con racti ns of muscle. The toxin can be mod-
ifi d by formalin reatment so that it retains its epitopes,
but loses its toxicity. The resulting molecule (kn wn as a
toxoid) is us d as a vaccine (Fig. 1.16).
Whole infectious agents, such as the poliovirus, can be at-
tenuated so they retain their antigenicity, but l se their
pathogenicity.
I flammatio
Tissue damage caused by physical agents (e.g. trauma or
radiation) r by pathogens results in th ti sue response of
i flammation, which has three principal components:
• increased blood supply to the infected area;
• increased capillary per eability due to retraction of the
end thelial cells lining the vessels, permitting larger
molecul s than usual to escape from the capillaries;
• migr tion of leukocytes out of the venules into the
surrounding tissues – in the earliest stages of
inflammation, neutrophils are particularly prevalent, but
in later stages monocytes and lymphocytes lso migrate
towards the site of infection or damage.
Q. W t advantage could the inflammatory responses
have in the defense against infection?
A. The i flammatory respo ses allow leuk cytes, a ti odies,
and complement systemmolecules (all of which are required
for the phagocytosis and destruction of p thogens) to enter
the tissu s at the site of infection. Lymphocytes are also
required for the recognition and destruction of infected
cells in the tissues.
Reaction to extracellular and intracellular pathogens
interferons
complement antibody
virus
infection
viral
replication
resistance
antiviral
killing
infected
cell
CTL
Fig. 1.15 Different immunological systems are effective against
different types of infection, here illustrated as a virus infection.
Antibodies and complem nt can block the extracellular phase of
the life cycle and promote phagocytosis of the virus. Interferons
pr duced by infected cells signal to uninfected cells to induce a
s ate of antiviral resist . Viruses can multiply only within living
cells; cyt toxic T lymphocytes (CTLs) recognize and destroy the
infected cells.
Principle of vaccination
vaccination
primary
antibody
response
natural
infection
secondary
antibody
response
acquired
im unity
toxintoxoid
time
antibody
response
memory cells formed
Fig. 1.16 Chemical modification of tetanus toxin produces a
toxoid, which has lost its toxicity but retains many of its epitopes.
A primary antibody response to these epitopes is produced
following vacci ation with the toxoid. If a natural infection occurs,
the toxin restimulates memory B cells, which produce a faster and
more intense secondary response against that epitope, so
neutralizing the toxin.
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Figur  1. Sh ws an v rview of th  lls and of innate (left) and adaptiv  ( ight) i munity as 
well s the link by antig n presentati n via MHC-I or MHC-II (middle). Image was modified 
f om immunology 8th dition4.
T e orch stration and initiation of o r h s  d e se is th  i na  immune syst . 
This part of the immune sy te  i  capabl  of eliminating the i vading hogen 
efficiently. Cells inv lved in our in ate im une syste  ar  the phagocytic c lls 
(macrophages/mo ocytes, dendritic lls and neu r phils) and o her leukocytes 
(natural killer cells, as  cells, eosinophils a d basophil ) (Fi ur  1).  In addition, 
dendritic cells are myeloid c lls that fu ction as rof ssional ntige  presenting c lls, 
and theref re pl y an important role in the link b tween t e innat  and the adaptive 
immune sys em. 
In ate im un  r sponses con i t ot only of cel ul r, but al o umoral co p nents. 
Among the humoral components of inn te immunity we encoun r natural 
antibodies, defensins, s well a  the complement ystem hat consists of 16 all 
proteins (components) present in the bl od. Compl ment c mp n nts are ctivat d 
sequentially via the classical, alte native, r th  lectin pat way, nd rovide innat  
immunity directly by lysing b cteria th ough the me bra e attack complex, and 
indirectly by inducing inflammation and stimu ating ph g c tosis5,6.
The adaptive immune system is also known as th  acq ired im une system, this part 
of the immune system uses antigen present tion as th  trigger to initiate s ecific 
immunity against the pathogen. The induced ada tive i mune resp nse agai st this 
specific type of antigen is performed by T- and B-lymp ocy es. Two mol cule  of the 
Major Histocompatibility Complex (MHC-I and MHC-II) are responsibl  for a tig n 
presentation. All nucleated cells are capable f presenti  antigen  via MHC-I, and 
can activate cytotoxic  (CD8+) T lymphocytes. The antigen presented by MHC-I is 
typically from a protein produced or present inside the cytosol of the cell. 
Cytotoxic T lymphocytes can therefore destroy cells presenting endogenously 
expressing unfamiliar viral peptides and malignant cells that present excessive 
amounts of an antigen7 (Figure 1).
Antigen presentation via MHC-II is performed by professional antigen presenting 
cells such as dendritic cells and macrophages. As phagocytes, these cells engulf 
pathogenic particles (e.g. bacteria, viruses or fungi) and degrade them to peptide 
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antigens8,9. These peptides derived from the degradation of microorganism inside 
the phagosome are loaded on MHC-II molecules. Helper (CD4+) T-lymphocytes 
recognize MHC-II peptide antigens and become activated10,11. Since activated helper 
T-lymphocytes are unable to destroy pathogens themselves, they release cytokines 
to stimulate, and attract different immune cells. One subtype of the T-helper cells, the 
Th2 cells, secrete signaling cytokines that mediate humoral immunity by activation 
and proliferation of B-lymphocytes. The main function of differentiated B-cells is 
to produce neutralizing antibodies (immunoglobulins) that deactivate pathogens11. 
Five different types of immunoglobulins (IgA, IgD, IgE, IgG and IgM) are present in 
our blood serum. All these different factors of the immune system are required to 
orchestrate an effective host response against pathogens4,12,13 (Figure 1). 
The homeostasis of our bodies heavily relies on a balanced immune system.  When the 
host-response against pathogens is defective, the patients will display an increased 
susceptibility to infection. 
Autoinflammation and autoimmunity
Defects in immune tolerance may induce an immune response against compounds 
of the host itself. Medical conditions caused by auto-reactive immunity can 
be subdivided into two groups.  Autoinflammatory diseases (e.g. IL-1 receptor 
antagonist deficiency) on one hand are caused by auto-reactive innate immune 
cells14. Autoimmune diseases (such as SLE) on the other hand are caused by defects 
in immune tolerance of B- and T-lymphocytes. The removal or inactivation of self-
reactive B- and T- lymphocytes is crucial to prevent autoimmune manifestations15. 
There are also diseases that display components of both (e.g. Behçet).
Primary immunodeficiency
Countless factors successfully cooperate in a healthy immune system, regulating 
proliferation of immune cells, production of cytokines and antibodies, signaling, 
and tolerance towards self-antigens. One single defective link in this chain may be 
sufficient to cause a disastrous effect for the host. 
Patients that suffer from primary immunodeficiencies (PIDs) have an increased 
susceptibility of infections, and are predominantly caused by defects in genes that 
are involved in the innate or adaptive immune system. The research described 
in this thesis focuses on this group of patients, and does not involve acquired 
immunodeficiencies such as patients infected with the human immunodeficiency 
virus (HIV) or patients treated with immunosuppressive medication4,16,17. 
Dysfunction of one or more pathways of the immune system determines the type of 
immunodeficiency. To gain insight in dysfunctional mechanisms of individual patients 
it is crucial to evaluate the disease phenotype by tracking the type and frequency of 
the infections, as well as any additional clinical features. In addition, functional testing 
by using blood from these patients can help to further characterize the specific type 
of the immunodeficiency. Quantification of immune cell fractions in whole blood and 
antibodies in blood serum, as well as in vitro stimulation assays of peripheral blood 
mononuclear cells (PBMCs) to detect altered cytokine production, may provide 
valuable information to understand the immunological defect of the patient17–20.
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 Genetics of primary immunodeficiencies
In order to understand underlying cause of the immunological defect in 
immunodeficient patients, it is important to look for genetic abnormalities present 
in these patients. We do this by studying the DNA of these patients.
DNA 
Deoxyribonucleic acid (DNA) is present in the nucleus of all nucleated cells. In humans, 
this double-helix structure comprises over 6.6 billion nucleotides divided over 46 
chromosomes21. The diploid genome contains two copies of 22 different autosomal 
chromosomes and two sex chromosomes (X and Y). Half of the genetic information 
(23 chromosomes) is inherited from each parent. Four different nucleotides are 
responsible for the genetic blueprint of every organism; the order of the nucleotides 
Guanine (G), Adenine (A), Cytosine (C) and Thymine (T) determines ones phenotype21. 
DNA is transcribed to complementary messenger ribonucleic acid (mRNA) molecules 
that transfer the genetic information from the DNA to the ribosomes.  Within the 
ribosomes, each mRNA codon (3 nucleotides) will be translated to an amino acid22–25. 
The chain of adjacent amino acids forms a protein. The protein coding regions of our 
genome, are the exons of the ~22,000 human genes. This small fraction (1-2%) of all 
genomic DNA is also referred to as the exome26. Depending on the specific function 
of the cell type, certain genes are activated since the function of the corresponding 
protein is required27. 
Genetic variation 
Genetic variation determines the phenotypic diversity amongst humans. Individuals 
from distant ethnic backgrounds have an increased genetic and phenotypic 
heterogeneity compared to individuals from the same ethnic background, or relatives. 
Humans receive half of their genetic variants from each parent and therefore we 
share 50% of our genetic variation with each of our parents28. Next to these shared 
genetic variants, recent whole genome sequencing (WGS) studies showed that 44-82 
de novo single nucleotide variants (SNVs) occur in the genome of any newborn29–31. 
Only one or two of the de novo variants, mostly arising from mistakes during DNA 
replication, affect the coding regions of the DNA. 
Types of genetic variants
SNVs are the most frequent type of genetic variation altering on average 3.5 to 4.4 
million nucleotides in comparison to the reference human genome. The majority of 
these variants (>99%) occur in the non-coding regions like the intergenic and intronic 
regions30,33. Interpretation of non-coding variants is challenging because there is 
no direct effect on the translated proteins; this thesis therefore focused on protein 
coding variants.
Variants in the coding regions have different outcome possibilities on the protein 
level. Nonsense variants cause a loss-of-function (LoF) effect by changing the wild 
type amino acid into one of the mRNA (stop) codons that truncates the protein. 
These altered mRNA molecules are usually recognized by the cell, and broken down
13
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Figure 2. Schematic image of a chromosome, the DNA molecule contains protein-coding and 
non-coding genetic information. One single nucleotide variant (SNV) in the coding region can 
alter the formed protein. (Image adapted from32)
in a process called nonsense mediated decay (NMD). Similarly, frameshift variants 
caused by small insertions or deletions (indels) into the DNA often cause an altered 
reading frame, and a premature stop codon downstream34–37. In case the wild type 
phenotype cannot be maintained by protein expression from one healthy allele, 
due to a LoF mutation on the second allele, the altered phenotype is a result of a 
mechanism called haploinsufficiency38. 
Missense or non-synonymous variants are substitutions on the DNA and mRNA 
level that change a single amino acid, and thereby alter the protein. These missense 
variants may have a LoF, a gain-of-function (GoF), a dominant negative, or an 
insignificant effect on protein function for their respective cellular pathway39–42. 
Despite availability of in silico pathogenicity predictors based on population 
frequency and evolutionary conservation, interpretation of these variants remains 
challenging43–45. Co-segregation analysis of these variants in families as well as 
experimental evaluation of the effect of the variant on protein function is important 
to provide additional evidence regarding the potential deleteriousness of the variant. 
In contrast to non-synonymous variants a significant proportion of SNVs represent 
to synonymous variants. Those are present on the DNA, and mRNA level, but the 
altered mRNA codon encodes for the same amino acid as the wild type codon, and 
there is no amino acid substitution, hence difference on the protein level28,46,47.
In addition to coding variants there is a possible strong effect of (canonical) splice site 
variants. Splice sites consist of splice donor and splice acceptor and are the intronic 
bases in direct proximity of coding exons, which recruit the splicing machinery. SNVs 
affecting splice sites may directly have a strong influence on splicing and possibly 
lead to skipping of one the exons of a gene, which may result in a truncated protein. 
Copy number variants (CNVs) affect larger genetic regions (1kb-several Mb in size) of 
the genome. On average 160 large CNVs are found per genome, in some instances 
CNVs contain multiple genes, of which one copy is lacking (deletion) or one extra 
copy (duplication) is present30,33,48,49. 
Despite their relative low frequency in each genome, CNVs can have a large effect, as 
they can directly lead to gene dosage effects, also known as haploinsufficiency. 
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Next to the above mentioned most prevalent forms of genetic variants other types 
of genetic variation include: repeat expansions50,51, and transposable elements52,53, 
and larger structural variants such as aneuploidies, translocations and inversions28,54.
Phenotypic outcome of genetic variants
The best understood genetic disorders are monogenic diseases, also known as 
Mendelian disorders. In these cases the disease phenotype is caused by a mutation 
in a single underlying gene. To date >3300 disease genes have been described55; 
amongst those >300 genes known to cause PIDs56.
Aside from this most obvious type of genetic disease, there are several mechanisms 
by which genetic variants can contribute to disease phenotypes. First, the variants can 
lead to partial defects on the protein level, as seen in digenic or oligogenic disorders, 
which are caused by a combined downstream effect of variants affecting two or 
more genes57–59. Second, genetic variants can lead to an increased susceptibility to 
infectious diseases. In this case, exposure to an environmental factor (pathogen) is 
required to develop the disease phenotype60. 
The influence of genetic variants on phenotypic traits has a wide spectrum of 
outcomes. On the opposite side of genetic variants causing genetic disorders are 
genetic variants that may have a benefit for the individual carrying this variant. Whilst 
the direct impact of these variants is less profound compared to disease causing 
variants, some of these can spread rapidly through the population and drive our 
evolution61,62.
Genetic inheritance
There are three main forms of inheritance for monogenic genetic disorders; autosomal 
recessive (AR), autosomal dominant (AD) and X-linked inheritance55. AR disorders are 
caused by two genetic variants (homozygous, or compound heterozygous) affecting 
the same gene, disrupting both alleles containing the same genetic information.  AD 
disorders are the cause of a single (heterozygous) genetic variant on one of the two 
alleles, which is inherited from an affected parent, or occurred de novo. X-linked 
or hemizygous disorders are caused by variants on the X chromosome and affect 
predominantly male patients, since they carry only a single X chromosome and are 
therefore more vulnerable for the effect of deleterious mutations28,38,63,64. 
Figure 3. Shows the basic models of monogenic inheritance. Both parents are unaffected 
carriers of an autosomal recessive (AR) trait. Every carrier of an autosomal dominant trait 
is affected; either the genetic variant is inherited from an affected parent, or the variant 
occurred de novo. X-linked inherited traits occur due to mutations on the X chromosome; 
because males have only one X chromosome, the causative genetic mutation can be inherited 
from unaffected mothers. 
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Genetic tests
Many genetic techniques have been developed to detect genetic variation. 
Traditionally, Sanger sequencing has been used to read the coding sequence of one 
gene at a time65. Over the last years, the application of massively parallel sequencing 
has greatly impacted the detection of all types of genetic variation in an affordable, 
reliable and rapid fashion66. At this moment whole genome sequencing (WGS) 
offers the possibility to identify the complete spectrum of genetic variation in an 
individual67. The high costs and the challenging analysis and interpretation of the 
large amounts of genetic data are, however, still limiting widespread application of 
this approach in research and diagnostics29,30.
Whole exome sequencing (WES) is an option to enrich for the 1-2% of protein coding 
parts in the genome prior to sequencing68,69. This in-solution selection for coding 
genes results in more manageable data at lower expenses. WES has revolutionized 
disease gene identification for a large variety of genetic disorders in research70–72. 
To provide molecular diagnoses for genetically heterogeneous disorders, such as 
developmental disorders, WES has also been successfully implemented as a single 
genetic test in diagnostics66,69,70,73,74.  
Targeted sequencing approaches 
Similar to selecting for coding regions prior to sequencing in a WES approach, other 
enrichment strategies select for smaller genomic target regions to reduce sequencing 
costs75. Since 2013 the use of single molecule molecular inversion probes (smMIPs) 
for targeted DNA sequencing has become more advantageous compared to other 
technologies76. The main advantages of smMIPs are the low experimental costs, and 
the random tag that allows tracing of individual capture events (molecules), which is 
particularly useful for reliable molecule counting applications, as well as detection of 
somatic mutations77.  
CNV detection
The karyotype was the first cytogenetic test, capable of detecting aberrant 
chromosome numbers, large deletions, insertions or translocations of DNA78. 
More recently, other methods have become available for detecting smaller copy 
number variants (CNVs). These include targeted multiplex ligation-dependent probe 
amplification (MLPA) analysis for up to 40 genetic regions and hybridization-based 
(SNP) microarray analysis for genome wide testing for CNVs48,79–81. However, this 
type of genetic variation can also be extrapolated from differential sequence read 
coverage statistics based on WGS, WES or more targeted sequencing reactions82,83.
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Aim of the thesis
In this thesis I aim to elucidate the genetic factors involved in various types of 
immunodeficiencies, and use downstream pathways as potential targets for therapy. 
The first sections of the thesis involve exome sequencing for primary 
immunodeficiencies. Chapter 2 describes the diagnostic utility of whole exome 
sequencing (WES) for 249 families suffering from a large variety of PIDs.  27% of all 
families in this heterogeneous patient group received a genetic diagnosis based on 
WES analysis. 
Next to finding known disease causing genes in diagnostics, chapters 3-5 are dedicated 
to identification of novel genetic variants that increase susceptibility to infections. 
Chapter 3 focuses on a single family with three affected individuals suffering from 
autoimmune manifestations. In this family a missense variant in SOCS4 was identified 
that resulted in a functional defect in cytokine suppression.
A very rare case with progressive multifocal leukoencephalopathy (PML) due to a 
JC-virus infection in the brain is described in chapter 4. PBMCs from this patient 
revealed a defect in IFN-γ production upon stimulation with virus-like ligands. Bi-
allelic variants in BAG3, a known interactor of the JC virus, likely influenced the 
disease pathogenesis in this patient.
Chapter 5 reports on ten families of a selected patient group with non-tuberculosis 
mycobacterial infections (pNTM), and a specific slender body habitus (pextus 
excavatum and scoliosis), also reported as Lady Windermere syndrome, were tested 
for genetic variants causing this phenotype. For three of the ten families, WES led to 
identification of missense variants in MST1R. Functional analysis of the downstream 
effect of these variants showed a reduced response of IFN-γ to mycobacterial 
infections.
Agranulocytosis is a medical condition characterized by reduced numbers of white 
blood cells (mainly neutrophils), which results in an increased risk of severe infections. 
Chapter 6 provides insight in agranulocytosis induced by thyrostatic treatment of 
Graves’ disease. Exome sequencing revealed rare missense variants in NOX3 to 
induce this medication induced complication in two families and two sporadic cases. 
At this moment the PBMC cytokine production assay relies on ELISA testing for 
cytokines in the blood supernatant. Chapter 7 of this thesis describes the development 
of a novel method based on mRNA expression analysis that could improve testing for 
cytokine production.  Whilst smMIPs for DNA are commonly used to detect genetic 
variants, this chapter focuses on technical developments for highly multiplexed 
targeted expression analysis with cDNA smMIPs. 
In chapter 8, identification of an in vitro deficit in IFN-γ production in PBMCs from 
patients suffering from severe recurrent mucocutaneous HSV infections, led to 
treatment with available recombinant rIFN-γ replacement therapy, and full recovery 
from their symptoms.
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Diagnostic exome sequencing: A generic test for 
254 patients with primary immunodeficiencies
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Abstract
Background: Diagnosis of primary immunodeficiencies is complex and expensive, yet 
important for the clinical management of the disease. 
Objective: To test the clinical utility and assess the diagnostic yield of whole exome 
sequencing (WES) for patients with primary immunodeficiencies. 
Methods: We have performed WES in a diagnostic setting for 254 PID patients from 
249 families. For the majority of cases the clinical diagnosis was based on clinical 
criteria including rare and/or unusually severe bacterial, viral or fungal infections, 
sometimes accompanied by autoimmune-manifestations, and was interpreted 
in the context of aberrant immune cell populations, aberrant antibody levels, or 
combinations of these factors.  
Results: For 62 patients from 58 families (23%), WES allowed us to provide a molecular 
diagnosis by focusing on disease-causing mutations in well-established primary 
immunodeficiency genes. An exome-wide analysis, considering mutations in novel 
disease genes and tissue-specific defects, resulted in a diagnosis for 10 additional 
families (4%). Altogether, WES granted a diagnosis in 72 patients from 68 families 
(27%). Of all 72 patients that received a genetic diagnosis, 62% had an autosomal 
recessive, 29% autosomal dominant, and 9% X-linked forms of PIDs. 81 (32%) of 
all families were referred from Saudi Arabia, with a diagnostic yield (56%) that was 
substantially higher than that in families of European descent (14%).  The defects 
identified affected only genes involved in immune signaling and immune effector 
mechanisms, rather than genes involved in pathogen recognition. 
Conclusions: WES proves to be a valuable first-tier test for PIDs that enables a 
diagnosis in 27% of families. 
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Introduction
Primary immunodeficiencies (PIDs) are genetically and phenotypically heterogeneous 
disorders characterized by an inborn increased susceptibility to infections. From the 
genetic perspective, over 300 genes have been identified as monogenic causes of 
PIDs84–87. The majority of disease-causing mutations in PID genes are reported to be 
inherited in a purely autosomal recessive (AR) manner (69%), compared to autosomal 
dominant (AD) (20%), AR and AD (5%), and X-linked (XL) (6%) inheritance84–87. 
The phenotype of PID patients ranges from frequent or more severe relatively 
common infections, to serious clinical manifestations due to rare pathogens that 
require immediate clinical care to prevent fatality87. In addition to infections, some 
patients with PIDs can also experience autoimmune or inflammatory conditions, 
as well as malignancy and developmental abnormalities86,87. PIDs are divided in 10 
specific subtypes according to the International Union of Immunological Societies 
(IUIS) PID classification86. The clinical variable phenotype of PIDs makes diagnosing 
patients based on their respective phenotypes often challenging. A recent publication 
describes that 55% of 110 cases were misdiagnosed based on their initial clinical 
characteristics88. In order to prevent this, a more robust and rapid identification of 
the underlying genetic defect would be of great clinical benefit: a ‘genotype-first 
approach’ may provide a molecularly defined diagnosis in a significant amount of 
cases.
Genetic diagnosis of PIDs has been available for a relatively long time, but until now 
it has been complicated by the need to pinpoint the gene of interest: invariably this is 
linked to the correct (and often difficult) clinical diagnosis in the first place. Fortunately, 
the availability of rapid and cheap sequencing methodologies now allows for more 
unbiased genetic diagnostics. Whole exome sequencing (WES) in particular has been 
shown to be an effective tool to elucidate the genetic defect underlying other types 
of heterogeneous disorders89,90. We performed WES to identify the genetic cause 
in patients suffering from a broad range of immune deficits. The identification of 
the genetic basis of PIDs provides insight into the molecular mechanisms of these 
diseases, and may offer customized treatment options91–93. Compared to targeted 
enrichment approach, WES has several major advantages: first, the in silico WES 
gene panel can easily be adjusted upon identification of novel PID genes; second, 
exome wide analysis allows analysis of mutations in novel genes not included in the 
gene panel; third, WES allows genome-wide data access and hence more reliable 
detection of copy number variants (CNVs) and regions of homozygosity (ROH)82,88,94–
97. To reduce the complexity of the analysis and speed up the process, WES can be 
combined with an in silico analysis of a set of already known disease genes72. 
Due to large genetic and phenotypic heterogeneity of PIDs, and the rapidly increasing 
number of PID genes identified over the last years18, we implemented WES as a 
single test in routine diagnostics for PID cases in 2013. Since then, a group of 254 
consecutively referred patients suffering from PIDs have been tested by WES, and 
here we report on their genetic diagnostic outcome.
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Methods
Samples
Between May 2013 and October 2016, 254 patient DNA samples (249 families) from 
the main referring clinics for WES PID cases to our diagnostic laboratory (160 families 
from The Netherlands, 8 from Finland, and 81 from Saudi Arabia) were submitted for 
whole exome sequencing. The average age at testing of our patients was 21 years 
(range from 1 month to 79 years), and the male/female distribution was 117M/137F 
(Details in Supplementary Figure F1 and Table T2). All patients were counseled, and 
provided informed consent for “PID gene panel only” or “gene panel and exome-
wide analysis”. 
Exome sequencing procedure 
Genomic DNA was isolated from whole blood. The experimental workflow of all 
exomes was performed at BGI Europe (Bejing Genome Institute Europe, Copenhagen, 
Denmark). All exonic regions were enriched using the Agilent (Agilent Technologies, 
CA, USA) SureSelect V4 (n = 85) or V5 (n = 169) kit and sequenced using an Illumina 
Hiseq (Illumina, CA, USA) sequencer with 101bp paired end reads to a median 
coverage of >75x.  Sequenced reads were mapped to the hg19 reference genome 
using the mapping algorithm from BWA98 (version 0.5.9-r16) and called by the GATK 
unified genotyper99 (version 3.2-2). All variants were annotated using an in house 
pipeline for exome analysis containing variant and gene specific information, amongst 
this the variant population frequencies from >5,000 in–house exomes89.
Exome variant interpretation
For the gene panel analysis, a bioinformatic in silico filter was applied to select 
for variants affecting the known >300 PID genes56. These variants were filtered for 
coding, non-synonymous variants with population frequencies below 1% in our 
in house database (a database of >5000 exomes), and subsequently evaluated 
regarding their possible pathogenicity. The latter was performed using population 
frequencies43, nucleotide conservation scores (PhyloP), and in silico pathogenicity 
predictions (SIFT100, Polyphen2101, Mutationtaster102) combined with genetic and 
phenotypic overlap with earlier described cases to estimate the contribution of the 
genetic missense variant to disease103.
81% of diagnosis-negative patients provided consent for exome wide analysis. In 
these cases we prioritized all variants obtained from exome sequencing for coding, 
non-synonymous variants with population frequencies of ≤1% in house and ≤5 
homozygous occurrences reported in EXAC43 for autosomal recessive candidates, and 
allele counts of ≤10x in house, or ≤20x in EXAC for autosomal dominant candidates. 
In the exome-wide analysis we focused on variants in recently described genes, and 
genes involved in immune pathways; based on GO terms, mouse knock out model 
phenotypes, or the Kyoto Encyclopedia of Genes and Genomes (KEGG). In addition, 
we filtered for variants in genes with known NCBI protein-protein-interactions with 
known disease genes for similar phenotypes104. 
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All identified genetic variants were judged on their possible pathogenicity based on 
practice guidelines of the Association for Clinical Genetic Science105, and the standards 
and guidelines of the American College of Medical Genetics and Genomics103. We 
only considered variants disease causing for which we found phenotypic103,105 overlap 
with earlier described cases55,85. In addition, we only report variants classified as class 
5 (pathogenic), class 4 (likely pathogenic) (Table 1), or class 3 (uncertain significance) 
(Table 2), because the variants classified as class 2 (likely benign) or class 1 (benign) 
are probably tolerated103,105. 
Homozygosity calling
Regions of homozygosity (ROH) were called using RareVariantVis97. Downstream 
filtering included filtering for larger (≥ 5Mb) homozygous regions, in which ≥ 85% of 
all variants were called to be homozygous. 
CNV calling
Copy Number Variant (CNV) calling was performed using CoNIFER to calculate RPKM-
based absolute Z-scores82,83. Rare copy number variants affecting PID associated 
genes were followed up similarly as the earlier described single nucleotide variants 
(SNVs), small insertions or deletions (indels). 
Validation of detected variants and follow up in families
All reported low quality variant calls (GATK quality by depth <500) were confirmed 
by standard Sanger sequencing. Patients with reported class 3 or class 4 variants 
were counseled to perform further analyses their respective families to obtain more 
genetic evidence (e.g. co-segregation or de novo analysis in autosomal dominant 
inheritance or carrier status analysis of parents and siblings in cases of recessive 
inheritance). 
Immunophenotyping
75% of patients the immunophenotypes were further characterized by determining 
one or more of the functional immunological defects. This included quantification 
of cellular subtypes and antibodies in whole blood, and measurement of cytokine 
production capacity upon in vitro stimulation assays. The latter experiments were 
performed similar to previous reports106. In brief, peripheral blood mononuclear 
cells (PBMCs) were isolated by density centrifugation, and cultured with medium, 
or medium supplemented with immune response inducing ligands or heat-killed 
pathogens. Cytokine production capacity was measured using an enzyme-linked 
immunosorbent assay (ELISA). 
Results
Patient cohort
In total 254 patients from 249 families were referred for exome sequencing. 213 
patients presented with unusual bacterial, viral or fungal infections or autoimmune 
manifestations or combinations of such (Figure 1A, Supplementary Table T1 and T2). 
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Immunophenotype defects were observed in 191 patients; of those 129 patients had 
aberrant blood cell counts, 102 patients showed altered antibody profiles, and 32 
patients revealed irregular cytokine production (Figure 1B, Supplementary Table T1 
and T3). 
Figure 1. Clinical and immunophenotypic overview of the 254 patients included in the 
diagnostic PID cohort, including percentages of patients with genetic diagnoses per subgroup. 
(A) For 213 patients, pathogens and/or autoimmunity were identified. (B) Immunophenotypic 
defects were characterized in 191 patients. Quantification of blood cell numbers, antibody 
levels, and cytokine production aided to determine the genetic diagnosis for these patients. (C) 
The diagnostic yield per cohort based on the country from which the patients were referred. 
Compared to European patients, a higher percentage of patients from Saudi Arabia received 
a genetic diagnosis. 
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Exome sequencing
Whole exome sequencing resulted in an average coverage of 120.7x (Agilent 
SureSelect V4) and 130.2x (Agilent SureSelect V5), covering 95.3% of the exome at 
least 20-fold. For the genes within our gene panel, the average coverage was 132.6x 
and 93% of the base pairs of these genes were covered at least 20 times (details in 
Supplementary Table T4). 
Figure 2. Schematic flowchart overview of the diagnostic exome procedure. Patients from 
249 families were referred for exome sequencing. Gene panel analysis resulted in a genetic 
diagnosis for 23% of families. 81% of diagnosis negative families provided consent for exome-
wide analysis of their data. This analysis resulted in a genetic diagnosis for 10 additional 
families (6% of exome-wide analyzed families, 4% of the entire cohort). Data of the remaining 
149 families are re-analyzed for analysis of novel, and recently published genes.  
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Exome variant interpretation 
For each exome, a bioinformatic in silico panel of genes was applied as a first tier test 
to select for variants affecting the >300 known PID genes56. This yielded on average 
1,542 genetic variants per individual. Additional filtering for coding, non-synonymous 
variants and population frequency ≤1% resulted in 10 to 40 variants per case, which 
were evaluated on their possible pathogenicity.
Disease-causing (class 4 or class 5) mutations were identified in at least one of the 
known PID genes in 58 families (23%). 81% of genetic-diagnosis negative patients 
provided consent for exome-wide analysis. (Re-) analysis for variants in recently 
published PID genes, and genes causing defects in immunological sub-pathways 
yielded an additional (class 4 or class 5) genetic diagnosis for 10 families (6% of all 
exome-wide analyzed samples; 4% of the entire cohort). The combined result of our 
two steps in analysis provided a (class 4 or class 5) genetic diagnosis in 27% of our 
families (Figure 2 and 3, Table 1, provided at the end of this chapter). In total 81 (32%) 
of all 249 families were referred from Saudi Arabia, the diagnostic yield (56%, 45/81 
families) in this sub-cohort that was significantly (P value 2.4e-11, two sided Fisher’s 
exact test) higher than that in families of European descent (14%, 23/168). For an 
additional 12 families (5%), WES analysis only identified potential pathogenic variants 
in known genes (class 3) with overlapping disease phenotypes (Table 2, provided at 
the end of this chapter). In 4 families, two independent genetic mutations in different 
genes were identified which both contributed to the patient phenotypes (Table 1: pt 
83.1, 147.1, 153.1 and 222.1). 
Figure 3. For one Saudi Arabian SCID patient  (146.1) WES based homozygosity mapping 
identified large homozygous region on chromosome 19. Further analysis of JAK3 revealed a 
homozygous deletion of exon 10.
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Homozygosity calling
We identified in total 1,399 large (≥ 5 Mb) homozygous regions in 165 of 254 patient 
exomes. 1,067 of these regions were identified in 81 patients from Saudi Arabia, 
318 regions in 68 Dutch patients, and 14 regions in 6 cases from Finland. 33 (82%) 
of all causative homozygous mutations in autosomal recessive genes were present 
in these homozygous regions. In one Saudi Arabian case suffering from SCID (T-, B+, 
NK-; Table 1, 146.1), homozygosity mapping revealed 3 large homozygous regions 
on chromosome 19 spanning in total 32.8Mb. One on these regions overlapped 
with the genetic location of JAK3; mutations in which are known to cause SCID. In 
depth analysis of JAK3 resulted in identification of a homozygous deletion of exon 10 
(Figure 3).
Figure 4. All 312 genes of the PID gene list were subdivided based on the function of their 
respective molecules. This resulted in 23 genes encoding for (pathogen recognition) receptors, 
115 genes encoding for  (signaling) adaptors and 174 genes encoding for effectors. The genes 
for which a disease causing mutation was identified in our cohort are marked in red. After 
WES analysis, there was a significantly (P value <0.0009 Chi-square test) higher number of 
adaptor genes (36) identified, compared to receptor 0, or effector genes 23.  
Molecular link to known cellular functions 
Interestingly, while the known genetic defects leading to immunodeficiencies can 
be broadly assigned to genes involved in pathogen recognition (receptors), immune 
signaling (adaptors) or effector immune factors (effectors), the defects identified by 
WES in our cohort only affected genes involved in immune signaling (adaptors) and 
immune effector mechanisms (effectors), rather than genes involved in pathogen 
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recognition (receptors) (Figure 5). There was a significant (P<0.0009, Chi-square test) 
relative increase in the defects identified in adaptors, compared to receptors and 
effectors.
Discussion
Here we show that the clinical and genetic heterogeneity of PIDs makes WES a 
valuable first-tier diagnostic tool for identification of genetic defects underlying PIDs. 
In this study we present routine diagnostic exome sequencing in a phenotypically 
heterogeneous group of 254 patients from 249 families. WES analysis led to 
identification of causative genetic mutations in established disease-causing genes in 
68 families (27%) and genetic variants likely contributing to disease in 12 families (5%). 
In four of the patients a dual genetic diagnosis was made based on two independent 
genetic mutations; this confirms the relative high prevalence of cases with two rare 
disorders similar to reports for developmental phenotypes108. 
The diagnostic yield in our study is in line with other studies describing targeted gene 
panel or exome wide analyses for heterogeneous groups of PID patients88,94,109,110. 
Phenotypic selection for more homogeneous patient cohorts with specific or more 
severe immunological defects results in increased percentages of diagnoses95,111,112. 
In addition, the PID-associated genes selected for the gene panels, and the stringency 
of variant prioritization, result in (minor) differences amongst these studies.
We observed a higher percentage of genetic diagnosis for families referred from 
Saudi Arabia (56%) compared to families from Europe (Figure 2). This significant (P 
value 2.4e-11, two sided Fisher’s exact test) difference likely arises from two major 
reasons. Firstly, the Saudi Arabian patients are referred for WES from a pediatric 
department at a very young age (average age of 5.5 years compared to 29.3 years 
for the European cohort, Figure 5A), which creates a selection bias towards more 
severely affected patients. Secondly, the increased level of consanguinity in the Saudi 
Arabian population creates a bias towards homozygously inherited immune defects. 
We detected homozygous mutations in 40/249 families, of which 33/81 were from 
Saudi Arabian families which have a significantly (P value <0.0001, Welch’s t-test) 
higher number of genomic homozygous regions (Figure 5B, Supplementary Table T5). 
Considering the percentage of PIDs caused by AR inheritance (69%), that influenced 
the percentage of families for which we could provide a genetic diagnosis. 
Not all homozygous disease-causing mutations described in this study are SNVs or 
indels commonly identified by WES. Homozygosity mapping on exome data can also 
reveal regions in which homozygous copy number variants (CNVs) may occur. As an 
example, we focused on a homozygous region on chromosome 19 and could identify 
a disease-causing homozygous single exon deletion (patient 146.1, JAK3 exon 10, 
Figure 3) in one SCID patient. The contribution of CNVs such as single exon deletions 
to disease are underestimated in many genetic analyses for PIDs88.  
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Figure 5. Differences in percentages diagnostic yield based on age and homozygous regions. 
(A) The age distribution of the entire cohort, the European cohort, the Saudi Arabian cohort 
and the cases with a genetic diagnosis. (B) The number of large (>5Mb) homozygous regions 
per cohort. The increased number of homozygous regions in the Saudi Arabian cohort 
influenced diagnostic yield of the overall cohort.
Next to the AR inherited variants, exome sequencing provided heterozygous rare and 
private variants that affect known PID (-associated) genes. In case a novel genetic 
variant did not pass the conservative guideline thresholds103,105, the variant was not 
considered pathogenic in this family. We acknowledge that these stringent criteria 
limited the diagnostic outcome of exome sequencing in our cohort at this stage, but 
feel this is important in order to prevent misdiagnoses. Systematic trio analysis74 and 
functional characterization of each novel missense variant are warranted to gain 
further insight in the disease mechanism on the individual level.
In this study most pathogenic (class 5) mutations were discovered in AR PID genes. 
There is a bias towards AR disease because all known AR PID genes are caused by 
genetic Loss-of-Function (LoF) mutations, and most LoF mutations are considered 
pathogenic in the classification. In contrast, the majority of AD inherited PIDs are 
the result of Gain-of-Function (GoF) or dominant-negative mechanisms113, and are 
therefore more likely the result of missense variants, or truncating variants affecting 
the last exon or the last 50 nucleotides of the penultimate exon of the gene103.
30
Ch
ap
te
r 2
These variants are only considered pathogenic (class 5) in case the exact same 
genetic variant was described earlier. Generally these types of variants are less likely 
pathogenic since the altered RNA is not predicted to undergo nonsense mediated 
decay and the altered protein is expressed36. 
WES identified more disease-causing mutations in specific subgroups of patients 
compared to others. Similar to earlier reports88, the more severely affected 
patients were more likely to receive a genetic diagnosis. First, evaluation of clinical 
characteristics revealed that the patients with a higher burden of infections caused 
by multiple pathogens and/or autoimmune manifestations were significantly (P value 
0.0003, two sided Fisher’s exact test) more likely to receive a genetic diagnosis (39%; 
47/119), compared to patients with infections restricted to a single pathogen that is 
generally expected to have more subtle immunological defects (15%; 14/94)(Figure 
1A). Moreover, patients with patent defects in important immune cells populations 
are expected to have more clinical manifestations. In line with this, a significant 
(P value 0.0008, two sided Fisher’s exact test) higher percentage of patients with 
aberrant blood cell populations received a genetic diagnosis (38%; 49/129), 
compared to patients with normal blood cell populations (18%; 23/125) (Figure 1B). 
In addition, an interesting observation was that only genes encoding for immune 
signaling adaptors or immune effectors were identified in our study, rather than the 
known genes in pathogen recognition receptors. Conceptually this may be due to the 
complexity and redundancy of receptors that recognize invading microorganisms, 
while the signaling and effector mechanisms often converge and are common for 
the different immune stimulatory pathways. In this respect, adaptor molecules 
often mediate multiple immunological pathways, thus explaining the more severe 
phenotype of these patients. 
Altered immunophenotypic spectrum of known mutations
The exact same pathogenic mutations as previously reported in literature, were 
identified in 40 patients from our cohort. In 36 (90%) of these patients the presented 
immunophenotypic characteristics were similar to earlier described cases. However, 
WES revealed the same TRAF3 variant p.(R118W) as described in one patient with 
HSV encephalitis107 in 4 patients within our cohort. Only one of the patients carrying 
a (paternally inherited) TRAF3 variant (Table 2: 76.1) suffered from HSV infections, 
which could also be caused by a (maternally inherited) frameshift mutation in GATA2 
p.(R86fs/wt)114. For the other cases, due to the lack of phenotypic overlap, the TRAF3 
variants were not considered causative for the immune deficiency in the patients 
(Table 1: 44.1, 99.1 and 217.1). In addition, this variant is relatively common in the 
population45 (population frequency of 0.3% in EXAC and our in house database) and 
appeared slightly more frequent in this study (1.5%). Due to the high population 
frequency and the disease heterogeneity we speculate that the TRAF3 variant 
p.(R118W) might result in a minor broad immunomodulatory defect, and additional 
genetic and environmental factors further determine the clinical presentation. We 
therefore considered concluded that this specific variant was not solely the cause of 
disease in these patients. 
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156 of currently diagnosis-negative patients provided additional informed consent 
for exome wide analysis of their data. For 10 of these patients, we identified disease-
causing variants in genes that were described only recently, or genes known to affect 
specific sub-pathways that have been previously published as a genetic cause of 
similar phenotypes. This is exemplified by one case (70.1) suffering from recurrent 
respiratory tract infections for which WES identified a homozygous mutation in the 
first amino acid of the protein RSPH9 p.(M1T/M1T). The genotype-first approach led 
to identification of the causative mutation leading to ciliary dyskinesia in this patient, 
which retrospectively fits the clinical diagnosis. Re-analysis of exome data for novel 
disease genes, as well as further functional, co-segregation and overlap analysis will 
ultimately lead to additional genetic diagnoses for a subset of these patients. 
In conclusion, exome sequencing proves to be a valuable first tier test for routine 
diagnostics in PIDs providing a genetic diagnosis in 27% of patients. Further studies 
to assess its value, as well as extension to full genome sequencing approaches, are 
warranted. 
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Patient ID Gender Age Patient Clinical diagnosis 
referred from (if known)
1.1 F 50 Netherlands APECED
29.1 F 28 Netherlands PAPA syndrome 
32.1 F 11mo Netherlands  Hermansky-Pudlak syndrome 2
33.1 M 53 Netherlands
46.1 F 15 Finland Chronic mucocutaneous candidiasis 
52.1 M 4 Netherlands Swachman-Diamond
61.1 F 12 Saudi Arabia
69.1 M 9 Netherlands Kabuki syndrome
70.1 F 27 Netherlands Ciliary Diskinesia
76.1 F 29 Netherlands Herpes simplex virus - associated
82.1 F 4 Saudi Arabia
83.1 M 2 Saudi Arabia Bare Lympocyte Syndrome II
84.1 M 9 Saudi Arabia Severe eczema
94.1 F 8 Saudi Arabia
100.1 F 8 Saudi Arabia IgG deficiency 
103.1 M 48 Netherlands CVID
105.1 M 5mo Saudi Arabia SCID, HLH
106.1 M 5mo Saudi Arabia Bare Lympocyte Syndrome II
107.1 M 21 Saudi Arabia XL-Thrombocytopenia
112.1 M 8mo Saudi Arabia SCID , OMEN syndrome 
113.1 F 13 Saudi Arabia Dyskeratosis congenita
114.1 F 8mo Saudi Arabia SCID
115.1 F 8mo Saudi Arabia SCID, ZAP70 deficiency
116.1 M 52 Netherlands CVID, Episodic vaculitis 
122.1 F 19 Saudi Arabia Gray platelet syndrome, B12↑
126.1 F 11 Saudi Arabia Hypogammaglobulinemia
127.1 F 10 Saudi Arabia Bronchiactasis, HGG
127.2 F 12 Saudi Arabia Hypogammaglobulinemia
129.1 F 8mo Saudi Arabia Chronic granulomatous disease
134.1 F 4 Finland ADA2 deficiency
138.1 M 1 Saudi Arabia Hypogammaglobulinemia
138.2 F 4 Saudi Arabia Hypogammaglobulinemia
142.1 F 20 Netherlands
145.1 F 5mo Saudi Arabia
146.1 M 11mo Saudi Arabia SCID, HLH
147.1 F 6 Saudi Arabia ALPS
148.1 M 6 Saudi Arabia C8A deficiency
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Mutation Variant class Mutation Identified # Hom Reference 
regions
AR (hom) Class 5 AIRE p.(R257*/R257*) 10 115
AD Class 5 PSTPIP1 p.(E250K/wt) 1 116
AR (CH) Class 4 (exome wide) AP3B1 p.(K59fs/D613fs) 0 117,118
AD Class 4 CXCR4 p.(S343fs/wt) 3 119
AD Class 4 STAT1 p.(Q243E/wt) 2 106,120
AD Class 5 TERC n.(37A>G/wt) 0 121
AD Class 4 (exome wide) CTLA4 p.(G146R /wt) 21 122
AD Class 5 KMT2D p.(E5425K/wt) 0 123,124
AR (hom) Class 4 (exome wide) RSPH9 p.(M1T/M1T) 7‡ 125
AD Class 5 GATA2  p.(R86fs /wt) 0 114
AR (hom) Class 5 LRBA p.(T1587fs/T1587fs) 21‡ 126
AR (hom) Class 5 RFXANK p.(D121V/D121V) 17‡ 127
AD Class 5 INSR p.(R145C/wt) 17 128
AD Class 4 SAMHD1 p.(F329fs/wt) 4 129,130
AR (CH) Class 5/Class 3 FANCA p.(L910fs/C1142Y) 11 131
AD Class 5 PIK3R1 c.(1425+1G>T/ wt) 7 132,133
AD Class 5 (exome wide) NFKB1 p.(S302fs/wt) 0 134
XL Class 5 IL2RG p.(I273fs) 3 135
AR (hom) Class 5 RAG1 p.(K186fs/K186fs) 14 136
XL Class 5 WAS p.(T48A) 16 137,138
AR (hom) Class 5 RAG1 p.(K186fs/K186fs) 27‡ 136
AR (hom) Class 4 WRAP53 p.(R387C/R387C) 18‡ 139
AR (hom) Class 4 DCLRE1C p.(P117Q/P117Q) 15‡ 140
AR (hom) Class 4 ZAP70 p.(S524C/S524C) 18‡ 141
AR (hom) Class 5 (exome wide) CECR1 p.(L503fs/L503fs) 32 142
AR (hom) Class 5 ITGA2B  p.(R1026W/R1026W) 8‡ 143,144
AR (hom) Class 5 DNMT3B p.(V836M/V836M) 11‡ 145,146
AR (hom) Class 5 ZBTB24 p.(Q498fs/Q498fs) 10‡ 147,148
AR (hom) Class 5 ZBTB24 p.(Q498fs/Q498fs) 13‡ 147,148
AR (hom) Class 5 CYBA  c.(58+4-7del/58+4-7del) 6 149
AR (hom) Class 5 (exome wide) CECR1 p.(R169Q/R169Q) 5 142
AR (hom) Class 5 AK2 p.(A182D/A182D) 11‡ 110,150
AR (hom) Class 5 AK2 p.(A182D/A182D) 13‡ 110,150
AD Class 5 (exome wide) CFTR p.(W1282*/wt) 0 151,152
AR (hom) Class 5 (exome wide) CFTR c.(579+1G>A/579+1G>A) 25‡ 151,152
AR (hom) Class 5 (exome wide) JAK3 Ex10 Deletion 10‡ 153,154
AR (hom) Class 4 CASP8 p.(A155S/A155S) 15‡ 155
AD Class 5 (exome wide) CBL c.(1228-2A>G/wt) 156
AR (hom) Class 5 C8A p.(Y210*/Y210*) 12‡ 157
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Patient ID Gender Age Patient Clinical diagnosis 
referred from (if known)
149.1 F 55 Netherlands Chronic mucocutaneous candidiasis 
153.1 M 15 Saudi Arabia T-cell acute lymphoblastic leukemia
154.1 M 3mo Saudi Arabia SCID, BCGitis
156.1 F 3 Saudi Arabia Congenital Neutropenia, Myelofibrosis
159.1 M 1 Finland X-linked thrombocytopenia
160.1 F 2 Saudi Arabia Swachman-Diamond, CD3 deficiency
161.1 M 2 Saudi Arabia Chronic granulomatous disease
162.1 M 9 Netherlands
165.1 F 8 Saudi Arabia Chronic granulomatous disease
168.1 M 3 Saudi Arabia Chronic granulomatous disease
169.1 M 57 Netherlands CVID, Malignancies
173.1 F 12 Netherlands Recurrent urticaria
185.1 F 8mo Saudi Arabia Bare Lymphocyte Syndrome  II
186.1 M 6 Saudi Arabia Microcytic anemia
188.1 M 6mo Saudi Arabia TORCH
189.1 F 4 Saudi Arabia Hypogammaglobulinemia
189.2 M 1 Saudi Arabia Hypogammaglobulinemia
190.1 M 4 Saudi Arabia
193.1 M 38 Saudi Arabia
195.1 M 1mo Saudi Arabia Transaldolase deficiency
196.1 M 7 Saudi Arabia Hypogammaglobulinemia
198.1 M 2 Saudi Arabia Hypogammaglobulinemia
199.1 M 3 Saudi Arabia Burkitts lymphoma, SCID
202.1 F 7 Saudi Arabia ALPS
204.1 M 6mo Saudi Arabia Hypogammaglobulinemia
213.1 M 3mo Netherlands Interstitial Lung disease
213.2 F 1 Netherlands
217.1 F 23 Netherlands Chronic granulomatous disease
220.1 F 16 Netherlands
222.1 M 29 Netherlands Complement deficiency
227.1 M 57 Netherlands Familial Cold Auto inflammatory Syndrome
236.1 M 6 Saudi Arabia Non-immune hemolytic anemia
239.1 F 4mo Saudi Arabia
240.1 F 2mo Saudi Arabia
242.1 F 4 Saudi Arabia  Hyper-IgE syndrome
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Mutation Variant class Mutation Identified # Hom Reference 
Inheritance regions
AD Class 5 STAT1 p.(Q271P/wt) 1 106,120
AR (hom) Class 5 NBN p.(Y197fs/Y197fs) 22 158
AD Class 4 RPL5 p.(G140S/wt) 159
AR (hom) Class 4 RAG2 p.(K106E/K106E) 10‡ 136
AR (hom) Class 4 VPS45 p.(L410P/L410P) 7‡ 160
XL Class 5 WAS p.(V75M) 0 137,138
AR (hom) Class 4 PRF1 p.(R410P/R410P) 24 161
AR (hom) Class 5 CYBA p.(A117E/A117E) 6‡ 149
AD Class 5 TNFRSF13B p.(C104R/wt) 0 162
AR (hom) Class 5 CEBPE p.(R135*/R135*) 13‡ 163
XL Class 5 CYBB p.(E347fs) 13 149,164
XL Class 4 MAGT1 p.(S24*) 0 165
AD Class 5 NLRP1 p.(L332fs/wt) 0 166
AR (hom) Class 5 RFX5 p.(V378fs/V378fs) 1‡ 167
AD Class 4 HBB  p.(Q7V/wt) 4 168
AR (hom) Class 4‡ RNASEH2B p.(D119G/D119G) 6‡ 169
AR (hom) Class 5 DNMT3B p.(V836M/V836M) 18‡ 145,146
AR (hom) Class 5 DNMT3B p.(V836M/V836M) 14‡ 145,146
AR (hom) Class 5 AK2 p.(A182D/A182D) 7‡ 110,150
AR (hom) Class 5 C7 p.(G378R/G378R) 13‡ 170
AR (hom) Class 5 (exome wide) TALDO1 p.(Q265fs/Q265fs) 26 171,172
AR (hom) Class 5 DNMT3B p.(V836M/V836M) 10 145,146
AR (hom) Class 5 JAK3 p.(R403H/R403H) 6‡ 153,154
AR (hom) Class 4 LCK p.(R480fs/R480fs) 17‡ 173
AD Class 5 CARD11 p.(G123S/wt) 17 174,175
AR (hom) Class 5 DNMT3B p.(V836M/V836M) 21‡ 145,146
AR (hom) Class 4 DHFR p.(G21R/G21R) 0 176
AR (hom) Class 4 DHFR p.(G21R/G21R) 1 176
AR (hom) Class 5 NCF2  p.(Y293*/Y293*) 4‡ 177
AD Class 4 CARD11 p.(T43P/wt) 1 174,175
AR (hom) Class 5 C7 p.(G379R/G379R)   11‡ 170
AD Class 4 MEFV p.(M680I/wt) 11 178
AD Class 5 NLRC4 p.(S445P/wt) 1 179,180
XL Class 5 G6PD p.(V461G) 11 181
AD Class 4 ANK1 p.(Q1313*) 1 182
AR (hom) Class 5 MTHFD1 p.(R173C/R173C) 39‡ 183,184
AD Class 5 STAT3 p.(V713M) 3 185,186
36
Ch
ap
te
r 2
Table 1. Shows all causative mutations identified in 72 patients from 68 families suffering 
from primary immunodeficiencies. These 72 are part of a diagnostically tested cohort of 254 
PID patients from 249 families. The “variant class” column also indicates variants that were 
identified by exome-wide analysis. ‡the homozygous mutation was identified in one of the 
large homozygous regions.  Abbreviations used: AR = Autosomal Recessive; AD = Autosomal 
Dominant; XL = X-linked; hom = homozygous; CH = Compound heterozygous; APECED = 
Autoimmune PolyEndocrinopathy-Candidiasis-Ectodermal-Dystrophy; CVID = Common 
Variable Immunodeficiency; HLH = Hemophagocytic Lymphohistiocytosis; PAPA = Pyogenic 
Arthritis Pyoderma gangrenosum and Acne; SCID = Severe Combined Immunodeficiency; 
TORCH =  toxoplasmosis, other infections, rubella, cytomegalovirus infection, and herpes 
simplex.
Patient ID Age Patient Clinical diagnosis
referred from (if known)
8.1 M 4 Saudi Arabia
19.1 M 55 Netherlands
28.1 M 26 Netherlands Myelodysplastic syndrome (<50%)
42.1 F 44 Netherlands Hyper-IgE syndrome
53.1 M 43 Netherlands Unexplained fever
76.1* F 29 Netherlands Herpes simplex virus - associated
78.1 M 5 Saudi Arabia Short bowel disease
95.1 F 23 Netherlands Hidradenitis suppurativa
132.1 M 70 Netherlands Allergic bronchopulmonary aspergillosis
152.1 F 8mo Saudi Arabia Immunodeficiency 26
178.1 F 16 Netherlands Hypogammaglobulinemia
181.1 F 12 Netherlands Sjögren syndrome
191.1 M 44 Netherlands Common variable immunodeficiency
209.1 M 6mo Netherlands Group B streptococcus sepsis conjunctivitis
221.1 F 23 Netherlands Autoimmune lymphoproliferative syndrome
233.1 F 36 Netherlands Common variable immunodeficiency
249.1 M 11 Netherlands Autoinflammatory disease
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Table 2.  Shows variants of unknown significance (class 3) and variants in TRAF3 identified in 
17 patients suffering from primary immunodeficiencies. These 17 are part of a diagnostically 
tested cohort of 254 PID patients from 249 families. The “variant class” column also indicates 
variants that were identified by exome-wide analysis.*Only 1 (76.1) of 4 patients carrying a 
variant in TRAF3 suffered from infections with herpes simplex virus, which might also result 
form a mutation in GATA2 p.(R86fs/wt). ‡the homozygous mutation was identified in one of the 
large homozygous regions. Abbreviations used: AR = Autosomal Recessive; AD = Autosomal 
Dominant; XL = X-linked; hom = homozygous; CH = Compound heterozygous. 
Supplementary information: 
All supplementary information of this chapter is provided online, and can be reached 
using this link: https://drive.google.com/open?id=0B4sckPZ9RGdiclk1YkF4c1Q0QU0
Genetic Inheritance Variant Variant Identified # hom Reference
diagnosis Class regions
Possibly AR (hom) Class 3 (exome-wide) RNF31 p.(L156H/L156H) 15‡ 187
Possibly XL Class 3 (exome-wide) CYBB p.(L25F) 0 188
Possibly AR (hom) Class 3 (exome-wide) YARS2 p.(L61V/L61V) 15‡ 189
No AD Class 5 TRAF3 p.(R118W/wt) 0 107
Possibly AD Class 3 (exome-wide) NFKB1 p.(N519D/wt) 2 134 
Other* AD Class 5 TRAF3 p.(R118W/wt) 0 107
Possibly AR (hom) Class 3 SLC37A4 p.(H349Y/H349Y) 18‡ 190
No AD Class 5 TRAF3 p.(R118W/wt) 1 107
No AD Class 3 TRAF3 p.(V240I/wt) 1 107
Possibly AR (CH) Class 3/Class 3 PRKDC p.(S187G/W4038C) 1 191
Possibly AR (CH) Class 3/Class 3 (exome-wide) DOCK2 p.(L683F/G1087S) 1 192
Possibly AD Class 3 (exome-wide) PRKCD p.(M458R/wt) 0 N/A
Possibly AD Class 3 (exome-wide) PIK3CD p.(R953C/wt) 1 132
No AD Class 5 TRAF3 p.(R118W/wt) 1 107
Possibly AD Class 3 FAS c.(30+3G>C/wt) 2 193
Possibly AD Class 3 CARD11 p.(C1060Y /wt) 0 174,175
Possibly AD Class 3 TERT p.(T726M/wt) 1 194
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Abstract
 
Objective: The aim of our study was to find the genetic and immunological defects 
underlying familial manifestations of an autoimmune disorder. 
Methods: Whole exome sequencing was performed on the index patient with various 
manifestations of autoimmunity, including hypothyroidism, vitiligo and alopecia. 
PBMCs and DNA of family members were used for functional and genetic testing of 
the candidate variants obtained by Sanger sequencing. 
Results: Exome sequencing identified 233 rare, coding and non-synonymous variants 
in the index patient, five were highly conserved and affect genes that have a possible 
role in autoimmunity. Only a heterozygous missense mutation in suppressor of 
cytokine signaling-4 (SOCS4) co-segregated with the disease in the family. SOCS4 is a 
known inhibitor of epidermal growth factor (EGF) receptor signaling, and functional 
studies demonstrated a specific up-regulation of the EGF-dependent immune 
stimulation in affected family members. 
Conclusions: We present a family with autoimmune disorders, most likely resulting 
from dysregulated immune responses due to mutations in SOCS4.
Chapter 3
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Introduction
Autoimmune disorders are characterized by loss of immunological tolerance towards 
self-antigens, leading to inappropriate activation of the immune system and, thereby, 
collateral tissue damage195. Genetic predisposition is an important part of the complex 
aetiology of autoimmune disorders, as demonstrated by the fact that many genetic 
variants have been associated with an increased risk of autoimmunity. The majority 
of these variants contribute significantly but to a limited extent to the overall risk, 
with low genetic penetrance196–198. However, in familial cases of autoimmunity, there 
is less interindividual genetic variation, which allows for identification of genetic 
determinants with a strong influence on the risk of autoimmunity. This may provide 
novel insight into the biological pathways important in the pathogenesis of this 
disorder.
Here, we describe a family in which the index patient and her brother and mother 
were affected by autoimmune manifestations. Exome sequencing was performed on 
DNA obtained from the index patient with the aim of identifying the genetic cause of 
the autoimmune phenotype in this family69. Subsequently, we reduced the number 
of candidate genetic variants by filtering for rare variants involved in immunological 
pathways. To confirm our findings, Sanger sequencing of these variants was 
performed to check the co-segregation with autoimmunity in the family. In addition, 
the most likely candidate variant was investigated immunologically to functionally 
validate the genetic findings.
Materials and methods
Study subjects
A 12-year-old patient was seen at the Departments of Pediatric Endocrinology and 
Pediatric Immunology of the Academic Medical Center, University of Amsterdam with 
symptoms of autoimmune hypothyroidism, alopecia totalis and nail dystrophy of all 
twenty nails. The patient came from a consanguineous family of Turkish descent. 
Her mother and father were first cousins (Figure 1). Detailed autoimmune diagnostic 
evaluation, including autoantibody tests for systemic autoimmune disease, provided 
no diagnostic information (antinuclear antibody, anti-extractable nuclear antigens, 
antidouble-stranded DNA and rheumatoid factor were all negative). Tests for 
antithyroperoxidase antibodies were positive (>3000 kU L−1), but for antithyroglobulin 
and thyroid-stimulating hormone receptor antibodies were negative. The mother, 
grandmother and great grandfather of the index patient also had a history of 
hypothyroidism. Her brother had extensive vitiligo, whereas her father had no 
symptoms of autoimmunity.
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different symptoms of autoimmunity. One grandmother, grand-grandfather and an aunt 
were also known with thyroid disease. The SOCS4 p.T266M variant co-segregates with the 
autoimmune phenotype in the family. DNA was only available from individuals III.1, III.2, IV.1 
and IV.2. Seven siblings of generation II were not tested for autoimmune manifestations.
Genetic analysis by whole-exome sequencing
DNA from the index patient was isolated from whole blood, enriched with SureSelect 
v2 exome (50 Mb) (Agilent Technologies, Santa Clara, CA, USA) and sequenced (5500XL 
sequencer; Life Technologies, Foster City, CA, USA). Sequence reads were mapped 
to the reference human genome (hg19) using LifeScope v2.1 (Life Technologies). 
Variants were called using high stringency settings and annotated with an in-house 
pipeline90 containing information from dbSNP134. Variant filtering was applied as 
previously reported30,73,90,199. In brief, we only selected variants affecting coding 
exons, microRNAs and canonical splice sites. Subsequently, synonymous variants 
were filtered out, and only rare variants (frequency of <0.25% in both dbSNP134 and 
our in-house database containing >5000 exomes) with high quality were reported 
(Supplementary Table S1).
All genes with rare non-synonymous variants were systematically checked for 
involvement in immunological pathways or phenotypes (gene ontology term, mouse 
knockout phenotype, Kyoto Encyclopedia of Genes and Genomes association with 
infectious disease or Jak-STAT pathway) or the interferon pathway. The latter check 
was based on an NCBI gene search using the term ‘interferon’ (Supplementary Table 
S1).
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Genetic co-segregation analysis by Sanger sequencing
DNA from all family members was isolated from whole blood using the DNeasy 
kit (Qiagen, Venlo, the Netherlands). All candidate variants retrieved from exome 
sequencing were subsequently validated by Sanger sequencing, and co-segregation 
with autoimmunity was analyzed.
Immunological testing
Isolation and stimulation of peripheral blood mononuclear cells (PBMCs) were 
performed as previously described106. In short, venous blood was collected into 
EDTA-containing tubes and PBMCs were isolated by density centrifugation of blood 
[diluted 1 : 1 in phosphate-buffered saline (PBS)] over Ficoll-Paque (Pharmacia Biotech 
AB, Uppsala, Sweden). Cells were washed three times in PBS and re-suspended in 
RPMI 1640 medium (Dutch modification) (Gibco, Paisley, UK) supplemented with 
50 mg L−1 gentamicin, 2 mmol L−1 L-glutamine and 1 mmol L−1 pyruvate. Cells were 
counted in a Coulter Counter Z (Beckman Coulter, Mijdrecht, the Netherlands) and 
adjusted to 5 × 106 cells mL−1. PBMCs (5 × 105) in a volume of 100 μL were added 
to round-bottom 96-well plates (Greiner, Alphen aan den Rijn, the Netherlands) 
and incubated with either 100 μL culture medium (negative control) or one of the 
stimuli before measurement of cytokine production [24 h incubation for IL-1β, IL-6, 
tumor necrosis factor (TNF)-α and interferon (IFN)-γ and 7 days for IL-17]. Cytokine 
production was measured in the supernatants by enzyme-linked immunosorbent 
assay (ELISA; Sanquin, Amsterdam, the Netherlands) after stimulation of PBMCs 
with lipopolysaccharides (LPS) derived from Escherichia coli (10 ng mL−1), ligand for 
TLR2 (Pam3Cys; 10 μg mL−1) or epidermal growth factor (EGF; 10 μg mL−1) in family 
members carrying the variant, and compared with that of three unrelated healthy 
individuals and the patient’s (unaffected) father. All experiments were performed in 
duplicate.
Expression analysis
Stimulated and un-stimulated PBMCs from patients and control subjects were 
assessed. mRNA was isolated using Trizol (Life Technologies), and cDNA synthesis was 
performed using Superscript III (Life Technologies). Two primer pairs for each gene 
of interest were selected from the primerbank database from Harvard University 
(http://pga.mgh.harvard.edu/primerbank/). Quantitative analysis was performed by 
quantitative PCR (7900 Fast Real-Time PCR System; Life Technologies), and expression 
was calculated using the ΔΔct method200.
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Results
Genetic analysis of whole-exome sequencing
Exome sequencing of DNA obtained from the index patient was performed and 
provided 6.3 Gb of mapped sequencing data, resulting in a median coverage 
of the exome of 71.5-fold with at least 20-fold coverage for 78.3% of the exome 
(Supplementary Table S1). Standard variant filtering (Supplementary Table S1) 
resulted in 233 rare, non-synonymous and canonical splice site variants of high 
quality. From these 233 variants, we selected the candidate gene variants filtering for 
gene function, nucleotide conservation and population frequency (see ‘Methods’ for 
further details). This analysis resulted in five genetic variants that were moderately 
to highly conserved (PhyloP>2.5) and affected genes known to play a role in (auto-) 
immunity. Of these five, only the p.T266M SOCS4 variant co-segregated with disease 
within the family (Figure 1, Table 1 and Supplementary Figure S1). This SOCS4 residue 
is highly conserved both at the nucleotide (c.797C>T; PhyloP 6.26) and amino acid 
levels from humans to zebra fish (Figure 2). According to in silico prediction programs 
such as SIFT, PolyPhen and MutationTaster, the identified variant is predicted to be 
‘deleterious’, ‘probably damaging’ and ‘disease causing’.
Additional filter Gene name mRNA AminoAcid PhyloP* Inheritance
gene/protein function change change
OMIM Disease gene; (AR) TG c.3149G>T p.W1050L 4.207 Father
Autoimmune thyroid disease 
OMIM Disease gene; 
Autoinflammatory syndrome
NLRP3 c.2519C>T p.T954M 3.543 Father
Immune response; LIFR c.3279G>C p.N1093K 4.47 Father
KEGG name Jak-STAT pathway
Immune response; IL7 c.165A>C p.I55M 2.536 Father
KEGG name Jak-STAT pathway
Immune response; SOCS4 c.797C>T p.T266M 6.273 Mother
KEGG name Jak-STAT pathway
Table 1. The genetic variants identified in the affected patient, selected for their function in 
the immune system. Disease co-segregation analysis of all selected variants was determined 
by sequencing these variants in the parents and affected brother. OMIM; Online Mendelian 
Inheritance in Man; AR, Autosomal recessive; KEGG, Kyoto Encyclopedia of Genes and 
Genomes; *PhyloP relates to nucleotide conservation in 46 vertebrate species. * PhyloP 
relates to nucleotide conservation 46 Vertebrate species.
The population frequency of this variant is very low, as only three other individuals 
(two families) have been reported with the same variant in databases containing 
exome data of 11 500 individuals [combined data from our in-house database and 
the Exome Variant Server (EVS), NHLBI GO Exome Sequencing Project (ESP), Seattle, 
WA, USA (http://evs.gs.washington.edu/EVS/) (25/08/2014)]. Additional assessment 
of 50 exomes from a population of Turkish origin did not reveal the presence of this 
mutation (data not shown).
44
Ch
ap
te
r 3
Figure 2. Schematic overview of SOCS4. The variant in our index patient is shown at the 
protein and mRNA levels, and compared to sequences (from various other species) that were 
obtained from the University of California, Santa Cruz genome browser (http://genome.ucsc.
edu/). The mutated nucleotide and amino acid sequences are shown to be highly evolutionary 
conserved from humans to zebra fish. SOCS, suppressor of cytokine signalling; SH2 domain, 
Src Homology 2 domain.
Immunological validation
SOCS4 is a member of the suppressor of cytokine signaling family of cytokine receptor 
modulators. Specifically, SOCS4 modulates signaling through the EGFR. Therefore, we 
investigated whether the mutation described has any effect on the EGF-dependent 
stimulation of cells. To do so, PBMCs isolated from the index patient, the affected 
mother, the unaffected father and three unrelated healthy control subjects were 
stimulated with EGF, or the ligands for TLR2 (Pam3Cys) and TLR4 (LPS). IL-1β, IL-6, 
TNFα and IFN-γ production by PBMCs was measured in the supernatants after 24 h, 
and IL-17 production after 7 days of stimulation. We did not observe any cytokine 
production in un-stimulated cells, and stimulated cells were negative for production 
of TNFα and IFN-γ. The ELISA measurements revealed a more than six-fold increased 
IL-6 production capacity of PBMCs isolated from patients upon stimulation with 
EGF and Pam3Cys, compared with stimulation of control cells (Figure 3). Pam3Cys 
stimulation also resulted in an increase in IL-1β production of more than threefold in 
patients compared to control subjects. No differences in cytokine production were 
observed when cells were stimulated with LPS. IL-17 production was only assessed 
upon stimulation with 10 μg mL−1EGF and did not differ between patients and control 
subjects.
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Figure 3. Cytokine production by peripheral blood mononuclear cells obtained from three 
healthy control subjects and the index patient and her unaffected father and affected mother 
after stimulation for 24 h (IL-6 and IL-1β) or 1 week (IL-17) with epidermal growth factor 
(EGF), Pam3Cys or lipopolysaccharides (LPS). IL-6 production is strongly elevated in affected 
individuals upon stimulation with EGF (a) and Pam3Cys (b), but not LPS (c). IL-1β production 
can be measured after Pam3Cys (d) and LPS (e) stimulation; differential production of IL-1β 
between patients and healthy control subjects was observed after Pam3Cys stimulation. IL-17 
production was detected after EGF stimulation (f); however, no significant difference in IL-17 
level was detected between patients and control subjects (error bars represent SEM).
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Expression analysis
To assess the putative effect of the mutation at the RNA level, we performed SOCS4 
expression analysis on mRNA from patients and control subjects. No difference in 
SOCS4 expression was observed between patients and controls (Figure 4a), indicating 
that the mutated allele is normally expressed in the patients.
It has previously been shown that EGFR expression in monocytes is very low or even 
absent201. In this study, quantitative analysis showed that EGFR is expressed at low 
levels in PBMCs obtained from patients and control subjects (Figure 4b), with no 
significant differences in expression level between the two groups.
RNA in stimulated and un-stimulated cells from patients and control subjects was 
assessed for the T-cell activation markers CD62L and CD69; no significant differences 
were observed between patients and healthy subjects (Figure 4c,d).
Figure 4. Expression analysis of patient versus control RNA in peripheral blood mononuclear 
cells (PBMCs). (a) and (b) epidermal growth factor receptor (EGFR) and suppressor of cytokine 
signalling 4 (SOCS4) expression levels in patient and control PBMCs were not significantly 
different. (c) and (d) CD69 and CD62L expression were slightly elevated in patient compared 
to control cells; however, the difference was not significant (error bars represent SEM).
Discussion
Here, we describe a family with autoimmune manifestations transmitted in an 
autosomal dominant pattern. In this study, we identified for the first time a missense 
SOCS4 mutation that is likely to contribute to or cause the disorder in this family. This 
hypothesis is supported by (i) the co-segregation of the mutation with the disease 
in the family, (ii) the known immune-modulatory function of SOCS4, (iii) in silico 
analyses of the mutation and (iv) immunological validation showing hyperactivation 
of EGFR-mediated signals (the target of SOCS4) in the cells isolated from affected 
members of this family.
The T266M SOCS4 variant is very rare in the general population, as only two other 
families have been found with the same genetic variant in databases containing 
samples from over 11 500 individuals. To our knowledge, symptoms of autoimmune 
disorders were not investigated in these other two families. One case of this variant 
was reported in another Turkish family from our in-house database, while the ethnic 
background of the second family is unknown. To exclude the possibility of this being 
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a common Turkish genetic variant, we traced the ancestral roots of both families and 
concluded that they are from different provinces in Turkey. Furthermore, this variant 
was not found in the exome data of 50 additional healthy volunteers with a Turkish 
genetic background. Based on these considerations, we can conclude that the genetic 
variant that we identified is very rare in the general population and might explain the 
autoimmune phenotype in this family. In addition, the reduced genetic tolerance to 
functional variation in SOCS4, as indicated by its residual variation intolerance score 
(−0.42)202, and the high evolutionary conservation of the nucleotide and amino acid 
sequences suggest a strong natural selection against variation within this region of 
SOCS4202.
SOCS4 is known to be responsible for inhibition of immune signaling by 
signal transducer and activator of transcription 3 (STAT3) inhibition and EGFR 
degradation203,204, thereby affecting IL-6 production205. Additionally, the results of a 
recent study in homozygous SOCS4 knockout mice showed a significant increase in 
production of pro-inflammatory cytokines, including IL-6, upon viral stimulations205. 
To validate immunologically the functional consequences of the T266M SOCS4 
mutation identified in this family, we assessed the differences in cytokine production 
between cells isolated from patients and healthy control subjects. PBMCs obtained 
from the index patient, the affected mother, the unaffected father and three healthy 
control subjects were stimulated with EGF or TLR ligands, and the production of IL-1β, 
IL-6, IL-17, TNFα and IFN-γ was measured. Stimulation of PBMCs with EGF resulted 
in an increase in IL-6 production by more than six-fold compared to cells from the 
unaffected father and healthy control subjects. This suggests that EGFR signaling, 
which is controlled by SOCS4, is hyperactive in cells isolated from affected patients, 
supporting a role for this pathway in the disease pathogenesis; this is consistent with 
the abundance of data suggesting a role of IL-6 in many autoimmune diseases (see 
below).
IL-6 is an inflammatory cytokine implicated in autoimmune diseases, and it has been 
suggested this role is at least in part due to its capacity to evoke pathogenic Th17 
responses206. Th17 cells, and the derived cytokines IL-17 and IL-22, are considered to 
be important factors driving autoimmunity, as demonstrated by data from knockout 
mouse models and the efficacy of treatment with antibodies blocking either IL-6 
or IL-17 in patients with multiple sclerosis, rheumatoid arthritis, systemic juvenile 
idiopathic arthritis or Castleman’s disease207–211. However, no increase in IL-17 
production was observed in the patients in this study, suggesting that the induction 
of autoimmunity in this family is unlikely to be mediated by Th17-derived immune 
responses, but rather through the direct effects of IL-6. The molecular mechanisms 
through which the SOCS4 mutation and the subsequent overproduction of IL-6 lead to 
this particular clinical phenotype need further investigation: specific tissue expression 
of EGFR and SOCS4, or differences in the cytokine milieu between various tissues, 
may be responsible. In addition, it is noteworthy that IL-6 was mainly measured to 
demonstrate hyperactivity of EGF-induced signals, and additional molecular and 
functional effects of SOCS4 dysfunction are to be expected.
It is interesting that TLR2-induced (but not TLR4-induced) IL-6 production was 
increased in the presence of the SOCS4 mutation, suggesting that in addition to a 
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role in EGFR and STAT3 signaling, SOCS4 may also modulate TLR2 signaling. An effect 
of SOCS4 on TLR2 signaling is supported by the increased IL-6 response observed 
in SOCS4 homozygous knockout mice stimulated with the H1N1 virus, a pathogen 
that has previously been shown to induce TLR2 signaling205,212,213. Future studies 
are warranted to further evaluate this possibility. By contrast, no differences in IL-6 
production were observed between patients and control subjects upon activation of 
TLR4 signaling by LPS.
Recently, activating germline mutations in STAT3 have been reported to cause various 
types of autoimmune phenomena, some of them similar to those observed in our 
patients214. Based on this, it may be expected that similar mechanisms operate in 
our patients, with defective inhibition of STAT3 activation resulting in hyperactive 
signaling and an autoimmune response. To our knowledge, this is the first case report 
of a point mutation in SOCS4. It has previously been suggested that the protein may 
function as a tumor suppressor in human breast and gastric cancers204,215,216. In a 
study in mice, it was shown that down-regulation of SOCS4 was crucial for STAT3 
overactivation preceding epithelial tumor initiation217.
In summary, we propose that the T266M mutation in SOCS4 leads to impaired function 
of the SOCS4 protein, which results in insufficient modulation of EGFR signaling and 
defective inhibition of STAT3. Subsequently, the hyperactive EGFR pathway leads 
to overproduction of the downstream cytokine IL-6. Elevated levels of IL-6 through 
EGFR and TLR2 stimulation could therefore represent the underlying mechanism of 
the autoimmune disorder in this family, and one could even envisage this cytokine as 
a target for therapy considering that anti-IL-6 blockade with tocilizumab is clinically 
available. However, additional studies of the potential role of rare SOCS4 mutations 
in patients with (familial) autoimmune syndromes are first needed, in order to 
understand the complex mechanisms leading to autoimmunity, and to establish the 
potential role of this pathway as a therapeutic target.
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Supplementary information:
Sample Index patient
Total mapped bases (Gb) 6.32
On and near target % 84.5%
Median fold coverage 71.5
Average fold coverage 90.2
% Covered > one-fold 93.3%
% Covered > 10-fold 84.5%
% Covered > 20-fold 78.3%
Total variants 43,447
Coding, canonical, microRNA 16,570
Non-synonymous 8,239
Rare variants <0.25% SNP, in-house exomes 360
Variant in >5 reads; and >25% variant reads 233
Evolutionary conserved variants in (auto-) immune pathways 5
Supplementary Table S1. Variant filtering used of the index patient’s exome sequencing 
data; Exome sequencing statistics and the filter settings applied to exclude non-coding, non-
synonymous, common and low quality variants.
Supplementary Figure S1. Sanger validation of the SOCS4 mutation and segregation analysis 
in the family. 
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Abstract
Progressive multifocal leukoencephalopathy (PML), a demyelinating disease of the 
brain, is typically diagnosed in immunocompromised persons. Here, we describe the 
diagnostic challenge of PML in an apparently immunocompetent patient. Thorough 
analyses, including cytokine release assays and whole exome sequencing, revealed 
a deficit in the antiviral interferon gamma production capacity of this patient and 
compound heterozygous mutations in BCL-2-associated athanogene 3. Interestingly, 
both factors are associated with reduced expression of John Cunningham virus 
T-antigen, a protein that plays a key role in viral replication in infected cells. After 
validation in other patients, our findings may contribute to novel insights into the 
etiology and possibly treatment of PML.
Chapter 4
Chapter 4: 
Progressive multifocal  leukoencephalopathy in an 
immunocompetent patient
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Introduction
Progressive multifocal leukoencephalopathy (PML) is a destructive demyelinating 
disease of the central nervous system caused by the John Cunningham virus (JCV), 
which belongs to the family of polyoma viruses. The onset of the disease is subacute, 
with a broad range of clinical features. Its course is progressive and often fatal218. 
Carriership of JCV is common among healthy individuals and it remains latent 
in the kidney, lymphoreticular, or brain tissue. Approximately 70% of adults are 
seropositive for JCV. Reactivation of the virus, resulting in PML, occurs typically under 
immunosuppressive conditions218. The growing number of immunosuppressive 
and immunomodulatory therapeutics has resulted into an increased number of 
individuals at risk for PML219. Although the common denominator in all these 
conditions is suppression of cellular immunity (either iatrogenic or endogenous), 
PML may also occur in patients with minimal or occult immune suppression (e.g., 
idiopathic CD4+ lymphocytopenia, chronic kidney, or liver disease)220 and even 
occasionally in apparently immunocompetent patients221. Here, we present a case of 
PML in an apparently immunocompetent patient in whom a deficit of the interferon 
γ (IFN-γ) pathway, and compound heterozygozity for mutations in BCL2-associated 
athanogene 3 (BAG3) were identified.
Patient and Methods
Case presentation
A 49-year-old Caucasian male presented with rapidly progressive symptoms of 
aphasia, dyscalculia, hyperesthesia of the right arm, and headache. Two months after 
the first symptoms, his clinical condition worsened acutely with an inability to speak 
and to carry out activities of daily living, apraxia, confusion, and severe headache. 
His vital signs were normal and neurologic examination confirmed a nonfluent 
aphasia, dysgraphia, mild facial paresis on the right, a right-sided hemianopsia, 
hemi-hypaesthesia, and hyperreflexia without extensor plantar responses. He 
used no medication and had no significant medical history. The family history was 
unremarkable for neurologic conditions. Laboratory tests showed normal leukocyte 
counts, including CD3, CD4, and CD8 counts (ratio T4/T8), low infectious parameters, 
negative serology for human immunodeficiency virus (HIV), Lues, Borrelia, and Herpes 
Simplex Virus (HSV). Cerebrospinal fluid (CSF) analysis showed normal cell counts, 
protein and glucose levels, no oligoclonal bands or markers of neurodegeneration 
(except for a slightly elevated Tau [431 ng/L], normal <300 ng/L), and cytological 
analysis showed no signs of malignancy. Cerebral MRI showed confluating subcortical 
white matter T2 hyperintensities predominantly in the left hemisphere, which 
extended on consecutive MRIs without contrast enhancement or mass effect (Figure 
1). PCR for JCV in serum and CSF was negative.
A stereotactic biopsy of the left frontal lobe showed perivascular lymphocytic 
infiltration with sporadic enlarged nuclei, which resembled astrocytes. No pathologic 
oligodendrocyte nuclei were found and immunohistochemical staining for SV-40 
(polyomavirus) was negative. However, a positive PCR alone is no confirmation of 
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active virus replication. 
The PCR for JCV on the biopsy material, however, was positive. The normal immune 
status and the lack of evidence for an active JCV infection led to the primary diagnosis 
of tumefactive multiple sclerosis, and the patient was treated consecutively with 
methylprednisolone intravenously, glatiramer acetate (20 mg/mL once daily), 
acetaminophen (1000 mg four times a day), and plasmapheresis222. As deterioration 
continued the biopsy material was re-examined 7 months after symptom onset, in 
a tertiary center with extensive expertise on PML. The presence of foam cells, some 
bizarre astrocytes, and sporadic oligodendrocytes with ground glass appearance 
combined with the clinical course led to a revision of the diagnosis to PML, and 
the patient was started on mirtazapine (15 mg once daily). Unfortunately his 
condition was progressive and he died 9 months after the initial presentation due 
to cardiopulmonary complications of a bilateral pneumonia. Autopsy confirmed the 
diagnosis of PML. Macroscopy showed extensive white matter hyperintensities in both 
hemispheres, with focal gray glass lesions, suggestive for PML. Microscopy showed 
large white matter hyperintensities with prominent demyelination, and a granular 
tissue loss. Extensive reactive astrocytosis, and astrocytes with enlarged polymorph 
hyperchromatic nuclei were found, indicating a viral cytopathogenic effect. A few 
oligodendrocytes with enlarged nuclei, perivascular foamy macrophages, and some 
lymphocytic infiltration were seen.
Figure 1. MRI images 4 months after first presentation. (A) Fluid-attenuated inversion recovery 
(FLAIR) MRI: large confluating asymmetric white matter hyperintensities lesions in the frontal 
and parietal lobes. (B) T1-gadolinium sequences without contract enhancement.
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Immunological assessment
After the diagnosis of PML an assessment of the capacity of cells isolated from the 
patient to respond to microbial stimuli was initiated. Peripheral blood mononuclear 
cells were isolated from blood collected from the patient, and stimulated with 
the TLR4-ligand lipopolysaccharide (Escherichia coli LPS 10 ng/mL), the TLR3-
ligand PolyI:C (5 μg/mL), and a fungal stimulus (heat-killed Candida albicans 105 
microorganisms/mL). IFN-γ production capacity was measured using an enzyme-
linked immunosorbent assay.
Genetic analysis
Whole exome sequencing was performed as described earlier90,104. In brief, DNA 
was isolated from whole blood, enriched with SureSelect v2 exome (Agilent 
Technologies, Santa Clara, CA) (50 Mb) and sequenced on SOLiD 4 (Life Technologies, 
Foster City, CA). Variants were called using high stringency settings and annotated 
with an in-house pipeline containing information from dbSNP134. Variant filtering 
was applied as previously reported; in brief, we selected variants affecting coding 
exons, microRNAs, and canonical splice sites. Subsequently, synonymous variants 
were filtered out, and only rare variants (frequency of <0.25% in both dbSNP134 and 
our in-house database containing >2000 exomes) with high quality were reported 
(Table 1). All genes with rare nonsynonymous variants were systematically checked 
for involvement role in immunity; based on Gene Ontology terms, mouse knockout 
phenotypes, information from the Kyoto Encyclopedia of Genes and Genomes or 
direct interaction with JCV according to NCBI (the latter was performed by searching 
for JCV in NCBI, and selecting for genes in humans).
Sample PML patient
Total mapped bases (Gb) 5.5
On and near target % 82%
Median fold coverage 57.6
Average fold coverage 81.7
% Covered > one-fold 94.1%
% Covered > 10-fold 82.8%
% Covered > 20-fold 74.5%
Total variants 35,322
Coding, canonical, microRNA 14,595
Non-synonymous 7,211
Rare variants <0.25% SNP, in-house exomes 188
Variant in >5 reads; and >25% variant reads 106
Variants in immune-related pathways 17
Associated with JC-virus (NCBI) 2 variants, 1 gene (BAG3)
Table 1. Exome sequencing statistics and the filter settings applied to exclude noncoding, 
nonsynonymous, common, and low-quality variants. Abbreviations used: PML, progressive 
multifocal leukoencephalopathy; BAG3, BCL2-associated athanogene 3; JCV, John Cunningham 
virus. 
55
Chapter 4
Results
Immunological assessment
While cytokine production upon stimulation with LPS and C. albicans was normal 
compared to eight healthy individuals. IFN-γ production induced by PolyI:C was 
severely impaired in the patient versus control stimulation (Figure 2). We were unable 
to perform extensive immunophenotyping of T-, B-, and NK-cell subpopulations as 
our patient deceased shortly after the diagnosis of PML.
Figure 2. Interferon-γ (IFN-γ) production capacity was measured in the progressive 
multifocal leukoencephalopathy (PML) patient and compared with eight healthy controls 
upon stimulation with the TLR3 ligand PolyI:C (5 μg/mL) (left) and Candida albicans (1 × 105 
microorganisms/mL) (right). The PML patient showed a clear defect in IFN-γ production upon 
PolyI:C stimulation compared to controls, whereas stimulation with Candida does not result 
in significant differences.
Genetic analysis
Whole exome sequencing provided 5.5 Gb of mapped sequencing data, resulting in 
an average coverage of the exome of 81.7-fold. Standard variant filtering resulted 
in 106 rare, nonsynonymous, and canonical splice site variants. Only 17 genetic 
variants remained after filtering for genes with a possible role in immunity (Table 2). 
A genome-wide search in NCBI for genes associated with JCV interaction resulted in 
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21 genes. An overlap between these 21 genes, and the 106 rare variants resulted in 
one gene for which JCV interaction was described earlier223,224; we found two very 
rare heterozygous variants in exon 2 of the BAG3. Co-segregation analysis within the 
family shows that both unaffected parents carry one of the variants in a heterozygous 
state, and both variants are absent in the healthy brother (Figure 3). The variants (p. 
P77L; p.I94F) have been reported at population allele frequencies of 0.029% and 
0.076%, respectively. In addition, rare (<1%) homozygous protein-altering variants 
are only reported in 16 of >60,000 controls43.
Table 2. Seventeen rare variants with association to immune system for the respective 
genes.  BAG3, BCL2-associated athanogene 3; JCV, John Cunningham virus. A, NCBI human 
gene name interaction with JCV and number of PubMed publications (N); B, mouse knockout 
phenotype “immune”; C, Gene Ontology term “virus”; D, GeneOntology term “interferon”; E, 
Kyoto Encyclopedia of Genes and Genomes class “immune”; F, Kyoto Encyclopedia of Genes 
and Genomes class “infectious.” PhyloP* relates to the amino acid conservation among 46 
species. ExAC (Exome Aggregation Consortium43).
Selection 
criteria
Gene name Gene 
component
Amino acid 
change
ExAC allele frequency ExAC # of alleles/
total
A(2), B BAG3 Exon p.P77L 0.0002883 35/121,382
A(2), B BAG3 Exon p.I94F 0.000758 92/121,376
B CDC73 Exon p.R229G 0 0
B TP53BP2 Exon p.M399V 0.000239 29/121,318
B CPN1 Exon p.E56X 0 0
B KDM5A Exon p.V629M 0.00002485 3/120,732
B HYDIN Exon p.N935S 0 0
B CBFA2T2 Exon p.G282S 0.00000824 1/121,404
B NIPBL Exon p.N1284S 0.00002486 3/120,678
B CALCR Exon p.E132D 0 0
B ATP7A Exon p.H1036R 0 0
B, D AHNAK Exon p.D5419N 0.0004119 50/121,374
B, E, F ITGA4 Exon p.K241R 0 0
C IFI16 Exon p.R165H 0.0001236 15/121,400
D KYNU Exon p.V435M 0 0
E ARRB1 Canonical SA site N/A 0.00000824 1/121,376
F LAMB3 Exon p.R878C 0.00005767 7/121,396
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SIFT 
prediction
Polyphen prediction PhyloP* Grantham 
score
Tolerated Benign −0.157 98
Deleterious Probably damaging  2.098 21
Deleterious Probably damaging  2.305 125
Tolerated Benign  2.459 21
N/A N/A  0.354 1000
Deleterious Possibly damaging  4.234 21
Not scored Probably damaging  4.186 46
Tolerated Benign  1.669 56
Deleterious Benign  2.760 46
Deleterious Benign  0.020 45
Deleterious Probably damaging  4.925 29
Deleterious Probably damaging  0.387 23
Tolerated Benign −3.015 26
Tolerated Benign −3.320 29
Deleterious Probably damaging  3.041 21
N/A N/A  5.068 0
Deleterious Probably damaging  1.177 180
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Figure 3. Family pedigree of our progressive multifocal leukoencephalopathy (PML) case; 
the unaffected parents were both carrier of one rare BCL2-associated athanogene 3 (BAG3) 
variant (paternal variant p.P77L, c.230C>T; maternal variants p.I94F, c.280A>T). The 
compound heterozygosity for these BAG3 variants most likely affects the resistance against 
John Cunningham virus (JCV) in the index patient. Neither of the two variants is present in the 
unaffected brother.
Discussion
Although rare, similar cases of PML in apparently immunocompetent individuals 
have been reported221,225,226. Due to its variable demographics, presenting symptoms, 
and prognosis, the diagnosis of PML remains a challenge, especially in apparently 
immunocompetent individuals. The diagnosis can be strengthened by a positive PCR 
for JCV in the CSF, which has a high sensitivity and specificity. However, the severity 
of the immunosuppression seems to determine the accuracy of the available tests, 
as is illustrated by the low JCV DNA copy numbers in the CSF of highly active anti-
retroviral therapy treated (HAART) HIV patients, as well as in nearly half of the 
multiple sclerosis patients treated with the monoclonal antibody natalizumab who 
were diagnosed with PML227–229. Moreover, JCV PCR in CSF of PML cases with occult, 
minimal, or no detected immune suppression was often found negative221. Also, 
substantial variability exists with regard to detection levels and consistency between 
laboratories even in testing the same sample set. If clinical suspicion remains high 
and JCV PCR in CSF is negative, a brain biopsy should therefore be performed. It is 
important to realize that JCV DNA is widespread in the brain of healthy adults and 
that the viral DNA load seems to increase in immunosuppresive conditions, as was 
observed in an autopsy study in HIV patients without PML (no clinical symptoms 
during life and no neuropathologic evidence of PML)230. Expression of viral proteins, 
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which can be demonstrated by immunohistochemistry is, however, considered a 
pathognomonic sign of PML. In our case, viral DNA was found in the biopsy material, 
however, expression of viral proteins was not observed. Therefore, PML was initially 
not considered the most likely diagnosis in this immunocompetent patient.
Identifying factors that determine JCV reactivation in an immunocompetent patient 
will profoundly contribute to the understanding of pathogenesis of PML231. Moreover, 
it might contribute to novel treatment options. IFN-γ is an important cytokine in 
human antiviral cellular immune response. The observation that the IFN-γ response 
in our patient was decreased after stimulation with PolyI:C, a synthetic TLR3 ligand 
used to simulate viral infections, suggests a specific deficit in the cellular antiviral 
immune response. Interestingly, IFN-γ was recently reported to inhibit expression 
of JCV T-antigen, the major viral regulatory protein232. In addition, this study showed 
a significant decrease of JCV DNA copies in cells upon IFN-γ treatment in vitro. The 
observed IFN-γ deficit is most likely an important factor in the pathogenesis of PML 
in our patient; whole exome sequencing was performed in order to identify any 
genetic defects that could contribute to this deficit. Compound heterozygous BAG3 
variants in our patient are worthy candidates for increased susceptibility to PML as 
BAG3 is implicated in autophagy and apoptosis through intracellular protein control. 
It was previously shown that overexpression of BAG3 results in a decrease of the 
JCV replication, and reduced T-antigen expression through autophagic degradation, 
thereby controlling the JCV lytic cycle and its interaction with host cells224. Although 
it remains speculative, the observed genetic variants in BAG3 might compromise the 
response against JCV T-antigen in our patient, leading to insufficient IFN-γ production, 
and subsequently PML.
Obviously this case report has several limitations and the results should be interpreted 
with caution. First, although the segregation analysis showed an autosomal recessive 
inheritance, the family is rather small, which makes the pathogenicity uncertain.
Validating our findings in other cases is therefore crucial, however, due to the rarity 
of PML in apparent immunocompetent patients this remains extremely challenging. 
We took up this challenge and performed genetic testing for BAG3 variants in two 
previously reported apparent immunocompetent PML cases225,226. Unfortunately, 
no BAG3 variants were discovered in these patients. Given the number of factors 
suggested to be involved in the reactivation of JCV in order to develop PML and 
therefore increased heterogeneity between these patients, this might not be 
surprising231,233. In addition to the genetic variants in BAG3, we also provide evidence 
for low INF-γ levels in this case. However, a possible association between the IFN-γ 
deficit and the BAG3 variants remains to be shown.
This case report shows that specific defects in the IFN-γ production upon stimulation 
may be present in PML patients without known immune deficits. Patients suspected 
of PML without immunosuppression should, in addition to regular immunologic 
screening, be tested for IFN-γ deficiency to confirm our findings. In these conditions 
treatment with IFN-γ might potentially be an option for PML, similar to other 
conditions treated with recombinant IFN-γ234.
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Abstract
Susceptibility to NTM infections in patients with Lady Windermere syndrome is 
associated with MST1R variants.
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To the Editor:
The prevalence of pulmonary nontuberculous mycobacterial (pNTM) disease is 
increasing235. The most commonly isolated disease-causing NTMs belong to the 
Mycobacterium avium complex235. Susceptibility to and clinical manifestation 
of NTM disease are largely governed by the immune status of a person. 
Disseminated or extrapulmonary NTM infections are strongly associated with severe 
immunosuppression, such as those with frank defects in the interferon (IFN-γ) 
interleukin (IL)-12 axis236. Isolated pNTM is strongly associated with certain underlying 
conditions, such as cystic fibrosis, chronic obstructive pulmonary disease and primary 
ciliary dyskinesia237,238. However, substantial numbers of pNTM patients have no 
apparent risk factors, and a significant proportion of them exhibit a body morphotype 
characterised by lifelong slender body habitus, pectus excavatum, scoliosis and 
mitral valve prolapse239,240, also called the Lady Windermere syndrome. A modest 
reduction in IFN-γ production and an increase in transforming growth factor (TGF)-β 
levels have been described241–244. Fowler et al.245 quantified ciliary beat frequency of 
58 pNTM patients and 40 controls and found reduced ciliary beat frequency in the 
pNTM patients. Szymanski et al.246 performed whole-exome sequencing on patients 
with pNTM, their unaffected family members and a control group and concluded that 
pNTM is a multigenic disease, encompassing potential defects in proteins encoded 
by cilia genes, the cystic fibrosis transmembrane conductance regulator gene, 
connective tissue genes and certain immune-related genes.
Since pectus excavatum and scoliosis have been described in several genetic disorders 
that are not necessarily notable for increased susceptibility to lung infections, this 
body phenotype in pNTM patients may have a more specific genetic basis, that could 
account not only for their body phenotype, but also their increased vulnerability 
to pulmonary infections247. Our goal was to determine the genetic basis of Lady 
Windermere syndrome, namely the pNTM with pectus excavatum and scoliosis 
(pNTMPEX/scoliosis) by performing whole-exome sequencing in 11 individuals with this 
phenotype and functional validation of the genetic findings.
11 individuals with pNTMPEX/scoliosis (two sisters and nine sporadic cases) were recruited 
from National Jewish Health and the University of Colorado Anschutz Medical 
Campus (Denver, CO, USA) as part of a prior study239. In whole-exome sequencing 
MST1R was the only gene with a previously described role in innate immunity or cilia 
function that harboured rare nonsynonymous variants in three families.
The two sisters (patients 1 and 2 in family 1; Figure 1a) carried a very rare missense 
variant (p.V900M) in MST1R, having a very low population frequency of 0.0004794 
or 28 per 58 406 public exomes based on Exome Aggregation Consortium (ExAC) data 
(http://exac.broadinstitute.org). Co-segregation analysis in their extended family 
revealed that three siblings and three children are carriers of the same MST1R variant 
(Figure 1a). Two of the nine sporadic pNTMPEX/scoliosis cases also have missense variants 
in the MST1R gene. Patient 3 had a private missense variant not previously reported 
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(p.M1383T) and patient 4 possessed a rare missense variant (p.D176N) with a very 
low population frequency of 0.0009082 or 53 per 58 360 public exomes (http://exac.
broadinstitute.org). Co-segregation analyses within the respective families showed 
that in patients 3 and 4 of families 2 and 3, the MST1R variant was paternally inherited 
(Figure 1a). Sanger sequencing revealed that all 29 pNTM patients without pectus 
excavatum or scoliosis were negative for rare MST1R variants.
Figure 1. a) Family 1. The two sisters with pulmonary nontuberculous mycobacterial disease 
with pectus excavatum and scoliosis (pNTMPEX/scoliosis) carry a mutation (Δ) in MST1R. Three of 
their siblings also have ΔMST1R and two of them have chronic respiratory symptoms. 
64
Ch
ap
te
r 5
Family 2. The index patient with pNTMPEX/scoliosis has ΔMST1R. One brother of the index patient 
has the same MST1R mutation and has frequent chest infections. #: Because two of his 
children carry the MST1R mutation, the deceased father of the family is the expected carrier 
of the mutation, although his DNA was not available. 
Family 3. The index patient with pNTMPEX/scoliosis has ΔMST1R. Both the father and daughter of 
the index patient also carry the MST1R mutation; the father has a chronic cough, whereas the 
daughter has no health issues or complaints.
We next addressed cytokine production of pNTMPEX/scoliosis patients. Whole-blood 
stimulation experiments revealed significantly lower M. intracellulare-induced 
IFN-γ production in all pNTM patients compared to the control group, as previously 
reported239 (Figure 1b). In addition, IL-10 production in the pNTMPEX/scoliosis patients 
was lower after stimulation with LPS, Staphylococcus epidermidis or M. intracellulare 
(data not shown). The mean concentrations of IL-6 were not significantly different 
between pNTMPEX/scoliosis patients and controls (data not shown). In contrast, the anti-
inflammatory cytokine TGF-β was significantly increased in pNTMPEX/scoliosis patients 
compared to controls (data not shown), also shown in a prior study241. Comparing 
pNTMPEX/scoliosis patients with and without the variant in MST1R revealed equally low 
or even lower levels of IFN-γ in whole-blood stimulation (Figure 1b).
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and pNTMPEX/scoliosis patients carrying the MST1R mutation (pNTMPEX/scoliosis /ΔMST1R) (n=2) 
was stimulated with a medium control, lipopolysaccharide (LPS), heat-killed Staphylococcus 
epidermidis and live Mycobacterium intracellulare. Interferon (IFN)-γ was measured in the 
supernatant using ELISA. The Mann–Whitney U-test was used to determine whether the 
means were significantly different. c–f) Peripheral blood mononuclear cells of healthy donors 
were stimulated for 48 h with c) heat-killed M. avium (n=6); d) live M. avium (n=6); e) heat-
killed M. avium plus interleukin (IL)-12 (n=6) or f) IL-12/IL-18 (n=7) in the presence of a MST1R-
neutralising antibody (anti-MST1R) or its isotype control antibody. IFN-γ was measured in the 
cell culture supernatant using ELISA. The Wilcoxon signed rank test was used to determine 
whether the mean values were significantly different. N/A: not available; wt: wild-type; 
*: p<0.05; ns: nonsignificant.
To investigate the immunological relevance of MST1R, we stimulated peripheral 
blood monocyte cells (PBMCs) from healthy individuals with heat-killed M. avium, 
live M. avium, heat-killed M. avium+IL-12 or IL-12+IL-18 in the absence or presence 
of a MST1R-neutralising antibody, and measured IFN-γ levels (Figure 1d–f). Blocking 
MST1R resulted in a significantly lower level of IFN-γ in response to live M. avium±IL-12
and a trend toward reduced IFN-γ production with heat-killed M. avium (Figure 1c–e). 
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However, with IL-12+IL-18 stimulation of the PBMCs, there was no difference in IFN-γ 
production with or without anti-MST1R antibody (Figure 1f). Furthermore, blocking 
MST1R had no effect on M. avium (heat-killed or live) stimulation of IL-10, IL-6 or 
TGF-β by the PBMCs (data not shown). Taken together, the increased TGF-β response 
was independent of MST1R, since it was observed in all pNTM patients, while the M. 
avium-specific IFN-γ response was specifically dependent on MST1R. This reveals a 
previously undescribed potential mechanism by which MST1R plays a host defence 
role against NTM.
Interestingly, MST1R variants were recently reported in three pNTM patients in a 
cohort of 77 NTM patients246. While this is consistent with our findings, it is interesting 
to speculate that the higher frequency of MST1R variants in our smaller cohort 
may be due to more stringent selection of patients with both pectus excavatum 
and scoliosis. To evaluate this possibility, we performed Sanger sequencing in 29 
patients without these physical characteristics and found no rare genetic variation in 
MST1R. How MST1R variants might be related to the presence of pectus excavatum/
scoliosis is unknown; furthermore, because pectus excavatum/scoliosis are also 
present in some patients without MST1R mutations there is a strong possibility that 
pectus excavatum/scoliosis are associated with anomalies of more than one gene. 
Indeed, this notion is supported by the finding that pectus excavatum/scoliosis is 
seen in Marfan syndrome and in several other connective tissue disorders, such 
as the Loeys–Dietz and Shprintzen–Goldberg syndromes247. Interestingly, all these 
connective tissue disorders are caused by increased TGF-β signalling, albeit through 
different mechanisms.
MST1R is highly expressed on airway epithelial cells and increases mucociliary 
function, i.e. binding and activation of MST1R by its ligand macrophage-stimulated 
protein leads to a significant increase of the ciliary beat frequency 248. Thus, a defect in 
the mucociliary transport due to a MST1R mutation could lead to impaired clearance 
of NTM, resulting in a vicious cycle of airway inflammation and infection leading to 
the bronchiectasis typically seen in patients with pNTM. These genetic findings are 
consistent with the study showing that adult patients with pNTM and without known 
predisposing factors have reduced ciliary beat frequency245. Thus, defects in MST1R 
function can specifically attenuate IFN-γ production as well as decrease airway 
ciliary function, with both defects increasing susceptibility to pNTM. The decrease in 
IFN-γ production was specific for the stimulation with live M. avium, since blocking 
MST1R did not decrease IL-12+IL-18-induced IFN-γ production. The reason for this 
phenomenon is not known; it might be speculated that M. avium has a direct ligand 
for MST1R.
In conclusion, we have identified rare variants in MST1R in four out of 11 pNTMPEX/
scoliosis patients, and suggest that these genetic variants contribute to Lady Windermere 
syndrome by decreasing airway ciliary function and reducing IFN-γ production in 
response to NTM.
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Abstract
Purpose: Agranulocytosis is a rare and serious adverse effect of antithyroid drugs, 
with unknown etiology. The present study aimed to uncover a potential mechanism 
of antithyroid drug-induced agranulocytosis (ATDAC).
Methods: We studied two independent families with familial Graves’ disease, of 
which several members developed ATDAC. In addition, six sporadic ATDAC patients 
with Graves’ disease were investigated. We performed whole exome sequencing 
analysis of affected and unaffected family members to identify genetic susceptibility 
variants for ATDAC, followed by functional characterization of primary granulocytes 
from patients and unrelated healthy controls.
Results: Whole exome sequencing, co-segregation analysis and stringent selection 
criteria of candidate gene variants identified NOX3 as a genetic factor related to 
ATDAC. Functional studies revealed increased apoptosis of methimazole-treated 
granulocytes from patients carrying NOX3 variants. 
Conclusion: Genetic variants in NOX3 may contribute to antithyroid drug-induced 
apoptosis of granulocytes. These findings contribute to the understanding of 
mechanisms underlying ATDAC. 
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Introduction
Thionamides are widely used for treatment of hyperthyroidism. They inhibit thyroid 
hormone synthesis by blocking oxidation and organification of iodide. Although 
thionamides are generally well tolerated, several side effects may be present, 
including rash, pruritus, arthritis and liver toxicity249–251. In 0.1-0.35% of patients, 
antithyroid drug-induced agranulocytosis (ATDAC), defined as <500 granulocytes/
mL in peripheral blood, occurs.  ATDAC, which is a potentially life-threatening 
condition252–255, occurs more frequently during treatment with higher dosages of 
antithyroid drugs254 and in the first months of treatment, although several cases have 
been described with late onset ATDAC after several years of treatment256,257.
The underlying mechanism of ATDAC is so far not known. Based on examination 
of bone marrow it has been shown that in some affected patients the number of 
granulocytic precursors is severely reduced, whereas in others hypercellular bone 
marrow with dysmaturity of granulocytic cells is observed258. Previously, only studies 
on sporadic cases have been reported and have identified common genetic variants 
in Human Leukocyte Antigen (HLA) genes predisposing to ATDAC259–262. However, 
also rare or private variants could be of significant importance. Here, we describe 
two independent families and six sporadic patients with Graves’ disease (GD) that 
developed ATDAC during treatment with methimazole or propylthiouracil, which 
enabled us to study genetic and functional characteristics of ATDAC. 
Patients and Methods
Clinical Cases
Four members from one family were treated for GD at the Department of Internal 
Medicine, Slingeland Hospital, Doetinchem, The Netherlands (Family 1). Diagnosis 
of GD hyperthyroidism was confirmed by presence of TSH receptor antibodies and/
or characteristic scintigraphic findings. Three of the patients developed ATDAC: 
they had been treated for 1-7 years with methimazole (Thiamazole, 30 mg daily) in 
combination with levothyroxine (Thyrax, block-and-replace) and were subsequently 
treated with 131I radioactive iodide. Treatment with methimazole was continued until 
they developed ATDAC. The fourth GD patient of Family 1 had been treated with 
methimazole (30 mg daily) in combination with levothyroxine for one year and has 
been euthyroid since discontinuation of therapy. This patient has not developed 
ATDAC during treatment. Two members from a second family were treated for 
GD hyperthyroidism at the Departments of Internal Medicine of the St. Antonius 
Hospital, Nieuwegein, The Netherlands and Maxima Medical Center, Eindhoven, 
The Netherlands, respectively (Family 2). Both patients have developed ATDAC 
after treatment with methimazole (30 mg daily) or propylthiouracil (50 mg three 
times daily) in combination with levothyroxine for 1-7 years. One of the patients 
also received 131I radioactive iodide treatment. We also studied six sporadic patients 
who were treated for GD hyperthyroidism with methimazole (30 mg daily) or 
propylthiouracil (150 mg daily) and who developed ATDAC. One of these patients 
developed ATDAC after 2 months of methimazole treatment, which was followed by 
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131I treatment. In the other sporadic patients, ATDAC occurred after 1 to 25 months 
of thyrostatic treatment.
In all GD patients who have developed ATDAC, thyrostatic treatment was discontinued 
immediately resulting in rapid restoration of granulocyte counts to normal levels, 
which excludes thyrostatic-independent causes of agranulocytosis. One of the 
patients required administration of G-CSF. Written informed consent was received 
from participants prior to inclusion in the study.
Genetic and Co-segregation Analysis 
DNA from all GD patients of Family 1 (3 GD patients with ATDAC, 1 GD patient 
without ATDAC, 1 healthy family member), Family 2 (2 GD patients with ATDAC) 
and the sporadic GD patients was isolated from EDTA whole blood using standard 
procedures. Patients denoted with ‡ in Figure 1A were selected for whole exome 
sequencing analysis. DNA was enriched with SureSelect v4 exome (50Mb) (Agilent 
Technologies, Santa Clara, CA, USA) and sequenced on 5500XL sequencer (Life 
Technologies, Foster City, CA, USA). Sequence reads were mapped on hg19 using 
LifeScope v2.1 (Life Technologies). The whole exome sequencing data were analyzed 
for Single Nucleotide Variants and (small) indels; additional prioritization was solely 
done on frequency but did not favour Gain-of-Function (GoF) or Loss-of-Function 
(LoF) variants specifically. In this study all relatively rare, non-synonymous variants 
(stop, frameshift and missense) were included irrespective of their predicted 
mechanism (GoF/LoF) for the downstream overlap analysis. Only variants were 
selected affecting coding exons, microRNAs and canonical splice sites. Subsequently, 
synonymous variants were excluded and only rare variants called with high quality 
(<5% frequency in both dbSNP138 and our in-house database containing >2000 
exomes) were pursued. Variants were called by the diBayes algorithm using high 
stringency settings263. Small insertions and deletions were detected using the SOLiD 
Small InDel Tool. Variant filtering was applied similar to previous reports90,104. In brief, 
we filtered for coding, non-synonymous variants with a population frequency ≤ 5%. 
We checked for genes that carried rare variants in all affected patients of both families 
(Supplementary Table S1). Co-segregation of identified variants with occurrence of 
ATDAC covering both families was analyzed and was validated by Sanger sequencing 
for both familial and sporadic cases. Variants present in the uncle of Family 1 (GD, no 
ATDAC) were excluded as candidates for ATDAC. Genotyping of HLA genetic variants 
previously associated with ATDAC was performed by Sanger sequencing.
Functional Studies of Granulocytes
Based on the genetic findings, we analyzed functional consequences of NOX3 
variants in granulocytes. In vitro functional studies were performed in granulocytes 
obtained from four GD patients with ATDAC (denoted with * in Figure 1A) and four 
unrelated NOX3 wild-type healthy controls. Granulocytes were isolated from blood 
as described previously264.
For detection of NOX and SUMF2 gene expression, naïve granulocytes were treated 
with TRIzol (Invitrogen) and total RNA purification was performed according to 
manufacturers’ instructions. RNA was subsequently transcribed into complementary 
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DNA (iScript cDNA Synthesis Kit, Bio-Rad, CA, USA) followed by quantitative PCR 
using the SYBR Green method (Life Technologies, Carlsbad, CA, USA). Primers used 
for detection of NOX1-5, SUMF2 and the housekeeping gene β2-microglobulin (β2M) 
are listed in Supplementary Table S2. Gene expression values were calculated by 
employing the comparative threshold cycle (Ct) method. NOX3 protein expression 
in granulocytes was assessed by subjecting human granulocyte lysates to 
immunoblotting. Total protein amounts of 10 µg were loaded on to SDS-PAGE using 
10% polyacrylamide gels. After SDS-PAGE, proteins were transferred to nitrocellulose 
membrane (0.2 mm). The membrane was blocked with 5% (wt/vol) milk powder in 
TBS/Tween 20 for 1 hour at room temperature, followed by incubation overnight 
at 4°C with an NOX3 antibody (1:500, ab81864; Abcam) in 5% milk powder in TBS/
Tween 20 or with a GAPDH antibody (loading control, 1:10,000, ab8245; Abcam) 
in 5% milk powder in TBS/Tween 20. After overnight incubation, the blots were 
washed three times with TBS/Tween 20 and then incubated with horseradish 
peroxidase-conjugated swine anti-rabbit antibody at a dilution of 1:5000 in 5% (wt/
vol) milk powder in TBS/Tween 20 for 1 hour at room temperature. After being 
washed three times with TBS/Tween 20, the blots were developed with enhanced 
chemiluminescence (GE Healthcare) according to the manufacturer’s instructions.
For assessment of apoptosis, granulocytes were pre-incubated with either culture 
medium, 20 mg/L (within therapeutic range) or 100 mg/L (above therapeutic range) 
methimazole (Aspen Pharma, Oss, The Netherlands) or with 20 mg/L or 100 mg/L 
of the methimazole metabolite N-methylthiourea (N-MTU, Sigma-Aldrich, St. Louis, 
MO, USA) during 5 hours. Subsequently, granulocytes were assessed for presence 
of phosphatidylserine on the outer membrane (by annexin-V staining) and for 
intracellular propidium iodide (PI) by flow cytometry (Biovision, Milpitas, CA, USA). 
For assessment of oxidative burst, a hallmark of granulocyte function, cells were pre-
incubated with either culture medium, 20 mg/L or 100 mg/L methimazole or 20 mg/L 
or 100 mg/L of N-MTU during 5 hours. Subsequently, cells were either left untreated 
or were subjected to opsonized zymosan (800 µg/mL, Sigma-Aldrich). After addition 
of opsonized zymosan and luminol, ROS release was measured within a 1 hour time 
frame. 
Statistical Analysis
Data obtained from functional studies were statistically analyzed with the Mann-
Whitney U test. Differences were considered statistically significant at P < 0.05.
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Results
Genetic and Co-segregation Analysis
Pedigrees of the two families are shown in Figure 1A. Whole exome sequencing 
provided on average 4.8 Gb sequencing data per exome with on average 86.6% of 
the exome being covered at least 20-fold. Standard variant filtering resulted in an 
average of 500 coding, non-synonymous high quality variants with low frequency in 
the healthy population (Supplementary Table S1). No microRNA variants remained 
after these filtering steps. An analysis for large deletions and duplications (CNVs) 
was not performed. Filtering of overlapping gene names in all five patients (GD + 
ATDAC) from both families resulted in the identification of four candidate genes 
for familial ATDAC. All variants in all four genes were confirmed in the patients by 
Sanger sequencing; the variants in SUMF2 (p.Asp212Asn, rs35384521) and NOX3 
(p.Ala198Thr, rs117412760 and p.Asn8Ser, rs200245496) were not present in 
the uncle of Family 1 (GD, no ATDAC) and therefore remained the two candidates 
for familial ATDAC (Supplementary Table S1). Two different NOX3 variants were 
present in Family 2. These two non-synonymous variants have been reported in 
population based cohorts with >60,000 exomes with frequencies of 0.02 and 0.0005, 
respectively (Exome Aggregation Consortium (ExAC), Cambridge, MA (URL: http://
exac.broadinstitute.org) [July/2015]). Strikingly, one of those (p.Ala198Thr) was 
identical to the variant segregating completely with the ATDAC phenotype of Family 
1. Despite the non-Mendelian inheritance of this trait in Family 2, based on protein 
function NOX3 remained the best candidate gene for ATDAC. Despite the rarity of 
ATDAC, we have been able to identify six non-familial cases of thyrostatic-induced 
agranulocytosis by a national multicenter effort. Strikingly, presence of NOX3 variants 
in GD patients that have developed ATDAC was confirmed in two out of six included 
sporadic patients. One of the two patients was of South-Asian origin and harbored 
the non-synonymous p.Arg100Ile variant (rs199783499), a NOX3 variant with a 
population frequency of 0.003 and restricted to the South Asian population (Exome 
Aggregation Consortium (ExAC), Cambridge, MA (URL: http://exac.broadinstitute.
org) [July/2015]). The other sporadic patient carried the NOX3 mutation p.Ala198Thr. 
The patient with the NOX3 p.Arg100Ile variant developed agranulocytosis after two 
months of methimazole treatment, which was followed by 131I treatment. In the 
sporadic patient with the NOX3 p.Ala198Thr mutation agranulocytosis also occurred 
after 2 months. The other four NOX3 wild-type patients developed agranulocytosis 
ranging from 1 to 25 months after initiation of antithyroid drug treatment.
Since specific HLA-associated polymorphisms have been demonstrated to predispose 
to ATDAC, all patients were analyzed for seven genetic markers within the HLA-
locus. Interestingly, the patients bearing NOX3 variants were carriers of zero, one or 
maximally two ATDAC-associated HLA risk alleles, whereas patients with wild-type 
NOX3 were shown to harbor at least five or up to seven HLA risk alleles (Table 1). 
Detailed patient characteristics are listed in Table 1. Localization of the variants in the 
NOX3 gene and protein and Sanger chromatograms of all analyzed individuals are 
depicted in Figure 1B and Supplementary Figure S1, respectively.
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Family 1
Individual Index patient Sister Mother Uncle
NOX3 genotype Heterozygous Homozygous Heterozygous Wild-type
Ala198Thr Ala198Thr Ala198Thr WT
Gender Female Female Female Male
Origin Caucasian Caucasian Caucasian Caucasian
Agranulocytosis Yes Yes Yes No
Thyrostatic dose Methimazole Methimazole Methimazole Methimazole
(daily) 30mg 30mg 30mg 30mg
Preceding duration of thyrostatic treatment 7 years 1 year 1.5 year 1 year
SNP genotype alleles HLA Risk allele evaluation
rs652888 G*/A G*/A G*/A A/A A/A
rs199564443 C*/CTTTT CTTTT/CTTTT CTTTT/CTTTT CTTTT/CTTTT CTTTT/CTTTT
rs1071816 C*/T C*/T T/T C*/T C*/T
rs114291795 G*/C C/C C/C C/C C/C
rs1811197 A*/G G/G G/G G/G G/G
HLA-B*27:05 +*/- - - - -
HLA-B*08:01 +*/- - - - -
Number of risk alleles (max 12) 2 1 1 1
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Figure 1. (A) Pedigrees of multiple Graves’ disease patients in two independent families. All 
except one of these GD patients have developed antithyroid drug-induced agranulocytosis as 
a consequence of thyrostatic treatment. ‡ Patients analyzed by whole exome sequencing. * 
Patients involved in functional studies. (B) Schematic representation of the NOX3 gene and 
NOX3 protein with indicated the location of identified NOX3 variants.
Table 1. Clinical and genetic characteristics of two families of Graves’ disease patients and six 
sporadic Graves’ disease patients with or without antithyroid drug-induced agranulocytosis 
and with or without NOX3 variants. The 4 sporadic patients without variants in NOX3 have a 
higher number of HLA-associated risk alles* for thyrostatic treatment induced agranulocytosis. 
Family 2 Sporadic Sporadic Sporadic Sporadic Sporadic Sporadic
Index patient Sister Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Heterozygous Heterozygous Heterozygous Heterozygous Wild-type Wild-type Wild-type Wild-type
Ala198Thr Asn8Ser Arg100Ile Ala198Thr WT WT WT WT
Male Female Female Female Female Female Female Female
Caucasian Caucasian Caucasian Caucasian Caucasian Caucasian Caucasian Caucasian
Yes Yes Yes Yes Yes Yes Yes Yes
Methimazole Propylthiouracil Methimazole Methimazole Methimazole Methimazole Methimazole Methimazole
30mg 150mg 30mg 30mg 30mg (3 months) 30mg 30mg 30mg
Propylthiouracil
150mg (9 months)
7 years unknown 2 months 2 months 1 year 2 years 1 month 1 month
HLA Risk allele evaluation
G*/A G*/A A/A A/A G*/A G*/A G*/A G*/A
CTTTT/CTTTT CTTTT/CTTTT CTTTT/CTTTT CTTTT/CTTTT C*/CTTTT CTTTT/CTTTT C*/CTTTT CTTTT/CTTTT
C*/T C*/T T/T T/T C*/T C*/C* C*/C* C*/T
C/C C/C C/C C/C G*/C C/C C/C G*/C
G/G G/G G/G A*/G A*/G A*/G A*/G G/G
- - - +* - +* +* +*
- - - - - +* +* +*
2 2 0 2 5 6 7 5
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Figure 2. Functional characterization of granulocytes obtained from GD + ATDAC patients with 
NOX3 variants. (A) Gene expression of NOX1-5 and SUMF2 in granulocytes obtained from GD 
+ ATDAC patients (N=4) or unrelated healthy controls (HC, N=4). Data are mean ± SD. ND: not 
detectable. (B) Protein expression of NOX3 in granulocytes obtained from one healthy control 
and the index patients of Family 1 and 2. (C) Measurement of apoptosis of granulocytes from 
GD + ATDAC patients (N=4) and granulocytes from unrelated healthy controls (HC, N=4) after 
5 hour preincubation with different dosages of methimazole or its metabolite N-MTU. Data 
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are expressed as percentage of positively stained cells for either Annexin V alone or for the 
combination of Annexin V and PI. Data are mean ± SD, * P<0.05. (D) Assessment of opsonized 
zymosan induced reactive oxygen species production by granulocytes from GD + ATDAC 
patients (N=4) and granulocytes from unrelated healthy controls (HC, N=4), with or without 5 
hour preincubation with different dosages of methimazole or its metabolite N-MTU. Data are 
expressed as mean relative light units per second (RLU/s) ± SD, * P<0.05. Each experimental 
condition was performed in quintuple. GD: Graves’ disease; ATDAC: antithyroid drug-induced 
agranulocytosis; HC: healthy control.
Gene and Protein Expression Analysis
To investigate the effect of variants in the NOX3 and SUMF2 gene on its gene expression, 
mRNA of all NOX genes (NOX1-5) and SUMF2 was measured in granulocytes from 
four GD + ATDAC patients and unrelated healthy controls. No significant differences 
were observed between granulocytes from GD + ATDAC patients and unrelated 
healthy controls for any of these genes (Figure 2A). Of note, NOX4 and SUMF2 
mRNA expression could not be detected. NOX3 protein expression was confirmed 
by immunoblotting of granulocyte protein lysates obtained from one healthy control 
and from the GD + ATDAC index patients of both families (Figure 2B).
Apoptosis
The proportion of granulocyte apoptosis induced by methimazole and its metabolic 
derivative N-MTU indicates that apoptosis is clearly elevated in granulocytes obtained 
from GD + ATDAC patients as compared to granulocytes from unrelated healthy 
controls after methimazole or, to a lesser extent, N-MTU pretreatment (Figure 2C).
Granulocyte Oxidative Burst
In the absence of methimazole or N-MTU, granulocytes from GD + ATDAC patients 
carrying NOX3 polymorphisms displayed similar ROS production induced by zymosan. 
However, after methimazole pretreatment, the oxidative burst of granulocytes 
obtained from GD + ATDAC patients was severely reduced as compared to cells from 
unrelated healthy controls. Preincubation with 20 mg/L or 100 mg/L methimazole 
resulted in respectively 49% and 63% reduced ROS production in patient granulocytes 
as compared to their wild-type counterparts. Similar experiments with N-MTU 
demonstrated that the Area Under Curve of ROS production was again decreased 
in granulocytes from GD + ATDAC patients with a reduction of 33% and 35% for 20 
mg/L and 100 mg/L N-MTU, respectively (Figure 2D). Importantly, correcting ROS 
production for degree of apoptosis indicates that the decline in ROS production by 
granulocytes from GD + ATDAC patients after preincubation with methimazole or 
N-MTU largely parallels the increased apoptosis.
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Discussion
In the present study we describe a potential genetic cause of familial ATDAC and 
provide mechanistic insights into the etiology of this rare but severe adverse effect. 
This was enabled by the unique presentation of two independent families with 
multiple GD patients, of which all except one developed ATDAC. In addition, despite 
the rarity of ATDAC, six sporadic patients have been included. All together, in seven out 
of eleven GD + ATDAC patients a variant in the NOX3 gene, encoding NADPH oxidase 
3, was identified. NADPH oxidase 3 is a plasma membrane-associated enzyme and 
an important component of the oxidative burst machinery of granulocytes262,265,266. 
Our functional studies have revealed that granulocytes from GD + ATDAC patients 
carrying NOX3 variants display normal NOX3 mRNA and protein expression, however 
they exhibit increased apoptosis induced by exposure to thyrostatics. NOX3 variants 
were absent in the ATDAC-negative GD patient of Family 1 and have not been 
identified in previous GD genome-wide association studies, excluding an important 
role for NOX3 variants in genetic predisposition to GD267,268. The cosegregated gene 
variant in SUMF2 is unlikely to be involved in ATDAC because of the lack of SUMF2 
expression in human granulocytes. 
Two different non-synonymous NOX3 variants were identified in the two families. The 
p.Ala198Thr variant is shared by all affected family members of Family 1, with one of 
the affected patients in Family 2 and with one of the sporadic patients. Unexpectedly, 
the other affected patient of Family 2 had a different NOX3 variant: p.Asn8Ser. This 
observation should be interpreted within the context of the ATDAC phenotype as 
a pharmacogenetic association and not a strictly Mendelian trait. Another NOX3 
variant was detected in one of the sporadic patients: p.Arg100Ile. These variants 
could very well have similar consequences for NOX3 protein function, as they are 
all part of intracellular protein domains closely connected with transmembrane 
α-helices. Furthermore, these variants have different protein locations from those 
associated with experimental vestibular defects, thereby explaining the differences 
in the associated phenotypes269,270. 
Other genetic variants, specifically located within the HLA-locus on chromosome 
6, have been shown to increase susceptibility to ATDAC259–262. Moreover, in these 
studies, the risk of developing ATDAC was clearly associated with the genetic burden 
of HLA-associated polymorphisms. Interestingly, HLA-genotyping of ATDAC patients 
included in the present study indicates that the genetic burden of HLA-associated 
polymorphisms is significantly less in patients with NOX3 variants as compared to 
patients with wild-type NOX3. These findings indicate that the presence of NOX3 
variants is largely sufficient for development of ATDAC and could occur independently 
from HLA-associated ATDAC, although the extent of genetic penetrance remains 
uncertain. Therefore, ATDAC associated with NOX3 variants might represent a 
different pathogenic mechanism for the occurrence of ATDAC. 
We have shown that granulocytes from individuals carrying NOX3 variants display 
increased apoptosis upon ex vivo exposure to antithyroid drugs. Importantly, these 
functional data are based on four patients from two independent families, which 
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makes it unlikely that there is co-presence of other rare genetic variants that could 
account for the observed functional differences. At present we can only speculate 
on the possible mechanism for the observed associations. Granulocytes have the 
capability to metabolize drugs, especially those that have nitrogen or sulfur in a 
low oxidation state, including propylthiouracil and methimazole271. If the identified 
NOX3 variants would result in decreased NOX3 function, this would lead to impaired 
drug inactivation and accumulation of methimazole or N-MTU reaching toxic 
concentrations that evokes apoptosis of granulocytes or their precursors. However, 
based on the observation that all ATDAC affected patients harbor heterozygous NOX3 
variants, it is more likely that the observed NOX3 variants lead to gain of function 
and consequently to increased oxidation of methimazole and propylthiouracil into 
reactive metabolites. This has previously been suggested as a possible mechanism 
explaining idiosyncratic reactions and may be particularly important for medication 
containing nitrogen and sulfur in a low oxidation state, which is also the case for 
thyrostatics271. As these idiosyncratic reactions can occur at any time during the 
treatment it could explain the delayed occurrence of ATDAC in the familial cases. 
It remains to be determined whether the development of ATDAC in these patients 
has either a rapid or more gradual onset, although our in vitro studies suggest the 
former. Importantly, in the presence of NOX3 variants 131I treatment and infectious or 
other inflammatory triggers that affect bone marrow proliferation or maturation may 
represent other required risk factors for development of ATDAC and might explain its 
delayed occurrence in most of the patients described here272,273.
Importantly, our study is the first to provide insights into a potential mechanism 
of ATDAC. The present findings need confirmation in additional cases and could 
ultimately lead to screening methods to identify patients at risk and to prevent them 
from drug-induced agranulocytosis.
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Supplementary information
Supplementary Tables
Subjects Family 1 Family 2
Index Sister Mother Index Sister
GD +ATDAC GD+ATDAC GD+ATDAC GD+ATDAC GD+ATDAC
Total mapped bases (Gb) 4.1 4.5 4.1 5.7 5.4
Median fold coverage 53.4 56.1 53.9 73.0 70.8
Average fold coverage 65.0 69.0 65.4 83.5
% covered >1-fold 98.2% 98.6% 98.4% 98.9% 99.1%
% covered >10-fold 92.3% 93.5% 92.5% 94.5% 95.3%
% covered >20-fold 83.9% 85.7% 84.3% 89.1% 90.1%
Total variants 46342 46701 46991 49365 41691
Coding, canonical, microRNA 16998 17342 17302 17832 17920
Non-synonymous 8312 8574 8444 8621 8481
Low frequent variants <5% 803 883 803 663 722
variant reads >5 and >25% 470 521 492 502 515
Co-segregation in all 5 GD +ATDAC patients 4 (FLG2, NOX3, PCM1, SUMF2)
Not in GD patient without ATDAC of family 1 2 (NOX3 & SUMF2)
Protein function and granulocyte expression 1 (NOX3)
Supplementary Table S1. Whole exome sequencing results of Family 1 (three GD patients 
with ATDAC (index patient, her sister and mother)) and Family 2 (two GD patients with ATDAC 
(index patient and his sister)). Only variants were selected affecting coding exons, microRNAs 
and canonical splice sites. Subsequently, synonymous variants were excluded and only rare 
variants called with high quality (<5% frequency in both dbSNP138 and our in-house database 
containing >2000 exomes) were pursued. SNP: single nucleotide polymorphism; GD: Graves’ 
disease; ATDAC: antithyroid drug-induced agranulocytosis.
Gene Primer Sequence (5’-3’)
NOX1 FW GCACACCTGTTTAACTTTGACTG
REV GGACTGGATGGGATTTAGCCA
NOX2 FW ACCGGGTTTATGATATTCCACCT
REV GATTTCGACAGACTGGCAAGA
NOX3 FW CGTGGCGCATTTCTTCAACC
REV GCTCTCGTTAGGGGTGTTGC
NOX4 FW TGTGCCGAACACTCTTGGC
REV ACATGCACGCCTGAGAAAATA
NOX5 FW CTATTGGACTCACCTGTCCTACC
REV GGAAAAACAAGATTCCAGGCAC
β2M FW ATGAGTATGCCTGCCGTGTG
REV CCAAATGCGGCATCTTCAAAC
Supplementary Table S2. Sequences of primers used for measuring gene expression of NOX1-
5, SUMF2 and the housekeeping gene β2-microglobulin (β2M).
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Supplementary Figure
Supplementary Figure S1. NOX3 Sanger chromatograms of affected patients and unaffected 
family members. GD: Graves’ Disease; ATDAC: antithyroid drug-induced agranulocytosis.
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Abstract
We present an approach for quantification of differential mRNA expression by targeted 
resequencing of cDNA using single-molecule molecular inversion probes (cDNA-
smMIPs), which enable highly multiplexed resequencing of cDNA target regions of 
~100 nt and counting of individual molecules. We show that accurate estimates of 
differential expression can be obtained from molecule counts for hundreds of smMIPs 
per reaction and that smMIPs are also suitable for quantification of relative gene 
expression and allele-specific expression. Compared with low-coverage RNA-Seq and 
a hybridization-based targeted RNA-Seq method, cDNA-smMIPs are a cost-effective 
high-throughput tool for hypothesis-driven expression analysis in large numbers of 
genes (10 to 500) and samples (hundreds to thousands). 
Chapter 7: 
Quantification of differential gene 
expression by multiplexed targeted resequencing 
of cDNA
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Introduction
Whole-transcriptome or RNA sequencing (RNA-Seq) is a powerful and versatile 
tool for functional analysis of different types of RNA molecules in a wide variety 
of applications, ranging from fundamental cell biology to clinical studies of the 
consequences of genomic variation and environmental perturbations274,275. Besides 
genome-wide differential expression analysis, RNA-seq can be used to quantify allele-
specific expression, alternative splicing or gene fusions events274,275. A limitation of 
whole-transcriptome sequencing is that the per-sample reagent and sequencing 
cost can be prohibitive for hypothesis-driven studies where the aim is to quantify 
differential expression of a limited set of genes in a large number of experimental 
conditions or samples. Alternatively, quantitative PCR (qPCR) is a cost-effective 
and robust technique to assay a small number of genes in a medium number of 
samples. However, qPCR rapidly becomes labor-intensive and expensive as the 
number of samples and genes increases. Targeted resequencing approaches have 
the potential to close the gap between whole-transcriptome sequencing and qPCR. 
Hybridization-based capture approaches using biotin-labeled oligonucleotide RNA 
or DNA probes have been used to better characterize splicing or fusions of lowly 
expressed transcripts276–278. While significantly reducing the required total number 
of sequencing reads, these approaches still have considerable per-sample reagent 
costs, limiting scaling up to large numbers of samples. Other approaches such as 
Luminex xMAP handle thousands of samples for ~1000 genes279,280 but require 
specialized equipment.
smMIPs76 may fill the gap between qPCR and RNA-Seq as it allows a library-free 
enrichment (i.e., enrichment and library preparation in a single step), a high degree 
of multiplexing of both targets and samples, single molecule counting via degenerate 
tags, and the protocol to generate the sequencing library can be performed in a lab 
with standard PCR equipment. The cost of a single smMIP at ~7 USD76 is similar to that 
of a qPCR primer pair; one column-based synthesis of smMIPs (25 nanomole scale) is 
sufficient for millions of independent reactions. smMIPs were previously developed 
as a method for genotyping281,282 and targeted DNA resequencing in order to identify 
rare genetic variation in tens to hundreds of genes in thousands of individuals76 or 
estimate genomic copy number variation283. Circular padlock probes282, which laid 
the basis for smMIPs, have been used for estimation of allelic ratios in cDNA, but 
target only 1 nt of sequence and do not allow for single molecule counting284.
Here we show that smMIPs can be applied to cDNA to provide accurate estimates of 
differential expression, and that they are also suitable for quantification of relative 
gene expression and allele-specific gene expression. We compare the performance 
of cDNA-smMIPs to that of CaptureSeq and low-coverage RNA-Seq for targeted gene 
expression studies. Last, we show that cDNA-smMIPs are cost-effective compared to 
alternative approaches.
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Results
Outline of method
We developed an experimental approach and dedicated statistical model (Figure 1a) 
to quantify differential expression, relative expression and allelic ratios with molecule 
counts from cDNA-smMIPs. Our approach consists of applying single-molecule 
molecular inversion probes to cDNA (reverse transcribed RNA). The protocol is 
similar to that for MIP or smMIP-based resequencing of DNA76,77; the key differences 
are in the design of smMIPs and in the overall ratio of cDNA molecules to smMIPs, 
which we increased 10-fold compare to gDNA to account for the large dynamic range 
of transcript abundance (see Methods, ‘smMIP capture’). We designed between 5 
and 10 cDNA-specific smMIPs per gene, of which some span exon-exon boundaries, 
and some fall inside exons. We used individual molecule counts obtained from the 
unique molecular identifiers (UMIs) in the smMIPs to quantify expression with a 
Bayesian statistical model.
Comparison with external RNA Controls (ERCC)
To determine the accuracy of expression quantification with cDNA-smMIPs, we used 
artificial transcripts with precisely known concentrations (External RNA Control 
Consortium, ERCC)285. There are two mixes (ERCC1 and ERCC2) containing the 
same 92 ERCC transcripts. These transcripts have different concentrations in each 
mix: they are divided into four groups such that the ratio of concentrations ERCC1/
ERCC2 transcripts is respectively 0.5X, 0.67X, 1.0X (no difference) and 4.0X. We 
added ERCC1/2 RNA to total RNA from human peripheral-blood mononuclear cells 
(PBMCs), and generated cDNA from this combined artificial and human RNA sample, 
yielding one ERCC1/PBMC cDNA sample and one ERCC2/PBMC cDNA sample. Four 
smMIP captures per cDNA sample were performed (two with 10ng cDNA input and 
two with 50ng cDNA input) with 337 smMIPs targeting the 92 ERCC transcripts (5-9 
smMIPs/transcript).
In keeping with results from smMIP-based resequencing of DNA, there was considerable 
variation between probes targeting the same cDNA transcript (Supplementary Figure 
1 and Supplementary Table 1). However, we found that correlation with the known 
concentrations was high when we averaged the expression as estimated by multiple 
probes targeting the same transcript (R2 = 0.91 ± 0.02 from 8 technical replicates, 
Supplementary Figure 2). The transcript-level correlation was similar to that of the 
targeted RNA-Seq method CaptureSeq278, which uses hybridization of biotin-labeled 
oligonucleotide-probes to enrich for selected transcripts (Supplementary Figure 3).
Accuracy of differential expression estimates
We evaluated the accuracy of differential expression (DE) estimates. Variability in 
capture efficiency between smMIPs should not affect DE estimates because the 
abundance estimated by the same probe is compared between conditions. However, 
we noted that the difference in expression values between two replicates for ERCC1 
was correlated with the difference between two replicates for ERCC2, indicating 
the presence of a systematic probe bias that is independent of the experimental 
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condition (Supplementary Figure 4). We developed a Bayesian hierarchical model 
to estimate differential expression while correcting for this bias (see Methods). The 
model estimates a single normalized expression value for each probe and condition 
from all replicates for a given condition.
Our approach yielded accurate estimates of differential expression from individual 
cDNA-smMIP probes by combining counts from four technical replicates (Figure 
1b). We next averaged the differential expression estimates of probes targeting the 
same transcript to obtain a transcript-level estimate of differential expression. Also 
at the transcript level the accuracy (difference between expected and observed fold-
change) of cDNA-smMIPs was high, successfully distinguishing between 0.67 and 
0.5 fold changes (Figure 1c, Supplementary Table 1 and 2). Accuracy of CaptureSeq 
(based on respectively 4 and 5 replicates for ERCC1 and ERCC2) was lower, which 
underestimated the fold-change for transcripts with 4X difference in abundance.
Figure 1. Evaluation of cDNA-smMIPs for estimation of differential expression with artificial 
transcripts. a) Outline of the aproach. b) Accuracy of differential expression estimates from 
337 individual cDNA-smMIPs targeting 92 ERCC transcripts in condition ERCC1 and ERCC2. 
The 92 transcripts are divided into four groups; for each group the difference in transcript 
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abundance between condition ERCC1 and ERCC2 is known, and is indicated by the solid 
lines. Four technical capture replicates were performed on respectively one cDNA sample for 
condition ERCC1 and one cDNA sample for condition ERCC2. The expression value for each 
smMIP is estimated using a Bayesian model. Data points are coloured according to their 
expected expression fold-difference. c) Comparison of differential expression quantification by 
cDNA-smMIPs and the previously published method CaptureSeq278, which performs targeted 
RNA-Seq by biotin-labeled oligonucleotide hybridization. Only transcripts with log2-expression 
values greater than 4 were included for both methods. Differential expression estimated with 
the Bayesian model from respectively four ERCC1 and ERCC2 cDNA-smMIPs capture replicates 
is compared with differential expression estimates from respectively 4 ERCC1 and 5 ERCC2 
replicates for CaptureSeq (see respectively Supplementary Tables 1 and 2 for statistics).
However, the precision (variation in estimated fold-change within each group) of CaptureSeq 
was somewhat higher than that of cDNA-smMIPs (see Supplementary Figure 5 and 6 for 
comparisons between individual replicates for respectively cDNA-smMIPs and CaptureSeq). 
Thus, accurate quantification of relative gene expression, which involves comparisons of 
different genes in the same condition, requires multiple smMIPs per transcript; in contrast, 
accurate quantification of differential expression, which involves comparing the same gene 
in different conditions, can be achieved with a single smMIP, but can be further improved by 
combining estimates from multiple smMIPs.
To gain more insight into the relative performance of CaptureSeq and cDNA-smMIPs, 
we compared sensitivity of transcript detection. CaptureSeq detected low-abundance 
transcripts with higher sensitivity (Supplementary Figure 7a). It has previously been observed 
that CaptureSeq read counts saturate for the high-abundance ERCC transcripts and that 
consequently CaptureSeq read count is not linearly correlated with transcript abundance 
(Supplementary Figure 3 and Supplementary Figure 5 in reference278). This effectively increases 
sensitivity to low-abundance transcripts. In contrast, cDNA-smMIPs molecule counts were 
linearly correlated with ERCC transcript abundance (Supplementary Figures 8, 9); thus, more 
reads are accounted for by the high-abundance transcripts, and cDNA-smMIPs detected 
overall fewer transcripts than CaptureSeq. However, on the subset of ERCC transcripts whose 
concentration was in the range where CaptureSeq quantification is linear, detection sensitivity 
of cDNA-smMIPs and CaptureSeq was similar (Supplementary Figure 7b).
Evaluation using endogenous transcripts
We next evaluated the performance of cDNA-smMIPs on endogenous transcripts of 
Epstein-Bar transformed lymphoblast cell lines (EBVs). We used RNA-Seq data for EBV 
cell lines of 660 samples from the Geuvadis project286 to design smMIPs for the most 
highly expressed transcript of 12 genes (95 smMIPs in total), which spanned a range 
of expression values (Supplementary Table 3). To evaluate reproducibility, cDNA-
smMIP capture experiments were performed for two different cell lines originating 
from two individuals (EBV2 and EBV3), in two separate experiments. In the second 
experiment, two experimenters independently performed smMIP capture using 
the same cDNA sample as input. In the second experiment cDNA was created from 
the same RNA stock as the first experiment. Again, four technical capture replicates 
(two with 10ng cDNA input and two with 50ng cDNA input) per cell line were used 
in each experiment. We then applied our Bayesian model to estimate normalized 
smMIP expression values for each condition and averaged these to obtain gene-
level estimates of expression; the gene average was compared to the population 
average of log2(1+RPKM) gene expression values estimated by the Geuvadis project. 
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cDNA-smMIPs performed well, with Pearson correlation R2 between cDNA-smMIPs 
and RNA-Seq estimates of gene expression ranging from 0.81 - 0.92 (Figure 2a, 
Supplementary Table 4). We observed a slight discrepancy for the EBV2 cell line, 
where the correlation was respectively R2=0.91 and R2=0.81 in the first and second 
experiment. Interestingly, in the second experiment the concordance between the 
two independent experimenters was very high for this sample (R2=0.998, P=1e-14; 
two-sided Pearson correlation test), which suggests variability in cDNA synthesis as 
a potential cause for the discrepancy. The DE estimates for the two cell lines were 
reproducible between the first and second experiment (R2=0.85, P=9e-41; two-sided 
Pearson correlation test. Figure 2b).
Figure 2. Validation of cDNA-smMIPs using on lymphoblastoid cel lines. a) Quantification of 
relative gene expresssion on endogeneous transcripts of EBV-transformed lymphoblastoid 
cell lines compared with average gene expression from RNA-Seq data of 660 samples in the 
Geuvadis project286 for the same cell type. Two experiments were performed (exp. 1 and 
exp. 2); in the second experiment two technical replicates were created by two independent 
experimenters (designated by Rep. 1 and Rep. 2, see Supplementary Table 2). cDNA for 
experiment 1 and 2 was generated independently from the same RNA for EBV2 and EBV3. b) 
Concordance of differential expression between sample EBV2 and EBV3, for individual smMIPs 
(N=95).Comparison with low-coverage whole-transcriptome RNA-Sequencing.
We compared the performance of cDNA-smMIPs to unbiased low-coverage whole-
transcriptome RNA sequencing at the same number of sequencing reads. The 
expectation is that enrichment with cDNA-smMIPs results in increased sequencing 
depth at the transcripts of interest. Indeed, for our panel of 12 genes targeted with 
95 cDNA-smMIPs, molecule counts per gene were approximately 100 fold higher 
than fragment counts (read pairs) obtained with RNA-Seq (Figure 3a) at the same 
total number of reads. As a result, the number of genes for which expression was 
detected was increased (Figure 3b) and reproducibility of estimated fold-changes was 
higher (Figure 3c, Supplementary Figure 11) for cDNA-smMIPs. cDNA-smMIPs make 
it possible to obtain molecule counts for specific exons or exon-exon boundaries. 
As expected, the molecule counts of cDNA-smMIPs individual target regions are 
also similarly approximately 100 fold higher than the fragment count of whole-
transcriptome RNA-Seq in the smMIP target regions (Figure 3d). This facilitates 
expression analysis of specific isoforms
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Figure 3. Comparison of cDNA-smMIPs with low-coverage RNA-Seq. a) Differences in molecule 
count (cDNA-smMIPs) and fragment count/read pairs (RNA-Seq) for the 12 genes targeted in 
the cDNA-smMIPs assay. The data points are averages over the randomly sampled sets of 
fragments. b) Fraction of detected genes (genes with at least one mapped read) as a function 
of total number of reads. Each data point corresponds to a replicate. c) Reproducibility of fold-
changes was estimated as a function of the total number of sequencing read pairs. For cDNA-
smMIPs, the correlation is between log2(fold-change) estimated in experiment 1 (using two 
technical replicates per individual) and experiment 2 (two technical replicates per individual). 
For the low-coverage RNA-Seq, correlation is between log2 (fold-change) estimated in 
experiment 1 (one technical replicate for respectively individual HG00117 and NA06986) and 
experiment 2 (one technical replicate for each individual). Each data point corresponds to a 
random sampling (without replacement) of the number of fragments (=read pairs) given on 
the horizontal axis and is based on 8 and 4 technical replicates for respectively cDNA-smMIPs 
and RNA-Seq. Corresponding scatter plots between the replicate DE estimates are shown in 
Supplementary Figure 10. d) Comparison of molecule counts (cDNA-smMIPs) and fragments/
read pairs (RNA-Seq) mapping to the regions targeted by the cDNA-smMIPs. For each gene 
the average count across all smMIPs targeting the same gene is reported.
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Comparison with RNA-Seq in biological application 
We next sought to replicate with cDNA-smMIPs our previous study287  where we 
used RNA-Seq to characterize the immune response in human PBMCs following in 
vitro stimulation with heat-killed (HK) Candida albicans, a common cause of fungal 
infections. We obtained PBMCs from a new anonymous blood donor and added 
heat-killed C. albicans to the PBMC culture medium for a period of 24 hours as 
described previously287 (Figure 4). We used data from two smMIP capture replicates 
per condition (Supplementary Table 5). We then estimated differential expression 
between the stimulated PBMCs and the control condition without C. albicans. In 
order to compare with the RNA-Seq estimate, probe-level estimates of differential 
expression from the Bayesian model were averaged to obtain gene-level estimates 
and associated confidence intervals. We were able to replicate with cDNA-smMIPs 
our previous finding287 that mRNA levels of the interferon-gamma response genes 
IFIT1 and IFNG are strongly upregulated following C. albicans stimulation (Figure 4, 
Supplementary Figure 11). Thus, cDNA-smMIPs can be applied to primary cells to 
study the molecular mechanisms in biological systems.
Estimation of allelic ratios
Last, we used cDNA-smMIPs to estimate allelic ratios, i.e. allowing allele specific 
expression measurements. We designed 64 smMIPs for 32 common coding variants 
that are homozygous for the opposite allele in respectively the K562 and HEK293 
cell line. We serially diluted K562 cDNA with HEK239T cDNA, so that the fraction of 
K562 cDNA decreased exponentially at a rate of 0.75. Because a target gene is not 
expressed at exactly the same level in the K562 and HEK293T cell line, one cannot a 
priori predict precisely the expected ratio for the first dilution step. However, between 
subsequent dilution steps the ratio of allelic ratios is expected to be 0.75. Indeed, this 
is what we observed (Supplementary Figure 12, 13; Supplementary Table 6). We then 
selected three SNPs for each of which there were two smMIPs with non-overlapping 
extension and ligation probes, thus providing independent estimates. We found that 
the estimated allelic ratios were highly concordant between the two smMIPs (mean 
Pearson’s R2=0.96, Figure 5). 
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Figure 4. Expression changes following stimulation of PBMCs. a) Outline of PBMC stimulation 
experiment. b) Concordance of differential gene expression (Candida albicans vs Control) 
estimates from cDNA-smMIPs and previously published RNA-Seq data287. The cDNA-smMIPs 
and RNA-Seq experiments were performed on PBMCs from different individuals.
Figure 5. Estimation of allelic ratios with cDNA-smMIPs. Concordance of allelic ratios estimated 
from distinct smMIPs (respectively non-overlapping extension probes and non-overlapping 
ligation probes) targeting the same SNP in a serial dilution of cDNA from K562 cell line with 
cDNA from HEK293 cell line (8 dilution steps). For all SNPs, the two cell lines are homozygous 
for the opposite allele.
92
Ch
ap
te
r 7
Discussion
cDNA-smMIPs have the potential to address an important practical need in gene 
expression studies as a method that can measure expression a moderate number of 
genes of interest (~10 to 500) across a significant number of conditions or samples 
(~10 to 1000 or more) at low cost. Based on our calculations, cDNA-smMIPs are 
more cost-effective than qPCR, low-coverage RNA-Seq, and CaptureSeq (Figure 6, 
Supplementary Figure 14 and Supplementary Table 7). 
Figure 6. Cost comparison. Reported cost is per sample, assuming a total of 1000 samples, 
starting from RNA and including library preparation and sequencing. Breakdown of cost for 
cDNA-smMIPs is given in Supplementary Table 7.  For cDNA-smMIPs and qPCR, calculation is 
based on 100 target regions in 20 genes; reported cost also includes cDNA synthesis (iScript), 
purification and measurement of cDNA concentration (8.25 USD). Cost for RNA-Seq is based 
on Illumina Truseq V2 kit (48 reactions, 3724 USD, assuming 5 million paired-end reads on 
Illumina NextSeq at cost of USD 32.49). Cost for CaptureSeq is based on same Illumina Truseq 
V2 kit (48 reactions) followed by capture with Nimblegen SeqCap in 5-plex capture (87 USD/
sample) as previously described278,288 and 5 million paired-end reads on Illumina NextSeq(USD 
32.49). The current commercially available version of SeqCap also permits 12-plex capture.  
cDNA-smMIPs allow multiplexing of hundreds of capture targets and at least 384 
samples in a single sequencing run, using available barcoded PCR-primers76. The high 
throughput of smMIPs has previously been shown for DNA applications76,289–291. Total 
protocol duration is 2-3 days, with only ~5 hours of hands-on time. Furthermore, the 
protocol is highly amenable to automation. We have recently demonstrated such 
automation in the context of DNA-based resequencing with smMIPs291. 
To provide a reference for the performance of cDNA-smMIPs, we have included a 
comparison with CaptureSeq, a targeted RNA-Seq method based on an alternative 
enrichment strategy. However, it should be noted that CaptureSeq was primarily 
designed to target low-abundance RNA species, whereas our aim was to estimate 
differential expression between many samples across the full dynamic range. We 
included in our panel of targeted transcripts a number of highly expressed genes 
(both for the ERCC standards and the endogeneous genes). These highly expressed 
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targets still account for a substantial number of sequence reads; one can increase 
sensitivity to low-abundance transcripts by excluding highly expressed genes from 
the target panel.
There are several avenues for further improvement. First, we have not iteratively 
optimized the smMIP design or re-balanced concentrations of smMIPs in the capture-
pool to even out variation in capture efficiency between smMIPs or expected transcript 
abundance. This is common practice for smMIP-based DNA-resequencing76 and may 
also be beneficial for cDNA-smMIPs. Second, we find that the amount of input cDNA 
required (when not produced by ribosomal-depletion methods) varies with cell type, 
likely because the ratio between targeted transcripts and ribosomal RNA is variable. 
This may affect the number of unique molecules obtained from cDNA capture with 
smMIPs.  Last, the relatively low capture efficiency of smMIPs (compared to qPCR 
primers) increases the amount of input cDNA required to obtain a certain number of 
unique observations. This is reflected in the ratio of unique molecules to sequencing 
depth (Supplementary Table 2-4). However, this is offset by the ability to count the 
individual molecules (transcripts) with smMIPs, which strongly reduces the impact of 
PCR amplification and enables accurate quantification with modest amounts of input 
cDNA as we have shown here. The number of PCR cycles can generally be optimized 
to reduce PCR duplicates when samples are from the same tissue or cell type.
An important question is how to quantify the sensitivity of cDNA-smMIPs. Although 
cDNA-smMIPs can be applied to modest amounts of cDNA, our protocol cannot 
be directly applied to the extremely low amounts of cDNA typical of single-cell 
experiments. The probability to detect a given transcript furthermore depends 
on total sequencing reads and the other transcripts that are targeted in the same 
experiment. We therefore could not estimate from our data a sensitivity limit in 
terms of the minimum absolute number of target RNA molecules that must be 
present in a sample.  It is however possible to characterize sensitivity in terms of the 
average number of transcripts per cell. Figure 2d shows that we detect transcripts 
that have an FPKM of <1 in corresponding whole-transcripts RNA-Seq data (Figure 
3d shows the absolute number of molecules detected with smMIPs for the 
corresponding gene, AIRE). Transcripts with an abundance of 10 FPKM in EBV cells on 
average correspond to 1 transcript copy per cell292. Thus, transcripts that have a low 
abundance relative to other transcripts in a cell can indeed be detected with cDNA-
smMIPs. Furthermore, we expect that one can increase the probability of detecting 
extremely low-abundance transcripts by excluding high-abundance targets from the 
panel (because these reduce the probability that a low-abundance fragment will be 
sequenced) and increasing the amount of input cDNA.
We envision that cDNA-smMIPs may be useful to test the effect of many experimental 
perturbations (e.g. drug treatments, overexpression of genes or CRISPR/Cas9 genome 
editing293–295) on the expression of genes in specific pathways. Another interesting 
application and direction for future research is whether cDNA-smMIPs can be applied 
to cDNA derived from degraded RNA such as from formalin-fixed paraffin-embedded 
(FFPE) material. We have successfully applied smMIPs to DNA derived from FFPE 
material291, but as RNA fragments may have degraded more extensively than DNA it 
is still an open question of whether cDNA from FFPE material is suitable for targeting 
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with cDNA-smMIPs. A potential adaption of the approach described here could be to 
reduce the length of the target sequence of a smMIP (sequence between extension 
and ligation probe) so that potentially smaller cDNA fragments can be targeted with 
smMIPs.
In summary, we have shown that cDNA-smMIPs yield accurate estimates of differential 
expression, and are suitable to estimate relative gene expression and allele-specific 
expression. The use of molecular identifiers makes it possible to apply smMIPs to 
low quantities of input cDNA. The approach can be applied to cDNA from primary 
cells and cell line, is sufficiently scalable to perform hypothesis-driven expression 
analysis in large numbers of samples, and is more cost-effective than RNA-Seq and 
CaptureSeq.
Software
Instructions, example data sets, and open-source software to design and analyze 
cDNA-smMIPs are available from https://github.com/keesalbers/cdna-smmips. The 
software is also available as Supplementary Data File 1.
95
Chapter 7
Methods
EBV and PBMCs smMIP design 
To design smMIPs for cDNA, we adapted a previously described workflow “MipGen 
1.0” for DNA76,296. This workflow uses a number of properties of a smMIP to predict 
its performance; these include properties of the MIP itself (e.g. GC content) and its 
copy number in the human genome. The key difference with the design strategy for 
DNA is that we also design smMIPs that span exon-exon boundaries. It is customary 
to design qPCR primers that span an exon-exon boundary to improve specificity. 
However, we did not impose this requirement on the molecular inversion probes. 
Our script used the sequence of known transcripts from Ensembl (Version 75, 
hg19) as possible target sequences. We used the transcript that was estimated to 
be most highly expressed in EBV cell lines derived from European individuals from 
the Geuvadis project as the target sequence for which we designed probes. We 
converted the genomic coordinates of common variants from the 1000 Genomes 
Project (Phase I) to transcript coordinates. Together, the target sequences and known 
variants were used as input for the MipGen workflow. We did not use the tiling 
feature of MipGen. From the set of MIPs with a MipGen 1.0 performance score of 
5, we manually selected 96 to approximately cover the transcript selected for each 
gene resulting in a mix of exon-exon crossing and within-exon smMIPs. smMIPs were 
designed with a unique molecular identifier (UMI) of 9 nucleotides in between the 
extension probe sequence and the universal primer. The ligation and extension probe 
together were constrained to be 40 nt length in total, each probe individually at least 
16 nt long and at most 24 nt. With a common backbone sequence (which contains 
the universal primer binding sites) of CTTCAGCTTCCCGATATCCGACGGTAGTGT, this 
resulted in smMIP oligos of 40 + 9 + 30 = 79 nt. The target sequence was designed to 
be 112 nt. The designed cDNA-smMIPs are given in Supplementary Data File 2.
ERCC transcripts smMIP design 
We divided the ERCC transcripts into non-overlapping segments of 200 nt. For 33 of 
370 segments no smMIP with performance score of 5 could be found by MipGen 1.0, 
resulting in a total of 337 smMIPs for 92 ERCC transcripts. The median number of 
smMIPs per ERCC transcript was 4, with a range of 1-9. The designed cDNA-smMIPs 
are given in Supplementary Data File 3.
HEK293/K562 allelic ratio smMIP design
 In the absence of whole-genome sequencing data, we used public RNA-Sequencing 
data to call genotypes for common SNPs in HEK and K562 cell lines. We made the 
assumption that common variants in this data set would likely be present in the lines 
used in our laboratory. We aligned RNA sequencing data from study E-MTAB-3102 
(https://www.ebi.ac.uk/arrayexpress/) for two HEK293 replicates (ERR688856, 
ERR688857) and two K562 replicates (ERR688855, ERR68885) to hg19 human 
genome reference with STAR version 2.4.2297. We used Samtools version 1.2 and 
bcftools298,299 to call genotypes at all SNPs with allele count of at least 1000 from 
release 0.3 of the Exome Aggregation Consortium (ExAC) database (142659 sites in 
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total). A set of stringent filters on differences genotype likelihood and coverage of 
both alleles was used to identify opposite homozygotes in the two cell lines. This 
resulted in a set of 87 SNPs. To improve the comparability of the dilution curves 
for different SNPs, our goal to select genes that were expressed in both cell lines 
at similar levels. We selected the 32 SNPs for which the genes had the smallest 
difference in normalized coverage between the two cell lines. We first exhaustively 
generated all possible smMIPs covering these SNPs using the Ensembl (version 75) 
transcripts as targets. The probes were positioned such that in each transcript the 
targeted sequence was 100 bp. We used BWA to estimate the genome copy number 
count of each probe independently, and considered only smMIPs where both probes 
had genome copy count of 1. We then used version 2.0 of the MipGen software to 
calculate the predicted performance score. For each SNP we designed two smMIPs, 
covering as many annotated transcripts as possible while always taking the smMIP 
with the highest predicted performance score. All 64 selected smMIPs had predicted 
performance score greater than 0.50. The designed cDNA-smMIPs are given in 
Supplementary Data File 4.
smMIP analysis workflow 
Briefly, the workflow consists of the following steps: Match each read pair to a 
designed smMIP probe (allowing two mismatches); Remove likely extension-ligation 
dimers;For all reads assigned to a given smMIP probe, identify the molecule counts 
from the unique molecular identifiers; Determine the read-dependent threshold for 
UMIs due to sequencing errors; Estimate normalized expression levels from error-
corrected molecule counts integrating replicates using a Bayesian model.
For expression analysis, we determined molecule counts directly from the Fastq 
files. We did not first map the reads to a reference sequence, to prevent mapping 
biases. Although a reference sequence was used to select the probe sequence of 
the smMIPs, which may introduce a bias, it is possible that the targeted sequence 
contains unannotated (small) exons.
Correction for sequencing errors in unique molecular identifiers (UMIs) 
Sequencing errors in the UMI sequence of the smMIP may result in UMIs that 
are not associated with any cDNA molecule. As a result, after all UMIs associated 
with a molecule have been observed, the number of identified UMIs will continue 
to increase with sequencing depth until all possible UMIs have been generated by 
sequencing errors. This is especially problematic for low input samples where the 
number of unique molecules is low. With a sequencing error rate of 0.2% and a UMI 
of 9 nt, the probability of at least one sequencing error is 1.8%. Thus, the error rate 
may account for a significant fraction of the UMIs.
We have chosen a simple but robust heuristic to remove UMIs due to sequencing 
errors. The idea is that sequencing error UMIs will tend to have low coverage. Thus, 
for a given smMIP, we sort all UMIs by their read coverage (i.e., the number of reads 
with the same UMI) in descending order, and count only the UMIs for which the 
coverage is above a threshold R. R is chosen such the UMIs with coverage greater 
than or equal to R account for 95% of all the reads observed for the smMIP. This is 
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effective both for complex libraries (where the majority of UMIs are observed only 
once), and libraries with many PCR duplicates.
Bayesian hierarchical model to estimate differential expression
We constructed a statistical model to integrate observations from replicates into a 
single estimate of expression, and to quantify uncertainty in estimates of differential 
expression. We used a negative binomial distribution to model the unique molecule 
counts. We defined expression for a given probe as the logarithm of the mean of 
the negative binomial distribution; this expression value is corrected for probe 
bias and normalized for sequencing depth. We assume that the over-dispersion 
factor (relation between mean and variance) is the same for all probes. We allow 
for heterogeneity in the dispersion factor between experiments, as our results 
indicate that some experiments show more variability than others. The probe bias is 
estimated from differences in normalized counts (molecules per million molecules) 
between replicates and then used as a covariate in the model. We used Stan300 to 
perform inference in this model using Markov chain Monte Carlo sampling. Stan was 
run independently for each condition (a condition is defined as a set of replicate 
experiments) to generate 1000 independent samples. We used these samples from 
the posterior distribution to estimate differential expression between conditions. 
Details are given in the Supplementary Information.
Comparison with low-coverage whole-transcriptome RNA sequencing
A number of samples in the GEUVADIS Project286 were processed in replicate301 in 
the same laboratory. We selected two technical replicates for individual HG00117 
(1.M_111124_2 and 1.M_120209_1) and two technical replicates for individual 
NA06986 (1.M_111124_7 and 1.M_120209_1). These RNA-Seq libraries were 
all generated and sequenced at the University of Geneva. We subsampled the 
corresponding BAM files downloaded from ArrayExpress 10 times (without 
replacement) to total number of sequencing read pairs ranging from 200,000 to 
5,000,000. We randomly sampled reads by first sorting on the read identifier and then 
selecting reads in contiguous blocks of the desired size. As a result, the subsampled 
BAMs also include unmapped reads, as would be expected in a low-coverage 
sequencing experiment. We used the individual downsampled BAMs to estimate the 
number of fragments mapping to genes (using htseq-count), the number of detected 
genes (genes with mapped read count > 0). We used BWA-MEM302 to estimate 
the number of fragments mapping to the cDNA subsequences of 120 bp (Ensembl 
Version 75) targeted by the cDNA-smMIPs, as we found that BWA-MEM had higher 
sensitivity for identifying reads with partial matches than STAR.  We determined 
reproducibility of differential expression estimates as follows: using DESeq303, we 
estimated the log2(fold-change) between samples HG00117.1.M_111124_2 and 
NA06986.1.M_111124_7 (experiment 1), and the log2(fold-change) between 
samples HG00117.1.M_120209_1 and NA06986.1.M_120209_1 (experiment 2). We 
then computed correlation coefficients between the log2(fold-change) estimates 
from experiment 1 and 2 across the 12 genes.  
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Allelic ratio analysis
For allelic-ratio analysis, it was necessary to obtain allele counts for variants with 
a given reference sequence coordinate. As the UMI may affect mapability, we first 
processed the raw Fastq files to remove the UMI sequence from the read and to 
add the UMI to the read identifier using a custom script. We then mapped these 
processed Fastq files to the reference sequence using STAR297. Next, we used a 
custom Python script to count the number of molecules covering each allele for the 
targeted SNPs, given the BAM file with mapped read pairs. Again, we first assigned 
each read to a smMIP probe by matching of the probe sequence to the known smMIP 
probe sequences (allowing two mismatches). We then proceed to analyse each target 
variant one-by-one. This is necessary as two different smMIPs may target the same 
SNP and sequence fragments with the same UMI but from different smMIPs should 
be considered as independent molecules. Then, for a given smMIP probe, we used a 
majority vote to call the allele for all reads with the same UMI.
Allelic ratio dilution curve
cDNA of K562 (ECACC) and HEK293T (ECACC) cells was combined in a serial dilution. 
cDNA of K562 and HEK293T cells was diluted to a final concentration of 1ng/μl. The 
serial dilution started with 75% K562 cDNA and 25% HEK293T cDNA. For the following 
steps of the serial dilution, 75% of the cDNA from the previous step was combined 
with 25% HEK293T cDNA. This resulted in a series of 8 cDNA samples of which the 
concentration K562 cDNA exponentially decreased and the HEK293T cDNA increased 
accordingly. One sample with only K562 cDNA and one sample with only HEK293T 
cDNA were also included in the experiment. Subsequently, samples were divided into 
two 10 μl duplicates containing 10ng cDNA each. Capture was performed using the 
allelic-ratio smMIPS.
The HEK cell line is listed in the ICLAC database of commonly misidentified or 
contaminated cell lines. However, any possible contamination is irrelevant to this 
experiment as the dilution series provides an internal control. 
ERCC control transcripts
The synthetic ERCC controls (Thermo Fisher Scientific, Waltham, MA, USA) were 
diluted 1:100, and 46µl was used for cDNA synthesis after mixing with human PBMC 
total RNA using Superscript III Reverse Transcriptase (Thermo Fisher Scientific). 
Samples were purified using Qiaquick (Qiagen, Venlo, The Netherlands) columns, 
and cDNA was quantified using the Qubit ssDNA assay (Thermo Fisher Scientific). Of 
each sample 1 and 2ng cDNA was used for MIP capture, and all capture experiments 
were performed in duplicate. 
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Culturing of EBV cell lines
EBV cell culturing was performed as described previously304. Briefly, Human 
B-lymphoblast cells of two anonymized healthy individuals were immortalized by 
transformation with the Eppstein–Barr virus305. Cells were cultured in RPMI1640 
medium (Sigma, St Louis, MO) containing 10% (vol/vol) Fetal Bovine Serum (Sigma), 
1% 10 U/µl penicillin and 10 µg/µl streptomycin (Sigma), at a density of 0.5 × 106 cells/
ml. Fresh medium was supplied twice a week.
Culturing of HEK cell line
HEK293T cells (ECACC 12022001) were cultured in 100mm tissue-culture treated 
culture dishes (Corning, New York, USA) in DMEM medium containing 10% (vol/vol) 
Fetal Bovine Serum 1% penicillin/streptomycin and 1% sodium pyruvate (all Sigma-
Aldrich, St. Louis, USA). At passage 12, cells were detached using 0.25% Trypsin (BD 
Biosciences, San Jose, USA) after which ~3 million cells were used for RNA isolation.
Culturing of K562 cell line
K562 cells (ECACC 89121407) were cultured in 75 cm2 cell culture flasks (Corning, 
New York, USA) in RPMI 1640 medium containing 15% Fetal Bovine Serum, 2% HEPES 
and 1% penicillin/streptomycin (all Sigma-Aldrich, St. Louis, USA). ~6 million cells 
were used for RNA isolation.
Mycoplasma contamination of cell lines
All cell lines have been tested for mycoplasma contamination and were found to be 
negative.
Stimulation of PBMCs
Isolation and stimulation of peripheral blood mononuclear cells (PBMC) was 
performed as previously described106. In short, venous blood was collected into 
EDTA tubes and primary blood mononuclear cells (PBMCs) were isolated by density 
centrifugation of blood diluted 1:1 in PBS over Ficoll-Paque (Pharmacia Biotech AB, 
Uppsala, Sweden). Cells were washed three times in PBS and resuspended in RPMI 
1640 (Dutch modified) supplemented with 50 mg/L gentamicin, 2 mM l-glutamine, 
and 1 mM pyruvate. Cells were counted in a Coulter Counter Z (Beckman Coulter, 
Mijdrecht, the Netherlands) and adjusted to 5 × 106 cells/mL. Mononuclear cells (5× 
107) in a 2 mL volume were added to round-bottom 6-well plates (Greiner, Alphen a/d 
Rijn, the Netherlands) and incubated with either culture medium (negative control) 
or heat killed (HK) Candida (1x106/mL) for 24 hours before isolation of RNA using 
RNeasy mini kit (Qiagen, Venlo, The Netherlands).
cDNA synthesis EBV, PBMC, HEK293 and K562 cells 
The isolated total RNA was quantified using the Qubit RNA HS assay kit (Thermo 
Fisher Scientific, Waltham, MA, USA), cDNA synthesis of 2-5 µg of RNA was performed 
with iScript (BIO-RAD, Hercules, CA, USA) reverse trancriptase. After cDNA synthesis, 
the cDNA was purified using Qiaquick (Qiagen, Venlo, The Netherlands) purification 
columns, and cDNA quantity was measured using the Qubit ssDNA assay kit (Thermo 
Fisher Scientific). 
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CaptureSeq
We used the previously published data for the CaptureSeq protocol278. In that study, 
ERCC RNA was spiked into RNA from PBMCs from 9 human individuals (5 for ERCC1 
and 4 for ERCC2); cDNA synthesis and enrichment using CaptureSeq was performed 
separately for each sample, as previously described278. 
smMIP capture
The cDNA smMIP experimental procedure described below is largely based on the 
smMIP protocol developed for genomic DNA76,77. There are 8 different steps involved 
in this experimental protocol: 1) smMIP pooling; 2) smMIP phosphorylation; 3) smMIP 
capture; 4) exonuclease treatment; 5) real time PCR; 6) PCR; 7) sample pooling and 
purification, and 8) Illumina Nextseq500 sequencing.
Regarding the smMIP pooling, three independent cDNA-smMIP pools were used 
for experiments testing differential expression of ERCCs (337 smMIPs), differential 
expression of EBVs and PBMCs (95 smMIPs), and allele specific expression (64 
smMIPs). In all experiments 5µl of each of the 95 smMIPs were pooled into one 
single tube. 
The concentration of the smMIP pool was calculated using the following relation: 
Volume individual smMIP x Concentration individual smMIP = Volume smMIP pool 
x Concentration smMIP pool. The used smMIP capture protocol was altered from 
the protocol for genomic DNA76, which describes a MIP to gDNA molecule ratio of 
800:1, corresponding to 264,000 MIP molecules per ng gDNA. For cDNA smMIPs we 
used 10-fold more smMIPs, to compensate for the higher amount of RNA than DNA 
molecules per cell, i.e. 2,640,000 smMIPs per ng cDNA. Per sample 10ng of cDNA 
in 10µl (H
2
O), and for one blank(empty capture control) only 10µl H
2
O was pipetted 
in a plate or strip tube. The cDNA input amount may differ per celltype, for several 
samples we used 3 different input amounts, e.g. 1ng, 10ng, 50ng. 
For the smMIP phosphorylation an aliquot of 0.5µl per smMIP, i.e. 1/10th of the 
unphosphorylated pool was used, resulting in 47.5µl for 95 smMIPs. The mix for the 
phosphorylation (Supplementary Table 8) reaction contained: 1.9µl T4 PNK (1µl per 
25µl smMIPs, New England Biolabs, Ipswich, MA, USA), 6µl 10X  T4 DNA ligase buffer 
with 10mM ATP (New England Biolabs) , and 4.6µl H
2
O. This mix was transferred  into 
PCR tubes, and the smMIP phosphorylation program was performed in a thermocycler 
(DNA Engine, Bio-Rad, Hercules, CA, USA) consisting of the following steps: 1) 37°C 
for 45’, 2) 65°C for 20’, 3) samples were cooled down to 4°C (Supplementary Table 9). 
The smMIP capture master-mix was prepared for at least 30 reactions (due to low 
volume of required Ampligase DNA ligase). The capture master mix (Supplementary 
Table 10) for 30 reactions (450µl) contained 75µl 10X Ampligase DNA ligase buffer 
(Epicentre/Illumina, Madison, WI, USA), 9.9µl of the phosphorylated smMIP pool 
(0.833µM diluted 1:625), 0.96µl dNTPs (0.25mM, diluted from 100mM, Invitrogen/
Thermo Fisher Scientific, Carlsbad, CA, USA), 9.6µl Hemo Klentaq (10 units/µl, New 
England Biolabs), 0.30µl Ampligase DNA ligase (100 units/µl, Epicentre/Illumina), and 
354.3µl H
2
O (added to get to total volume). 15µl of master mix was added to each 
cDNA sample. The lid offset temperature of the thermocycler was adapted to 10°C, and 
the strip tubes were placed in a thermocycler. The capture program (Supplementary 
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Table 11) contained the following steps: 1) 95°C for 10’ to denaturate, and 2) 60°C 
for 24 hours.  At the end of the capture reaction, the samples were cooled on iceThe 
exonuclease treatment was performed immediately after the capture.
The exonuclease treatment master mix was prepared for the number of captured 
samples. Per sample the exonuclease mix (Supplementary Table 12) contained 0.5µl 
Exonuclease I (20,000 units/ml, New England Biolabs), 0.5µl Exonuclease III (100,000 
units/ml, New England Biolabs), 0.2µl 10X Ampligase DNA ligase buffer, and 0.8µl H
2
O. 
The total volume of 2µl mix was added to the captured samples, and the tube strips 
were placed back in the thermocycler.  The exonuclease program (Supplementary 
Table 13) included the following steps: 1) 37°C for 45’, 2) 95°C for 2’, 3) samples were 
cooled down to 4°C.
The real time PCR (Rotorgene, Qiagen, Venlo, The Netherlands) was used to determine 
the amount of PCR cycles needed for sufficient amplification; this was variable 
amongst different cell types and different smMIP pools. Per sample the real time PCR 
mastermix (Supplementary Table 14) contained 12.5µl iProof HF Master mix (Bio-rad, 
Hercules, CA, USA), 0.125µl Illumina PE FOR (100µM forward primer, supplementary 
Data File 5), 0.125µl Illumina PE BC1 (100µM reverse primer, Supplementary Data 
File 5), 0.125µl SYBR green (10,000x in DMSO, Thermo Fisher Scientific), and 7.125µl 
H
2
O. The total of 20µl master mix was added to and mixed with 5µl of exonuclease 
treated sample for the real-time PCR. The Real Time PCR program (Supplementary 
Table 15) included: 1) 98°C for 30”, 2) 98°C for 10”, 3) 60°C for 30”, 4) 72°C for 30”, 
5) return to step 2 for a total of 35 cycles, 6) 72°C for 30”, 7) cool down to 25°C. 
Supplementary Figure 15 shows an example image of the real time PCR results; here, 
the estimated optimal number of PCR cycles was 21 cycles. 
For the PCR reaction, 10µl of each exonuclease treated sample was pipetted into a 
strip tube and 1.25µl of a different barcoded reverse primer (Supplementary Data 
File 5) was added.  The PCR mastermix (Supplementary Table 16) contained: 12.5µl 
iProof HF Master mix (Bio-rad), 0.125µl Illumina PE FOR (100µM forward primer, 
Supplementary Data File 5), 1.125µl H
2
O. The total of 13.75µl master mix was added 
to and mixed with the 11.25µl of combined sample and the barcoded reverse primer. 
The PCR program (Supplementary Table 17) included: 1) 98°C for 30”, 2) 98°C for 10”, 
3) 60°C for 30”, 4) 72°C for 30”, 5) return to step 2 for a total of 21 cycles, 6) 72°C for 
30”, 7) cool down to 4°C. 
Prior to the Ampure XP bead purification, the bottle of AmpureXP beads (Beckman 
Coulter, Brea, CA, USA) was shaken thoroughly, since these beads settle overnight. 
The estimated volume to use was transferred to an Eppendorf tube, and let to adjust 
to room temperature 30’. 70% ethanol was prepared freshly for each purification. An 
equal amount  (5µl) of each amplified sample was pooled into one Eppendorf tube, 
with a maximum of 96 samples per tube.  The total volume of all samples in one tube 
was used to calculate the volume of Ampure XP beads to be added (0.85µl Ampure 
XP beads per 1µl sample).  After adding the beads to the samples, a vortex was used 
to mix, and the mixture was incubated at room temperature for 10’, and placed on 
a magnetic rack for 5’. The beads were washed twice with 700µl 70% ethanol; after 
the second wash, all ethanol was removed from the tube. The tube was left open, 
to evaporate the residual ethanol, and dry the beads. To elute the DNA, 25-50µl 
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(depending on amount of samples in the pool) of low TE was added to the beads, and 
a vortex was used to resuspend all beads. Subsequently the mixture was spun down, 
and placed on the magnetic rack for at least 1’. The supernatant (now containing the 
DNA) was transferred to a new eppendorf tube. 
The final results of the smMIP capture were analyzed on the Tapestation (Agilent 
Technologies, Santa Clara, CA, USA) (Supplementary Figure 17) using the D1000 
High sensitivity kit (Agilent Technologies). The final concentration of the smMIP-
captured pool was measured in duplicate using the Qubit fluorometer (Thermo 
Fisher Scientific) and the Qubit dsDNA high sensitivity kit (Thermo Fisher Scientific). 
After quantification, the sample pool was diluted to 4nM in 20µl for sequencing on 
the Illumina Nextseq500. 
Sequencing of smMIP libraries on the Illumina Nextseq500 requires spike in of custom 
primers. Therefore 9µl of custom primer “MIPBC_SEQ_FOR” to cartridge position 20 
(Read1); 9µl of custom primer “MIPBC_SEQ_REV” to cartridge position 21 (Read2), 
and 9µl of custom primer “MIPBC_SEQ_INDX” to cartridge position 22 (Index Read1) 
were added. The run was performed with 2x80 cycles, i.e. 2x79bp paired-end reads, 
and an 8bp index read. Custom primer sequences as published previously were used 
(Supplementary Table 18, IDT, 100µM, IDTE buffer). 
All reagents used are specified in Supplementary Table 19; all equipment used is 
specified Supplementary Table 20.
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Supplementary information: 
All supplementary information of this chapter is provided online, and can be reached 
via this link on the Nature communications website: 
http://www.nature.com/articles/ncomms15190#supplementary-information
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HSV-2 infections: Response to IFN-γ therapy
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To the Editor: 
Herpes viruses such as herpes simplex virus type 1 (HSV-1), herpes simplex virus 
type 2 (HSV-2), and varicella zoster virus cause vesicular lesions of the oral mucosa 
and skin, but can also affect other organs306. After acute infection, the virus resides 
in a latent state and reactivates when the host immune response is impaired. 
Although most herpes infections are self-limiting, immunosuppression predisposes 
to reactivation and severity307. 
Reactivations of herpes virus infections have been reported in patients with primary 
immunodeficiencies, and these studies demonstrated that innate pattern recognition 
is crucial for protection308. In some patients, the reactivation of HSV-2 may be very 
frequent and severe, and difficult to treat with antiviral therapy. 
The mechanism behind this increased susceptibility to severe recurrent skin infections 
with herpes viruses remains unknown in most patients. In this study, we identified 
defective IFN-γ production due to specific defects in double-stranded RNA (dsRNA) 
recognition in 3 patients with severe recurrent HSV-2 skin eruptions. Standard 
antiviral therapy failed, but all patients responded with impressive resolution of their 
symptoms upon substitution with recombinant IFN-γ. 
The first patient is a 39-year-old woman who suffered from recurrent HSV-2 skin 
infections on the right side of her face and ear since she was 3 months old, with 
frequencies varying from monthly to weekly. Treatment with intravenous acyclovir 
and prophylaxis with valacyclovir had little effect on the symptoms, despite 
no identification of antiviral resistance of the virus. No herpes infections were 
documented in her parents; the patient has no siblings or children (Supplementary 
Figure S1). 
The second patient is a 59-year-old woman who suffered from a severe infection with 
vesicular lesions when she was 11 years old and recurrent vesicular lesions on her 
left buttock every 3 to 4 weeks since she was 41 years old. HSV-2 was identified in the 
vesicular lesions. Prophylaxis with valacyclovir lost its efficacy because of acquired 
resistance. Her mother and grandmother have also reported recurrent herpetiform 
lesions, 1 sister (III.7) had recurrent genital herpes infections, and a niece (IV.2) had 
a severe varicella zoster virus infection at the age of 10 years (Supplementary Figure 
S1B). 
The third patient is a 49-year-old woman who suffered from severe recurrent 
oropharyngeal HSV infections since the age of 16 years, treated with valacyclovir 
prophylaxis. No viral infections were documented in the family, but her son suffered 
from Staphylococcus aureus endocarditis at age 9 years (Supplementary Figure S1C). 
Immunologic assessment did not reveal defects of T-, B-, or natural killer cells 
(Supplementary Table S1). Cytokine production capacity of PBMCs of patients with 
HSV-2 infections was normal upon stimulation with LPS, Pam3Cys, whole bacteria, 
or fungi. In contrast, polyI:C (TLR3 ligand) stimulations of PBMCs isolated from all 3 
patients resulted in complete absence of IFN-γ production (Figure 1A). PBMCs from 
patient 3 also showed defective IFN-γ production upon stimulation with S. aureus 
(Figure 1B), whereas the response to Candida albicans was normal (Figure 1C). 
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Production of type I interferons (IFN-α and IFN-β) by cells isolated from patient 1 and 
patient 2 was 30% to 50% of that of normal volunteers (no data were available from 
patient 3).
 
Figure 1. Immunological defect in patients with HSV compared with controls. IFN-γ levels 
(y-axis) were measured after in vitro stimulations with polyI:C (A), Staphylococcus aureus 
(B),or Candida albicans (C). In vitro stimulations were performed of PBMCs from patients 
and compared with 12 controls (x-axis). After 48 hours of stimulation, IFN-γ production was 
measured by an ELISA. The normal C. albicans–induced IFN-γ response in patients 1 and 2 
implicates the specific polyI:C and S. aureus defect in our patients. HK, Heat killed.
The functional data were supplemented by whole-exome sequencing that was 
performed in all three index patients similar to previous studies104 (detailed methods 
of the immunologic and genetic testing are given in the Supplementary Information). 
Exome sequencing did not provide rare variants in the same gene in all 3 patients. 
However, several rare variants in possible candidate genes were identified, with 
the most interesting candidates being as follows: patient 1, HDAC5 (p.E836Q and 
p.P886H) and NLRX1 (p.R860Q); patient 2, ZBTB25 (p.S7G) and IFIT1 (p.R77W); and 
patient 3, POL3RB (p.P162A) and POLR3E (p.R671Q). The only variants for which full 
segregation with the disease could be provided were the compound heterozygous 
HDAC5 variants in patient 1, and the heterozygous ZBTB25 variant in the family 
of patient 2 (Supplementary Figure S1B), which was present in all affected family 
members, but absent in other healthy siblings. The histone deacetylase 5 (HDAC5) 
was reported to regulate the inflammatory response in macrophages and influence 
anti–HSV-1 immunity309. The Zinc finger and BTB domain-containing 25 (ZBTB25) has 
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been proposed as a T-cell–enriched transcription factor that negatively regulates 
activation of the nuclear factor of activated T cells310. Details on all candidate variants 
are available in Supplementary Tables S2-S4.
Because of the defect identified in IFN-γ production, we assessed the clinical effect of 
replacement therapy with recombinant (r) IFN-γ (Immukine 3 times a week 100 mg 
subcutaneous injection). 
Treatment of patient 1 with rIFN-γ in combination with oral valacyclovir resulted 
in a strong decrease in reactivations from severe episodes every 4 to 6 weeks to 
1 mild episode a year. She twice attempted to stop the treatment followed by an 
immediate HSV-2 reactivation within 1 month. The patient has been treated with 
chronic administration of rIFN-γ for the past 3 years (Figure 2). 
Similarly, treatment of patient 2 with rIFN-γ decreased the frequency and severity of 
HSV-2 episodes from every 3 to 4 weeks with valacyclovir alone, to an average of 1 mild 
episode every 9 months. Treatment was stopped 4 times in 3 years (because of the 
adverse effects of rIFN-γ, mild flu-like symptoms, and inconvenience of subcutaneous 
injection), which was followed by immediate severe HSV-2 reactivation (Figure 2). 
Patient 3 started rIFN-γ therapy to suppress the illness that arose from S. aureus 
infection and abscesses on her left buttock. She recovered, and tolerated the 
treatment without any adverse effects. Six weeks after the start of rIFN-γ, she stopped 
valacyclovir prophylaxis. Two months after stopping valacyclovir, she developed a 
mild herpes labialis on her lower lip, which normally, according to the patient, would 
progress to a severe herpes stomatitis. Instead, the lesion resolved uneventfully and 
the patient has remained disease-free (Figure 2). 
Figure 2. Treatment overview for IFN-γ in our patients shows the recurrent HSV 
infections over time (t). Severe HSV infections are significantly reduced during the 
periods with IFN-γ therapy, and relapsed during the periods when treatment was 
stopped. Mild HSV infections were sporadically observed during periods of rIFN-γ 
treatment. Patient 3 shows the different infections over time (t). HSV infections 
similar to Steven-Johnson syndrome starting at age 16 years. After 4 severe episodes, 
she started valacyclovir prophylaxis for 17 years. At age 49 years, she suffered from 
a severe S. aureus infection and rIFN-γ treatment was started. Six weeks later, she 
stopped valacyclovir prophylaxis, and she remained infection-free since. 
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Recurrent herpes encephalitis is associated with defective viral dsRNA recognition 
due to defects in theTLR3pattern recognition pathway308. Our 3 patients with 
severe recurrent HSV mucocutaneous reactivations displayed functional defects in 
recognition of the dsRNA-like ligand polyI:C, resulting in defective IFN-γ responses. 
Natural killer and T-lymphocyte numbers were normal, although we cannot exclude 
functional defects in their antiviral function due to the IFN-γ deficiency. Initially 
registered for the treatment of chronic granulomatous disease234, rIFN-γ has been 
proposed as adjunctive therapy in patients with other infections311,312. In our patients, 
rIFN-γ induced a significant improvement in their clinical symptoms. When patients 1 
and 2 attempted to discontinue IFN-γ, they promptly displayed HSV- 2 reactivations, 
indicating that the improvement in symptoms was truly due to rIFN-γ administration. 
In conclusion, we described 3 patients with frequent and severe mucocutaneous 
reactivations of HSV-2, in whom a specific IFN-γ defect upon stimulation with dsRNA 
ligands was identified. Interestingly, none of the patients or their family members 
reported invasive infections such as herpes encephalitis. IFN-γ replacement therapy 
resulted in significant amelioration in all 3 patients, and we therefore propose that 
IFN-γ production capacity should be assessed in patients with severe recurrent HSV-
2 infections, and in case of defective production, replacement therapy with rIFN-γ 
should be considered.
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Supplementary information
Methods 
Immunological assessment 
Immunophenotyping of T-, B- and NK-cell subpopulations was performed by FACS 
analysis. The monocyte and T-cell function was assessed as previously describedS1. In 
short, venous blood was collected into EDTA tubes and primary blood mononuclear 
cells (PBMCs) were isolated by density centrifugation of blood diluted 1:1 in PBS over 
Ficoll-Paque (Pharmacia Biotech AB, Uppsala, Sweden). Cells were washed three 
times in PBS and resuspended in RPMI 1640 (Dutch modified) supplemented with 
50 mg/L gentamicin, 2 mM l-glutamine, and 1 mM pyruvate. Cells were counted in a 
Coulter Counter Z (Beckman Coulter, Mijdrecht, the Netherlands) and adjusted to 5 
× 106 cells/mL. Mononuclear cells (5 × 105) in a 100μL volume were added to round-
bottom 96-well plates (Greiner, Alphen a/d Rijn, the Netherlands) and incubated 
with either 100μL of culture medium (negative control) or one of the stimuli for 24 h 
(TNFα, IL-1β, IL-6), 48 h (IFN-γ) and/or 7 days (IL-17 and IL-22). Cytokine production 
was tested after stimulation of PBMCs with: LPS derived from E. coli (10 ng/mL), 
Pam3Cys (10 µg/mL), heat-killed C. albicans (105 microorganisms/mL), heat-killed 
S. aureus (107 microorganisms/mL), polyI:C (50 and 5 µg/mL). 10% human pooled 
serum was added when PBMCs were incubated during 7 days. After incubation the 
supernatants were stored at −20 °C until assay. Experiments were performed in 
duplicate. 
Exome sequencing
For all 3 patients exome sequencing was performed at the Bejing Genomics Institute 
(BGI). In brief, DNA was obtained from whole blood, enriched using SureSelect V5 
exome (Agilent Technologies, Santa Clara, CA, USA), and 100bp paired-end reads 
were sequenced with Illumina hiseq 2000 (Illumina, San Diego, CA, USA). Variants 
were called using high stringency settings calling and annotated with an in-house 
pipeline containing information from dbSNP138. Variant filtering was applied similar 
to previous reportsS2. In brief, all variants were restricted to variants affecting coding 
exons and canonical splice sites. Subsequently synonymous variants were filtered 
out, and only rare variants (<0.25% frequency in dbSNP138 and in >5,000 in-house 
exomes) with high quality were reported (Supplementary Table S2).
For patient 1, we performed systematic trio exome analysis of her and her healthy 
parents. For patient 2, we performed an exome overlap analysis between the 
index patient and her affected niece. Candidate variants were validated by Sanger 
sequencing, and further co-segregation analysis was performed in DNA isolated from 
saliva of other relatives (patient 2). For patient 3, no DNA samples from relatives 
were available for co-segregation analysis.
Due to the negative family history of patients 1 and 3, we applied additional variant 
filtering assuming a recessive inheritance pattern. Similar to the previously used 
frequency threshold of ≤0.25% for dominantly inherited rare variants, we applied a 
frequency threshold of ≤0.5% for the recessive analysis. 
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All genes with rare non-synonymous variants were systematically checked for 
involvement in immunological pathways or phenotypes (Gene Ontology term, mouse 
KO phenotype, KEGG class infectious disease, protein-protein interactions (PINAS3), 
pathogen-protein interaction (phistoS4), and contain binding sites for innate immune 
transcription factorsS5 (AP-1, IRF, STAT or NFkB) ; or presence in the interferon 
pathway. The latter was done based on NCBI gene search ‘interferon’ for human 
genes (Supplementary Table S4).
All variants were also analyzed for population frequency based on the Exome 
Aggregation ConsortiumS6 (ExAC). In addition, variant population load per gene 
was also calculated based on ExAC data. All candidate variants were judged on 
deleteriousness by several in silico prediction programs (PolyPhen2, SIFT).
Results 
Immunological defects
Immunophenotyping of circulating cells did not reveal any defects in the number of 
CD3+, CD4+, CD8+ (T-lymphocyte populations), CD19+ (B-cells) or CD3-CD56+CD16+ (NK 
cells) populations (Supplementary Table S1). The CD4/CD8 ratio was also normal.
Cytokine production capacity of PBMCs of patients with HSV-2 infections was normal 
upon stimulation of cells with LPS (TLR4 stimulation), Pam3Cys (TLR2 stimulation), 
whole bacteria or fungi (data not shown). In contrast, IFN-γ production capacity 
was significantly lower in PBMCs isolated from the HSV-2 patients when they were 
stimulated with polyI:C (Figure 2). PBMCs stimulated with PolyI:C did not induce the 
production of IL-17.
Genetic analyses of whole exome sequencing.
The clear and rare disease phenotype of the patients, combined with the identical 
functional defect in the production of IFN-γ upon challenge of their cells with polyI:C, 
made us hypothesize that a genetic defect may be responsible for the clinical picture. 
Exome sequencing resulted in 6.1, 5.5 and 8.8 Gb of mapped sequencing data, 
resulting in a median coverage of the exome of 73-, 65- and 106- fold with 86%, 85% 
and 98% of the exome being covered at least 20-fold respectively Supplementary 
Table S2).
Standard variant filtering for dominantly inherited genetic variants (Supplementary 
Table S3) resulted in 164 (patient 1), 167 (patient 2) and 280 (patient 3) rare, non-
synonymous and canonical splice site variants, respectively. No rare variants in 
overlapping genes were reported in all three patients. We did identify rare variants 
in the gene encoding for (CDHR2, HYDIN, MUC17 and NDUFV1) in patients 1 and 
2. These variants did not segregate with the disease in either one of the families, 
and were therefore excluded as candidate variants for the disease. The absence 
of variants in overlapping genes indicates that the underlying immunodeficiency 
may be genetically heterogeneous. Additional filtering for genes associated with 
immunological pathways revealed 23 (pt.1) 29 (pt. 2) and 33(pt.3) variants. 
The filtering for rare (≤ 0.5% in the healthy population) recessively inherited variants 
was applied to patients 1 and 3 due to their negative family history of infections. 
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Variants in TTN were excluded from the lists of both patients due to its size, and the 
high frequency of variation in healthy individuals in that gene. This analysis resulted 
in 1 recessive gene with a possible role in immunity or antiviral signaling in each 
patient. 
In patient 1, we identified two rare variants in Histone deacetylase 5 (HDAC5), 
the maternally inherited variant (p.E836Q) and the paternally inherited variant 
(p.P886H) confirmed recessive inheritance. HDAC5 was reported to regulate the 
inflammatory response in macrophages and influence anti-HSV-1 immunityS7. The 
changed nucleotides are both highly conserved (PhyloP>5.00) and the amino acid 
changes (p.E836Q and p.P886H) were predicted to be deleterious (SIFT) and probably 
damaging (PolyPhen2). In addition, this patient carries a paternally-inherited rare 
missense variant in the NOD-like receptor X1 (NLRX1 p.R860Q; Supplementary Table 
S4).  This protein modulates antiviral RIG-1-MAVS, NF-κB and ROS (Reactive Oxygen 
Species) signalingS8. 
For patient 2, various types of herpes infections in several family members suggest 
a mutual defect in the response against HSV. An overlap of the genetic variants 
obtained by exome sequencing our index patient and her affected niece resulted 
in 34 rare variants. Three of these variants involved genes with a proposed role 
in antiviral signaling (FHL2, EIF3E and ZBTB25). Only the rare (MAF = 0.00004S6) 
variant (p.S7G; Supplementary Figure S1B) affecting the Zinc finger and BTB domain-
containing 25, completely co-segregated with the susceptibility to herpes infections 
in the family. ZBTB25 has been reported as a T cell-enriched transcription factor that 
negatively regulates activation of nuclear factor of activated T cells (NF-AT)S9 which is 
an important regulator of IFNG mRNA transcriptionS10,S11. Thus, this ZBTB25 missense 
mutation remains a very good candidate for causing the susceptibility to herpes 
infections in family 2. Additionally, the rare missense variant affecting the Interferon 
Induced with Helicase C Domain 1 (IFIH1 or MDA5; p.R77W; Supplementary Table S4) 
possibly explains the more severe phenotype in our index patientS12, compared to her 
family members (Supplementary Figure S1B). 
In patient 3 exome sequencing identified rare missense variants in the RNA 
Polymerase III complex subunits B (POLR3B; p.P162A) and E (POLR3E; p.671Q) This 
complex is involved in the antiviral signaling against herpesviridae by sensing the viral 
dsDNA in the cytosol and transcribing it to dsRNAsS13. Unfortunately we were unable 
to perform co-segregation analysis in this family (Supplementary Figure S1C). We 
also identified a homozygous frameshift variant in CFHR3; known to cause aHUSS14. 
However, our patient did not suffer from the medical conditions involved in aHUS, 
and this same homozygous variant was reported in 19 healthy individualsS6.
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Supplementary Tables:
Patient 1 Patient 2 Patient 3
Populations Abs % Abs % Abs %
CD3 1.6 74 2.3 84 N/A N/A
CD4 1 46 1.4 60 N/A N/A
CD8 0.6 29 0.9 39 N/A N/A
CD4/CD8 ratio 1.57 1.5 N/A
CD19 0.3 13 0.1 4 N/A N/A
CD3-CD56 (NK) 0.1 6 0.2 9 N/A N/A
Supplementary Table S1. Immunophenotyping data was available for two of the three 
patients with recurrent viral infections.
Sequencing statistics per patient Patient 1 Patient 2 Patient 3
Total mapped bases [Gb] 6.1 5.5 8.8
On and near target [%] 85.0% 84.0% 83.8%
Median fold coverage 73.0 65.0 105.6
Average fold coverage 87.1 75.7 110.8
% covered > 1-fold 99.3% 99.5% 99.8%
% covered > 10-fold 90.8% 90.8% 99.1%
% covered > 20-fold 85.7% 85.0% 97.9%
Supplementary Table S2. Statistics of exome sequencing for three patients with recurrent 
viral infections.
Exome filtering per patient Patient 1 Patient 2 Patient 3
Total Variants 70076 72112 125159
Coding, canonical, 19420 19437 21463
Non Synonymous 9281 9376 10670
Rare variants <0,25% SNP, MDI 170 167 434
Variant reads > 5 and > 25% 164 167 280
Immune system and NCBI-Interferon related genes 23 29 33
Recessively inherited candidate genes 1 N/A 1
Supplementary Table S3. Variant  filtering steps for three pa tients with recurrent viral 
infections.
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Patient 1
Immunity 
Filters
Gene name Chromosome Position Ref Mut Total reads
A,B,E CD27 chr12 6560487 A G 55
A,B,C VEGFA chr6 43748525 A T 18
A, B ZEB1 chr10 31809562 A T 249
B,C NLRX1 chr11 119053027 G A 69
A FIGN chr2 164468098 G A 201
A HYDIN chr16 71220757 C G 71
A LITAF chr16 11650543 G A 103
A PPP2R3C chr14 35560349 T C 66
A PZP chr12 9309804 G T 136
A SLC22A6 chr11 62748499 C T 75
A FLG chr1 152281222 C T 147
A MASP1 chr3 186974465 T C 36
A POLH chr6 43572351 G C 47
A SIRT1 chr10 69648783 C T 36
A BCO2 chr11 112050172 T C 59
A HDAC6 chrX 48666691 A G 31
B NUDCD1 chr8 110305633 T C 116
C PRKCH chr14 61789013 A G 250
D RAB5C chr17 40282526 G A 108
F HDAC5 chr17 42160149 C G 9
F SDCCAG8 chr1 243471328 C G 29
Supplementary Table S4. Genetic variants obtained by exome sequencing, filtered for 
association with immune response and validated by Sanger sequencing. 
In yellow, we show our most likely candidate genes, which are discussed in the paper. LoF 
stands for all loss of function variants; nonsense and frameshift variants combined. PhyloP* is 
a calculated value to describe nucleotide conservation among 46 species. The ExAC database 
was used to determine the population frequency of candidate variantsS6. We have classified 
the variants rare for AD when they have a population frequency ≤0.25%. For AR variants the 
selected population frequency was adjusted to ≤0.5%.
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% Variant 
reads
Amino Acid 
changes
In house 
frequency
ExAC 
Frequency %
PhyloP Segregation 
status
40 p.R238G 2 0.002482 0.017 Mat
55.56 p.Y160F 0 0.0008133 1.902 Mat
51 p.Q434H 0 0 0.615 Pat
50.72 p.R860Q 0 0.01826 0.698 Pat
51.24 p.P82S 2 0.008178 4.73 Mat
38.03 p.Q41H 0 N/A -0.384 Mat
46.6 p.S15L 4 0.02307 1.371 Mat
53.03 p.Q347R 0 0 3.614 Mat
36.03 p.L1173M 0 0.002447 2.582 Mat
58.11 p.C332Y 0 0.0008417 1.262 Mat
27.21 p.S2047N 0 0 0.379 Pat (2%)
36.11 p.Y244C 1 0.02637 4.856 Mat
44.68 canonical ss 0 0 5.529 Pat
58.33 p.P231S 0 0 5.629 Pat
48.28 p.I87T 9 0.09063 -0.247 Pat
41.94 p.H255R 0 0 4.129 Pat
54.31 p.M194V 1 0 -0.31 Mat
48.4 p.K65R 9 0.06443 0.818 Mat
37.04 p.R32W 5 0.005017 0.691 Pat
44.4 p.E836Q 0 0 5.771 Mat
37.93 p.L260V 10 0.0412 1.175 Pat
Immunity filters we applied to the rare variants:
A = Mouse KO phenotype “immune system phenotype”
B = Genen Ontology term “immune” 
C = Interferon associated NCBI
D = Kyoto Encyclopedia for Genes and Genomes class “infectious disease”
E = Diagnostic list for immunodeficiencies
F= Interaction predictions using PINA, PHISTO, and contain binding sites for innate immune 
transcription factors5 (AP-1, IRF, STAT or NFkB).
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Patient 2
Immunity 
Filters
Gene name Chromosome Position Ref Mut Total reads
A, B, C, E IFIH1 chr2 163174589 G A 116
A, B, C SLC11A1 chr2 219254672 T C 91
A, C, D JAK1 chr1 65321324 G A 111
A, C, D PTPN6 chr12 7067226 G A 112
A, B TLR1 chr4 38799986 A C 61
A, B, C IL5 chr5 131877751 AT 150
A, C PLEC chr8 144991570 C T 131
A, C PLEC chr8 144995402 T A 34
A, C NLRC5 chr16 57075932 G A 9
A, D PLA2G6 chr22 38522397 T C 82
A, E TTC7A chr2 47221551 A G 35
A DUSP10 chr1 221879742 C A 17
A ITPKB chr1 226835021 C T 104
A CSRNP3 chr2 166536199 C A 155
A SPARC chr5 151052741 C T 84
A ERBB3 chr12 56495658 C G 65
A MEGF8 chr19 42873734 AT 51
A SSTR4 chr20 23017220 A C 92
A BCR chr22 23631703 G T 111
A CABIN1 chr22 24483619 C G 94
A DMD chrX 32509630 C T 15
B ENPP3 chr6 132004240 T G 93
B OPRK1 chr8 54163431 G C 139
E LRBA chr4 151770622 C T 177
C AEN chr15 89173315 G 24
C IFI44 chr1 79115914 G A 37
D EIF3E chr8 109229676 T C 31
F ZBTB25 chr14 64957233 T C 79
F FHL2 chr2 105979918 G A 51
Supplementary Table S4. Genetic variants obtained by exome sequencing, filtered for 
association with immune response and validated by Sanger sequencing. 
In yellow, we show our most likely candidate genes, which are discussed in the paper. LoF 
stands for all loss of function variants; nonsense and frameshift variants combined. PhyloP* is 
a calculated value to describe nucleotide conservation among 46 species. The ExAC database 
was used to determine the population frequency of candidate variantsS6. We have classified 
the variants rare for AD when they have a population frequency ≤0.25%. For AR variants the 
selected population frequency was adjusted to ≤0.5%.
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% Variant 
reads
Amino Acid 
changes
In house 
frequency
ExAC 
Frequency %
PhyloP Segregation 
status
50.86 p.R77W 6 0.08238 -0.171 No
52.75 p.L292P 10 0.0866 4.574 No
58.56 p.R506C 7 0.06398 0.484 No
37.5 p.V453M 9 0.08321 2.641 No
50.82 p.V156G 1 0 2.986 No
42.65 p.F88FX 1 0 2.804 No
50.38 p.R4277Q 3 0.0008205 4.187 No
67.65 p.T3000S 0 0 2.289 No
66.67 p.R1023Q 2 0.0009542 -0.749 No
49.38 p.M470V 10 0.05399 0.222 No
42.86 p.Y300C 3 0.003317 3.04 No
41.18 p.C293F 2 0.0493 5.716 No
56.86 p.R698H 0 0.0008268 3.202 No
48.39 p.A565E 5 0.01148 4.444 No
54.76 p.G53R 7 0.03903 5.195 No
41.54 p.P1283R 8 0 3.666 No
39.58 p.S2231SX 0 0.001682 4.181 No
46.74 p.Q367P 10 0.01608 1.133 No
45.95 canonical ss 0 0 5.703 No
51.06 p.Q1160E 0 0 5.767 No
33.33 p.V796I 6 0.03293 1.411 No
41.94 p.M353R 2 0.001627 2.328 No
55.4 p.P56R 1 0.001716 3.47 No
48.02 p.M1370I 2 0 4.453 No
73.91 p.V256VX 2 0 0.691 No
45.95 p.E12K 5 0.001631 0.415 No
41.94 p.I246V 0 0 5.011 No
39.24 p.S7G 0 0.004125 3.478 Yes
56.86 p.T171M 1 0.006295 1.821 No
Immunity filters we applied to the rare variants:
A = Mouse KO phenotype “immune system phenotype”
B = Genen Ontology term “immune” 
C = Interferon associated NCBI
D = Kyoto Encyclopedia for Genes and Genomes class “infectious diseasE = Diagnostic list for 
immunodeficiencies
F= Interaction predictions using PINA, PHISTO, and contain binding sites for innate immune 
transcription factors5 (AP-1, IRF, STAT or NFkB).
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Patient 3
Immunity 
Filters
Gene 
name
Chromosome Position Ref Mut Total reads
A,B,C,D,E CIITA chr16 11001913 C T 208
A,B,C IL27RA chr19 14143290 G A 108
A,B AQP9 chr15 58458983 G T 102
A,B IL6ST chr5 55237367 A 176
A,C ZFPM1 chr16 88600776 C T 87
A,E UNC13D chr17 73824098 C T 28
B,C IL32 chr16 3119304 A G 246
B,C POLR3B chr12 106770216 C G 182
A CBS chr21 44478972 C T 163
A CTSA chr20 44520230 C T 63
A DNAH11 chr7 21765475 T C 180
A DNAH5 chr5 13692193 C T 96
A DNASE1 chr16 3705881 A G 41
A GPR97 chr16 57713135 G A 74
A LGALS3BP chr17 76968419 G A 160
A SAMSN1 chr21 15884842 A G 137
A ST14 chr11 130068477 G A 68
A UACA chr15 70960399 G A 125
A VAV2 chr9 136675326 A G 63
B BPI chr20 36932645 A G 120
B PRELID1 chr5 176731648 A T 37
C ANXA2 chr15 60653207 G A 100
C DDX41 chr5 176943379 G A 65
C GAPDH chr12 6645898 G A 126
C POLR3E chr16 22343448 G A 110
D LAMA4 chr6 112496595 A G 123
D PLA2G3 chr22 31533854 C T 57
D THBS4 chr5 79351722 G A 118
E STXBP2 chr19 7712299 G A 67
F NUP153 chr6 17637566 G C 143
F PLEC chr8 144998132 G A 103
Supplementary Table S4. Genetic variants obtained by exome sequencing, filtered for 
association with immune response and validated by Sanger sequencing. 
In yellow, we show our most likely candidate genes, which are discussed in the paper. LoF 
stands for all loss of function variants; nonsense and frameshift variants combined. PhyloP* is 
a calculated value to describe nucleotide conservation among 46 species. The ExAC database 
was used to determine the population frequency of candidate variantsS6. We have classified 
the variants rare for AD when they have a population frequency ≤0.25%. For AR variants the 
selected population frequency was adjusted to ≤0.5%.
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% Variant 
reads
Amino Acid 
changes
In house 
frequency
ExAC 
Frequency %
PhyloP Segregation 
status
57.7 p.A856V 0 0 4.118 DNA N/A
43.5 p.E65K 0 0 -0.947 DNA N/A
52 p.A75S 0 0 -0.359 DNA N/A
48.9 p.Y767YX 0 0 4.623 DNA N/A
58.6 p.P804S 0 0 2.577 DNA N/A
64.3 p.R1074Q 0 0.006 5.434 DNA N/A
46.3 p.D172G 3 0 -1.683 DNA N/A
40.7 p.P162A 6 0.033 4.131 DNA N/A
50.3 p.D444N 3 0.03 5.202 DNA N/A
46 p.P26L 1 0.001 -0.496 DNA N/A
42.8 p.M2438T 2 0 4.839 DNA N/A
50 p.R4592Q 2 0.01 4.577 DNA N/A
58.5 p.Q60R 8 0.07 2.745 DNA N/A
44.6 p.R180H 4 0.0058 -0.856 DNA N/A
48.1 p.R333C 4 0.0025 -0.234 DNA N/A
51.8 p.I179T 0 0.0025 1.91 DNA N/A
48.5 p.D549N 0 0.013 -1.138 DNA N/A
54.4 p.T875M 0 0.0025 2.792 DNA N/A
33.3 p.I185T 0 0 3.681 DNA N/A
40 p.N11S 0 0 -0.068 DNA N/A
45.9 p.I39L 0 0.039 4.496 DNA N/A
59 p.T115M 1 0.01 2.611 DNA N/A
47.7 p.P70S 0 0.0008 2.121 DNA N/A
37.3 p.V60I 0 0.084 6.021 DNA N/A
45.5 p.R671Q 4 0.0297 1.532 DNA N/A
41.5 p.M426T 0 0.009 1.936 DNA N/A
42.1 p.R303Q 2 0.025 -3.192 DNA N/A
53.4 p.R136Q 1 0.006 0.757 DNA N/A
53.7 p.R544Q 1 0.005 5.442 DNA N/A
57.34 p.T761R 10 0.08648 3.281 DNA N/A
54.37 p.R2126C 10 0.01394 2.338 DNA N/A
Immunity filters we applied to the rare variants:
A = Mouse KO phenotype “immune system phenotype”
B = Genen Ontology term “immune” 
C = Interferon associated NCBI
D = Kyoto Encyclopedia for Genes and Genomes class “infectious disease”
E = Diagnostic list for immunodeficiencies
F= Interaction predictions using PINA, PHISTO, and contain binding sites for innate immune 
transcription factors5 (AP-1, IRF, STAT or NFkB).
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Supplementary Figure S1. The pedigrees of the families of the three parents with recurrent 
HSV-2 infections and segregation of candidate genetic variants.
A) In index patient 1 (photograph) we identified compound heterozygous variants in HDAC5 
by exome sequencing that might contribute to increased susceptibility to virus reactivations. 
B) Index patient 2 and her (un-)affected siblings and their children. Co-segregation analysis of 
variants was performed in all available family members. C) Index patient 3; her parents were 
unaffected. No DNA was available for co-segregation analysis. All index patients are indicated 
by an arrow.
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Chapter 9
The title of this thesis, “Primary immunodeficiencies – from genetic basis to 
therapeutic targets”, indicates that the ultimate goal of the research in this thesis is 
to aim towards personalized treatment in patients with immune defects, based on 
their genetic background. Overall it is reasonable to assume that understanding the 
underlying molecular defects may be a first step towards tailored therapy for patients. 
Especially in the field of immune disorders, with easy accessibility of affected tissue 
and availability of existing medication targeting immunological pathways, potential 
therapeutic options may be facilitated. 
The idea to develop specialized treatment per patient has been motivating clinical 
practice for almost 25 centuries. In ancient Greece, Hippocrates, the founder of 
modern medicine, promoted that diseases should be treated based on their cause, 
rather than on their symptoms. The natural diversity among his patients inspired him 
to treat patients with different medication313,314. 
Chapter 9: 
General discussion
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Genomics offers new opportunities 
In the 21st century, personalized medicine based on knowledge of the underlying 
molecular defect is slowly becoming a reality315. After more than ten years of 
research, the first human reference genome was published in 200126,53. However, only 
the more recently achieved implementation of next generation sequencing (NGS) 
provided the opportunity to perform less expensive and time-consuming sequencing 
and allowed the first reported personal genome67. While this development resulted 
in whole genome sequencing (WGS) of human genomes in large consortia30,316–318, 
whole exome sequencing (WES) is currently much more widely used and has led to 
a revolution in disease gene identification over the last years70,72,319. Throughout this 
thesis, we applied WES aiming to elucidate genetic factors of immune disorders as 
highlighted in chapters 2-6 and 8. 
The exome revolution
Over the last years WES has revolutionized medical genetic testing, leading to disease 
gene identification for many disorders70,319. The recent implementation of WES as a 
diagnostic tool has shown that this technique provides a molecular diagnoses for 25-
50% of patients, irrespective of their disease phenotype72,88,90. No other technique in 
genetic diagnostics has ever been this successful in finding genetic causes underlying 
heterogeneous disorders. 
WES in PID research
In chapters 3-5 of this thesis, WES contributed to find genetic factors underlying 
increased susceptibility to infectious diseases and autoimmune disease in research. 
In one single family with various manifestations of autoimmunity, chapter 3 
describes an ultra-rare variant in SOCS4, identified by WES. The SOCS4 variant was 
the only co-segregating variant with a known role in autoimmunity. The SOCS4 
protein was reported earlier to suppress STAT3 and EGF signaling, thereby inhibiting 
IL-6 production203,205. Evaluation of SOCS4 function upon stimulation with EGF and 
Pam3Cys in vitro, showed a defect in suppression of IL-6 and IL-1β production in both 
tested affected family members, compared to healthy controls.
The case report described in chapter 4, involves a very rare patient that developed 
PML without immunosuppressive medication221,226. PML, caused by a lytic JC virus 
infection in the brain, was lethal for our patient. Interestingly, WES identified bi-
allelic rare missense variants in BAG3, a protein known to interact with the T-antigen 
of JC virus. In addition, in vitro stimulation with PolyI:C showed a defect in IFN-γ 
production. Unfortunately, this patient deceased before an association between 
these two factors could be investigated.  Nevertheless, the in vitro IFN-γ defect 
could potentially lead to treatment for PML, similar to other conditions treated with 
replacement IFN-γ234. 
In chapter 5, we applied a phenotype-first approach to a well-characterized cohort 
of eleven female patients from ten families with “Lady Windermere syndrome”, 
presenting with pulmonary mycobacterial infections, pectus excavatum and scoliosis 
(pNTMPEX/scoliosis)237,239.  WES data analysis revealed missense variants in MST1R in four 
patients from three families. In vitro stimulation with mycobacterium intracellulare 
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showed reduced production of IFN-γ in all pNTMPEX/scoliosis patients, regardless of the 
MST1R missense variant. Interestingly, a recent publication reported MST1R variants 
in three patients of a clinically more heterogeneous cohort of 77 patients, focusing on 
all patients with pulmonary mycobacterial infections246. Although pectus excavatum 
and scoliosis are unlikely the effect of the MST1R variants, the observed difference 
emphasizes the importance of clinical characterization of sub-phenotypes. 
WES in PID diagnostics
The diagnostic value of WES for other similarly heterogeneous disorders led to 
the decision to apply WES as a genotype-first approach for a group of patients 
suffering from primary immunodeficiencies (PIDs). We performed an analysis of the 
diagnostic outcome of 254 consecutively referred PID patients in chapter 2. In line 
with other disease phenotypes, this study showed an overall diagnostic yield of 27% 
for patients suffering from PIDs. Subdividing the data based on clinical, functional 
and genetic characteristics into categories led to several interesting insights: First, 
more severely affected patients (based on the number of infections and immune-
phenotypes) were significantly more likely to receive a genetic diagnosis. Second, 
patients with more large homozygous regions in the genome were more likely to 
receive a genetic diagnosis. Third, the severe PID phenotypes were significantly more 
likely to be caused by mutations in so called ‘adaptor genes’, i.e. genes that encode 
for proteins that are involved in cellular signaling compared to ‘receptor genes’ that 
encode proteins needed as pattern recognition receptors or so called ‘effector genes’ 
that encode immunity effector molecules (cytokines, defensins and phagosome 
components). This could be explained by selecting for more severe PID phenotypes: 
As adaptor molecules are expected to play roles in multiple molecular pathways, 
the downstream effect of mutations in adaptor genes likely results in more severe 
diseases compared to mutations in receptor or effector molecules. 
Limitations of the exome-based approaches
Despite the successful examples discussed above, WES is currently unable to provide 
a genetic diagnosis for 50-75% of patients, regardless of the disorder88,90,320.  The 
diagnostic yield of WES is reduced by technical limitations, discussed in this paragraph 
and limitations in our current genetic knowledge, as discussed in the following 
paragraphs on data interpretation.
The first technical limitation is due to the target enrichment used in WES, which 
introduced a technical bias leading to poorly covered target regions for approximately 
5% of coding bases, and missed variants in those regions30,321. This mainly affects 
exons with high GC content, commonly the first exon of the gene. The GC-rich 
regions of the genome are more stable, and therefore more difficult to amplify in a 
PCR reaction. 
Another technical limitation of WES lies in the detection of copy number variants 
(CNVs) and other structural variants. Several bioinformatics tools have been 
developed to detect CNVs, most of which determine the number of alleles based on 
the coverage of the target regions amongst different individuals82,83,96. 
Two technical downsides of WES complicate detection of CNVs in WES data: first, 
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the sequencing data are limited to the exome targets (1-2% of the genome), which 
leaves gaps in regions with less exons, and limits the detection of CNV breakpoints 
to these target regions. Second, the short reads (100 to 150bp paired-end) that are 
commonly sequenced for WES analysis further complicate CNV breakpoint calling, 
since fragmented reads are unlikely to map to the correct location in the genome30,31. 
Despite the identification of a disease-causing JAK3 single exon deletion described 
in chapter 2, we have been unable to map the CNV breakpoints, and we may have 
missed similar events in other patients. 
A third technical limitation arises from complicated mapping of short sequencing reads 
in repetitive regions in the genome, like pseudogenes and segmental duplications. 
The short WES reads are incapable of spanning entire repetitive regions, which 
enable the reads to map to several locations, potentially introducing insufficiently 
covered exome regions and erroneously called variants324. 
Whole-genome sequencing (WGS) resolves technical limitations
Since the hybridization and amplification steps that complicate analysis of GC-rich 
regions of WES are redundant when performing WGS, WGS results in more uniform 
sequencing coverage over the entire genome. As a result, reports have shown that 
WGS yielded a genetic diagnosis for an additional 15% of patients compared to 
WES7,26.
Now that WGS using short read sequencing technologies becomes more affordable, 
the next technological improvement comes from sequencing longer reads. This will 
ultimately allow de novo assembly of full human genomes, and as such prevent 
mapping issues of short sequencing reads, leading to the detection of so far hidden 
structural variation325,326. Implementation of longer sequencing reads will further 
improve the diagnostic yield of WGS compared to WES. 
Challenges: interpretation of genetic variation
Over the last decade, the main challenge of genetic testing moved from generating the 
sequencing data to interpretation of these data. Our current knowledge is limited to a 
fraction of all human coding variants, and any WES or WGS experiment results in tens 
of thousands of coding genetic variants. In the most optimal scenario, prioritization 
of these variants results in the one or few of these variants that potentially causes, 
or contributes to disease. For management of these large sequencing datasets, 
and developing tools to streamline prioritization of genetic variants, bioinformatic 
support has become essential.  
Genetic variants that are commonly observed in the healthy population are not 
suspected to cause disease phenotypes, and are therefore excluded during variant 
prioritization. Information on variant frequencies, available from public and in-
house genetic databases, is therefore broadly applied in studies describing genetic 
research45. Regularly this paradigm is extended to variants occurring in other species 
by applying thresholds for nucleotide conservation scores, like PhyloP, assuming that 
throughout evolution the most essential nucleotides are unlikely to mutate327.  
The largest challenge lies with interpretation of missense variants, since truncating 
variants are expected to have a deleterious effect on the protein level. In PID 
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diagnostics and research currently pathogenicity predictors like SIFT, PolyPhen2 and 
MutationTaster are used to estimate the consequence of genetic variants100,102,144. 
However, the predictive value of these methods is limited, and functional tests are 
required to determine causality of genetic variants. The resources mentioned above 
were applied in chapters 2-6, and 8, searching for variants that contribute to the 
disease in patients with immune disorders. 
Interpretation challenge for suspected monogenic disorders
The potential effect of the majority of genetic variants identified by WGS or WES is 
poorly understood, even if these affect genes. After filtering for ultra-rare (<0.1% in 
the population), non-synonymous coding variants, approximately 100-200 genetic 
variants remain per case. For suspected monogenic disorders, like the diagnostic PID 
cases described in chapter 2, a genetic cause of disease is only identified for subset of 
patients. In case the exact same variant has been reported for the same phenotype, 
the variant is concluded to be pathogenic (class 5). However, for many other variants, 
estimating the potential pathogenic effect of variants is challenging. Ultra-rare 
variants identified in known disease genes, which have not yet been reported in other 
patients, are regularly classified as likely pathogenic (class 4) or variant of unknown 
significance (class 3), based on PhyloP and pathogenicity prediction tools100,102,144,327. 
In contrast, variants that are frequently observed in control populations are classified 
as likely benign (class 2) or benign (class 1)103,105.
Sequencing unaffected parents for the respective variant may provide evidence for 
pathogenicity at the genetic level. When looking at dominant monogenic diseases, 
the variant is expected to be novel in the patient if the parents are unaffected; 
these “de novo” variants mostly arise in the germline from mistakes during DNA 
replication29,31. In contrast, for recessive monogenic diseases, both healthy parents 
are expected to carry a genetic variant on one of their alleles, in case the patient 
inherited one mutated allele from each parent, this leads to the bi-allelic disease. 
It is difficult to obtain additional evidence at the inheritance level if parental samples 
or those of other family members are unavailable. For most patients evaluated in this 
thesis/in chapter 2, WES revealed candidate variants that may possibly contribute 
to the phenotype. For these variants, there currently is insufficient evidence for a 
downstream pathogenic effect on the cellular level to conclude on their respective 
causality. Although some of these variants are predicted to be pathogenic, and affect 
genes involved in immunity, pathogenicity of the variant remains unclear. Functional 
tests to determine the altered protein function are required to conclude on the 
pathogenic effect of the genetic variant. 
The complexity of correlating genetic variants to disease phenotypes further increased 
by identification of two independent disease causing mutations in single patients108. 
In chapter 2, we also observed two independent diseases in four patients, for which 
it was challenging to correlate the partial disease phenotypes to the respective 
genetic variants. Genetic complexity of two independent diseases was even more 
recognized in patients with a multifactorial disorder described in chapter 6. In this 
study we aimed to find a genetic factor contributing to agranulocytosis induced by 
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treatment for Graves’ disease (GD). GD is a relatively common (affecting 0.5% of men 
and 3% of women) late-onset autoimmune disease which regularly progresses to 
hyperthyroidism or an enlarged thyroid gland328.  To prevent progression to more 
severe diseases, GD patients are treated with thyrostatic drugs. One of the most 
common side effects of the thyrostatic treatment is agranulocytosis, occurring in 0.1-
0.5% of patients253. The patients described in chapter 6 belong to the rare subgroup 
that develops this complication as a result of the thyrostatic treatment. WES analysis 
of five rare familial cases revealed relatively common variants in NOX3 to be involved 
in therapy-induced agranulocytosis. Evaluation of NOX3 six additional sporadic cases 
showed that two of these cases also carried NOX3 variants. 
A small fraction of the patients without genetic diagnoses may also be explained 
by the limited availability of sequenced individuals or insufficient standardized 
characterization of disease phenotypes. For extremely rare disorders, finding a second 
or third family with the same genetic defect is extremely challenging. Systematic 
sharing of genotype and phenotype data is currently available through curated online 
tools like Genematcher and Matchmaker Exchange329,330. The challenge of finding 
second or third families with mutations in the same gene was also acknowledged in 
chapters 4 and 8 of this thesis. In both chapters, very rare medical conditions with 
severe viral infections were observed, due to a defect in 
antiviral IFN-γ production in the index patients. Genetic evaluation of other cases 
with similar disease phenotypes did not reveal similar genetic defects. This further 
illustrates the complexity of genetics in immunodeficiencies caused by genetic and 
phenotypic heterogeneity and argues for strong international collaboration and data 
sharing.
Incomplete penetrance
For many congenital (neuro-) developmental disorders, diagnostic WES procedures 
usually include DNA testing of the patient as well as both parents, in order to 
systematically identify all de novo mutations, which reduces the number of 
candidate variants by exome sequencing to 1 or 2 per exome74,89. The importance 
of de novo mutations became increasingly apparent as a cause of sporadic severe 
developmental disorders331. Since the Mendelian rules of inheritance are not self-
evident in PIDs, due to the high degree of phenotypic heterogeneity and obvious 
influence of environmental factors (pathogens), this is not (yet) common practice 
for these patients122. In contrast to developmental diseases, reports on PID regularly 
describe reduced or incomplete penetrance with mildly affected or subclinical 
parents carrying the genetic variant. A recent study described that the adaptive 
immunity rescued the innate immune defect in unaffected relatives of patients with 
TIRAP deficiency332. In addition, late onset of many PIDs further complicate analysis 
and interpretation of many genetic variants identified in PID patients333.
Pathogens influence PID development 
Next to the genetic background for increased susceptibility to infections, the host 
needs to encounter the pathogen to develop the disease. A temporarily weakened 
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host-defense mechanism during this first encounter could also increase the risk 
to severe recurrent infections334. As the time and exposure to pathogens is largely 
variable among individuals, this further complicates expected inheritance patterns 
for relatively mild PIDs.
From monogenic to polygenic diseases, common diseases and common traits 
As we start to understand the disease mechanisms for few rare monogenic 
disorders, the current knowledge of di-genic, polygenic and multifactorial diseases 
is limited335,336. For these disorders, the effect size of the single genetic variants 
involved in multifactorial diseases is less profound compared to the variants causing 
monogenic disorders337. These diseases are expected to be the result of a combination 
of underlying mechanisms, which can be genetic or environmental factors. Selection 
for genetic variants is more complicated because of several reasons: first, the variant 
can be relatively common in the population, which make filtering and prioritizing 
variants based on population frequency, evolutionary conservation and pathogenicity 
predictions complex338. Second, very large families need to be studied to find the 
disease causing combination of genetic variants. Third, there is a more likely influence 
of environmental factors in these diseases339. 
Targeted approach to understand common diseases
To better understand the combined effect of rare and common genetic variants to 
disease mechanisms, very large patient and control cohorts need to be analyzed. 
Since sequencing analysis of these large cohorts by WES or WGS is currently not 
affordable, we established a novel targeted re-sequencing method: Molecular 
Inversion Probes (MIPs). In unpublished projects, we aimed to understand influence 
of genetic variants in the IL-1 pathway on health and disease. First, by correlating the 
variants to altered cytokine production in healthy individuals. Second, by identifying 
underlying mechanisms of relatively common diseases with expected involvement 
of the IL-1 pathway, like gout, auto-inflammatory diseases and thyroid cancer. The 
expected effect size of each of these genetic variants is smaller compared to severe 
PIDs, and therefore large control and patient cohorts should be analyzed. Although 
generally considered a result of complex genetics, a minor subset of patients 
suffering from these relatively common diseases could still be caused by a single 
ultra rare genetic defect. It would be interesting to see if these patients have specific 
overlapping clinical or functional characteristics by which phenotypic subgroups can 
be distinguished. To enrich for the genetic target, we developed a (single molecule) 
MIP (smMIP76,77) gene panel for the genes associated with interleukin-1 (IL-1)340. This 
panel included the coding regions of 49 genes known to be involved in the IL-1 and 
IL-18 pathways, the inflammasome, autophagy and reactive oxygen species (ROS) 
production.  The MIPs filled a gap in genetic technology because this experimentally 
straightforward method allows low-cost sequencing of 10-200 genes in many 
samples.  MIPs targeting up to 5000 genetic regions (of 112bp) of interest can be 
pooled, and tested simultaneously per individual. A molecular barcode is added to 
each sample during PCR, which provides the opportunity to multiplex many samples 
in one sequence run. An additional advantage of smMIPs is the random tag in the 
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backbone of the MIP, which is sequenced along with the genetic target. This allows 
quantification of different MIP-captures and is used to reduce amplification artifacts 
and PCR-bias.
smMIP analysis in patients with gout 
In total we tested 1822 individuals using our IL-1 smMIP panel, 724 healthy individuals, 
684 patients with crystal-proven gout, and 414 patients from other disease cohorts. 
Gout is a late onset autoimmune disease, also known as inflammatory arthritis, 
affecting 1-2% of the elderly in developed countries341. Since gout is a late onset 
disease, some of the 1128 tested gout-negative individuals may still develop gout. 
First analyses for ultra rare variants revealed an increased number of genetic variants 
in IL-37 and SIGIRR in gout patients, compared to the other cohorts. Additional 
retrospective clinical and functional data are currently being collected to determine 
whether these patients have specific sub-phenotypes. From a biological point of view, 
the involvement of IL-37 and SIGIRR is intriguing since both proteins are required for 
inhibition of the IL-1 pathway, and protein defects could lead to an increased auto-
inflammatory reaction342,343. 
These preliminary data should be complemented with gene burden analyses based 
on statistical models, which are required even more to test the possible combinatory 
effects of multiple genetic factors in the IL-1 panel.
Non-coding variants – the next big challenge
Protein coding parts only comprise 1-2% of the human genome, which indicates 
that the current understanding of the vast majority of the human genome is limited. 
Variants affecting the large non-coding parts of the genome are commonly excluded 
from WES and WGS analyses, as there is no direct link to protein production. 
Estimating the downstream effects of variants in the intergenic region, introns and 
UTRs is challenging, as there is no direct link to protein production344. 
However, non-coding regions have a large influence on the regulating landscape of 
gene transcription345. Transcription regulation is cell type specific, and reports on 
these regulatory elements have shown that 80% of the human genome is involved 
in these processes346,347. In few examples it has been shown that mutations in these 
regions can cause disease, often creating alternative splice sites, or affecting gene 
promoter or enhancer regions348–350. In line with the increasing applicability of WGS, 
the effect of non-coding variants will be analyzed more frequently. To find disease 
causing non-coding genetic variants, complementing WGS with transcriptomic and 
epigenetic approaches may offer the opportunity to interpret the effect of genetic 
variants in regulatory regions.
Beyond the genome – from genomics to multi-omics
The next answers towards understanding the consequences of human genetic 
variation involve additional molecular readouts, such as: transcriptomics, proteomics, 
metagenomics (microbiome), epigenetics and metabolomics. The utility of these 
multi-omics approaches is now being evaluated on larger scales. As an example, the 
500 functional genomics (500FG) study assesses these approaches to understand 
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the inter-individual variation of immunological responses amongst 500 individuals 
without apparent diseases. The data on these extensively studied individuals provides 
cross-section of the healthy Dutch population351–354.
Utility of transcriptome analysis
Transcriptome (RNA) analysis has the ability to identify tissue specific molecular 
defects for patients. Tissue-specific RNA expression analysis of patients that did not 
receive a genetic diagnosis after WGS or WES, may reveal hidden genetic causes 
of disease like altered transcript levels and monoallelic expression. In addition, for 
patients with known disease causing mutations, transcriptome analysis might provide 
insights in the downstream effect of the genetic mutation. Since RNA expression of 
many genes is cell type specific, the affected tissue is required for transcriptome 
analysis. 
The potential value of a combined genome and transcriptome analysis for PIDs 
could be larger compared to other disorders. The easily withdrawn required tissue 
(blood) samples make PIDs optimal for studying alterations on the expression level. 
However, the genes involved in immune responses are not continuously transcribed, 
as expression of these genes is only induced upon an encounter with pathogenic 
antigens.
Transcriptome to identify causes of disease
Recent studies showed that 10-35% of WES or WGS genetic diagnosis-negative 
patients received a diagnosis based on transcriptome sequencing355,356. The identified 
variants in these studies mainly affected exon splicing, while other cases showed 
mono-allelic expression of rare variants. Retrospective analysis of the genomic 
data showed that either the variant was missed (WES) or the variant was earlier 
misinterpreted as a variant of unknown significance (VUS). These studies were 
performed on RNA of patients with mitochondrial or neuromuscular disorders, and 
are likely applicable for other diseases for which affected tissue is accessible. 
Transcriptome to understand downstream effect of genetic mutations 
In one study we have examined the transcriptional effects of Candida albicans 
stimulation of PBMCs in vitro287. This was evaluated further by comparing the control 
dataset to patients suffering from severe candida infections (Chronic Mucocutaneous 
Candidiasis, CMC). Patients with disease causing mutations in STAT1 known to 
cause CMC were tested for downstream effects on the RNA level106. Primary PBMCs 
of patients and controls were tested by whole transcriptome sequencing after 
stimulation with heat-killed Candida albicans. The results confirmed the known role 
for IFN-γ in response to Candida albicans, but also suggested involvement of other 
genes that were earlier associated with the response to viral infections. 
To experimentally assess the downstream effect of causative genetic mutations for a 
broad range of immunodeficiencies, with a defect in host responses against multiple 
pathogens, the transcriptional read-out should be measured after various stimulation 
conditions of PBMCs. These stimulations with different bacterial, viral and fungal 
ligands, and different incubation times for the early and late immune responses, 
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result in a large total number of conditions to be tested per individual. Performing 
all these tests in parallel requires a systematic approach for high throughput, highly 
multiplexed low cost RNA sequencing. 
Currently, there is no well-established method to examine these pathogen induced 
expression profiles on a large scale. Generally there would be two different 
methodologies for this purpose. 
First, an unbiased genome-wide approach like low-coverage RNAseq seems optimal 
to test for transcriptional aberrances357. However, this would also lead to sequencing 
of many abundantly expressed genes, for which the direct contribution to the immune 
system is limited. Ideally, similar to the analysis performed on WES data in chapter 
2, an in-silico step of analysis could create a baseline for these abundantly expressed 
genes, and include a targeted focus for genes involved in immune responses. The 
main advantage of this method is the technological ability to detect all possible 
altered splicing events. 
Second, targeted resequencing of cDNA limits sequencing of redundant genes by 
enriching for genes of interest, provides direct information on the genes involved 
in the immune response, and indicate the possible defective molecular pathway in 
patients suffering from PIDs. In chapter 7 of this thesis, we recognized this need and 
developed smMIPs for detection of cDNA. As a result, smMIPs provided accurate 
estimates of (differential) expression, based on cDNA obtained from various cell 
types. Although this method is more cost-effective, detection of altered splicing 
event is restricted to the exon boundaries of one of the target regions. 
Creating a functional read-out
One advantage for immune disorders is the relatively easy accessibility of affected 
immune cells. Throughout this thesis we used peripheral blood mononuclear 
cells (PBMCs) to get additional insights into the underlying genetic defect. Next to 
mimicking the disease phenotype in cell-based systems, one can also take advantage 
of the known pathways in which the mutated protein plays a role. Based on this 
knowledge functional tests can be designed to compare the effect of the mutation 
to cells that do not have the mutation. Not only does this allow validation of a defect 
caused by a mutation but also speculation on how to design treatment. 
The access to PBMCs makes the research on PIDs different from many other topics, as 
one limitation of many genetic tests is the lack of functional evidence to interpret all 
identified genetic mutations for their possible pathogenicity. Only since very recently 
the genome of affected tissue cells obtained from controls can be edited, introducing 
the exact same genetic variant that was identified in the patient, using the exact 
same genetic background as in controls. These developments of methods based on 
CRISPR/Cas9 allow large-scale genome editing possibilities in cultured cells358,359. For 
genes causing developmental phenotypes in humans, the affected tissue is difficult 
to access, and therefore animal models or induced pluripotent stem cells are widely 
used360,361. Although the developments in the field of genome editing are promising, 
transferring these methods to the primary cell mixture of PBMCs will be extremely 
challenging, which currently limits possible applications for PIDs. 
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Pathogen characterization
Next to understanding differences in host responses against pathogens, it would be 
equally important to understand the differences among pathogen strains. Regarding 
this aspect, the most optimal scenario would be to isolate and sequence the pathogen, 
to identify the species and strain, and assess possible changes on the DNA level. 
For example, it is known from influenza type A, that the sixteen hemagglutinin and 
nine neuraminidase subtypes could theoretically result in 144 different virus types362. 
Similarly, for some cases with progressive multifocal leukoencephalopathy (PML) 
without immunosuppression it is known that the JC virus isolated from infections in 
the brain was genetically altered363. Unfortunately, the patient reported in chapter 
4 deceased before the genetic makeup of the virus in this case could be examined. 
Next to implementation of NGS for human genetics, NGS provided opportunities 
for genome sequencing of pathogens. In addition to accurately determining the 
subtype, whole genome assembly of pathogens could reveal more virulent genetic 
rearrangements as well as information on antibiotic resistance364. Overall, it is crucial 
to recognize the pathogen, as the type may have significant effects on the clinical 
management of the disease. 
From immune deficiency disorder towards treatment
Another advantage of the availability of affected cells in PID patients is the increased 
potential for personalized treatment. Molecularly diagnosing the disease is not an 
endpoint for patients suffering from immune disorders. Whether the identified 
defect is observed on the DNA, RNA or protein level is important for understanding 
the disease, but could be irrelevant for the treatment options. Next to in vitro 
stimulations to understand the disease mechanism, PBMCs can also be applied to 
test the efficacy of medication when the mechanism is known (Figure 1). 
One example is shown in chapter 8, describing an observed defect in virus induced 
cytokine (IFN-γ) production in three patients with severe recurrent mucocutaneous 
HSV infections. Despite the absence of a clear-cut genetic mutation, the symptoms of 
these patients fully resolved upon treatment with IFN-γ replacement therapy. 
In other studies, genetic mutations in known or novel immunodeficiency genes 
resulted in altered treatment of the disease. Examples are abatacept treatment for 
patients suffering from autoimmune lymphoproliferative syndrome caused by LRBA 
mutations365, and Ruxolitinib treatment proved to be effective for a single patient 
suffering from autoimmune cytopenias and CMC due to a STAT1 GoF mutation366. 
These are just two examples of tailored treatment for mutations in genes, for 
which we also identified patients in chapter 2, as such the respective individuals 
may possibly benefit from these treatment options in the future. This highlights the 
importance to identify the genetic and/or functional defect as a first important step 
towards treatment options. 
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Figure 1. A schematic overview of how finding defects in molecular mechanisms of PIDs may 
lead to personalized treatment for PID patients in the future. A reliable read-out is essential 
to determine the functional defect in vitro. Drug testing on the cellular level may lead to novel 
treatment applications. 
In conclusion, the future prospects for patients with primary immunodeficiencies 
include WGS combined with other -omics approaches to obtain complete 
understanding of the molecular defect. Confirmation of the defect by genome editing 
based functional assays could lead to a molecular diagnosis for up to 80% of immune 
deficient patients. In an ideal scenario, the read out of the follow up can be applied 
as a molecular target to test in vitro effects of adjuvant medication. Once the defect 
has responded to in vitro treatment, personalized therapy could be available for this 
patient.
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AD  Autosomal dominant
ATDAC  Antithyroid drug-induced agranulocytosis
AR  Autosomal recessive
bp  Base pair
CD  Cluster of differentiation
cDNA  Complementary deoxyribonucleic acid
CMC  Chronic mucocutaneous candidiasis
CNV  Copy number variant
CSF  Cerebrospinal fluid
CVID  Common variable immunodeficiency
DE  Differential expression
DNA  Deoxyribonucleic acid
EGF  Epidermal growth factor
ELISA  Enzyme-linked immunosorbent assay
ERCC  External RNA controls consortium
ESP  Exome Sequencing Project
ExAC  Exome Aggregation Consortium
FFPE  Formalin-fixed paraffin-embedded
Gb  Giga bases
GoF  Gain of function
HIES  Hyper IgE syndrome
HK  Heat-killed
HIV  Human immunodeficiency virus
HSV  Herpes simplex virus
IFN-γ  Interferon-gamma
Ig  Immunoglobulin
IL  Interleukin
Indel  Insertion-deletion
JCV  John Cunningham virus
LoF  Loss of function
LOH  Loss of heterozygosity
LPS  Lipopolysaccharide
Mb  Mega bases 
MHC  Major Histocompatibility Complex
MIP  Molecular inversion probe
mRNA  Messenger ribonucleic acid
NGS  Next generation sequencing
NMD  Nonsense-Mediated mRNA Decay
PBMC  Peripheral blood mononuclear cell
PCR  Polymerase chain reaction
PID  Primary immunodeficiency
PML  Progressive multifocal leukoencephalopathy
pNTM  Pulmonary non-tuberculous mycobacterial
Pt  Patient
qPCR  Quantitative polymerase chain reaction
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RNA  Ribonucleic acid
ROH  Region of homozygosity
RPKM  Reads per kilobase per million mapped reads
SCID  Severe combined immunodeficiency
SLE  Systemic lupus erythematosus
smMIPs  Single molecule Molecular Inversion Probes
SNP  Single nucleotide polymorphism
SNV  Single nucleotide variant
TLR  Toll like receptor
TNF  Tumor necrosis factor
UMI  Unique molecular identifiers
VUS  Variant of unknown significance
WES  Whole exome sequencing
WGS  Whole genome sequencing
XL  X-linked
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Summary
Patients with primary immunodeficiencies (PIDs) suffer from disease due to inborn 
errors in their immune system. PIDs are caused by a defective immune system, which 
is unable to effectively defeat pathogens such as bacteria, viruses and fungi. The 
genetic background of an individual influences the ability to effectively fight these 
intruding pathogens, leading to an increased susceptibility to infections.
One of the benefits of studying PIDs is the accessibility of affected tissue; peripheral 
blood cells can be easily withdrawn and stimulated in vitro with ligands that mimic 
infectious agents. Observed differences in cytokine production provide insight in the 
functional defect at the cellular level, and may indicate the most optimal targets for 
treatment. 
In this thesis we aimed to: 1) Find the genetic factors underlying various immune 
defects in patients suffering from primary immunodeficiencies; 2) Determine the 
functional defects using in vitro stimulation assays; 3) Apply this knowledge to 
determine which existing drugs could resolve clinical symptoms of PID patients. 
Chapter 1 provides a comprehensive introduction to the chapters of this thesis, 
explaining the importance of a functional immune system and how primary 
immunodeficiencies can be caused by genetic mutations. We have applied whole 
exome sequencing (WES) to search for genetic mutations causing severe monogenic 
forms of PIDs. 
In chapter 2, we reported on the diagnostic yield of WES for a large (N=254) 
heterogeneous group of patients with immune defects. In this study, WES provided a 
genetic diagnosis for 23% of all families by revealing pathogenic mutations in known 
PID genes. Exome-wide analysis for recently reported genes and genes involved in 
specific immunological pathways resulted in a diagnosis for an additional 4% of all 
families. An increased diagnostic yield was observed for patients from Saudi Arabia 
(56%), compared to European patients (14%). In addition, severely affected patients, 
with multiple infections or cellular defects were (>2x) more likely to receive a genetic 
diagnosis compared to mildly affected individuals. 
Next to applying WES for diagnosing known diseases in patients suffering from PIDs, 
we also performed WES in a research setting to identify novel genetic defects leading 
to immune disorders.  
In chapter 3 we have identified an ultra rare missense variant in the gene encoding 
for the Suppressor of Cytokine Signaling 4 (SOCS4) underlying various autoimmune 
manifestations in one family. Our index patient was severely affected, and suffered 
at young age from hypothyroidism, hair loss and nail dystrophy. Her mother and 
brother presented with milder manifestations of autoimmunity, hypothyroidy and 
vitiligo, respectively. Co-segregation analysis revealed that the rare SOCS4 variant was 
present in all three affected family members. Functional follow up revealed increased 
levels of IL-1β and IL-6 upon in vitro stimulations of Peripheral Blood mononuclear 
Cells (PBMCs) with EGF. These high cytokine levels confirmed the diagnosis of 
autoimmunity and indicated options for targeted therapy. 
Progressive multifocal leukoencephalopathy (PML) is a rare brain infection with 
JC-virus. PML occurs most frequently in patients with immunosuppression, like in 
HIV seropositive individuals. The patient described in chapter 4 is one of the few 
immunocompetent patients who have been reported to develop PML. Interestingly, 
cytokine measurements showed a defect in IFN-γ production, and WES revealed 
compound heterozygous variants in the gene encoding for the BCL2 Associated 
Athanogene 3 (BAG3), which were both reported to interact with the T-antigen of the 
JC-virus. Similar to other diseases, replacement IFN-γ therapy might have potential 
beneficial effects in patients with these kind of genetic defects. Sadly, the patient 
described in this study deceased prior to initiation of this treatment. 
In chapter 5, we focused on a homogeneous group of 11 patients from 10 families with 
mycobacterial infections, pectus excavatum and scoliosis. Their clinical phenotype is 
also known as Lady Windermere syndrome. In 4 of these patients (3 families) WES 
revealed a rare missense variant in the gene encoding for the Macrophage Stimulating 
1 Receptor (MST1R). In vitro stimulation of PBMCs with Mycobacterium avium 
intracellulare revealed reduced IFN-γ production in patients compared to controls. 
In addition, MST1R has an important role in mucociliary function of epithelial cells. 
166
Su
m
m
ar
y
167
Sum
m
ary
Dysfunctional MST1R could result in insufficient clearance of mycobacteria, and 
therefore an increased number of pulmonary infections. 
Genetics of a pharmacogenomic complication was evaluated in chapter 6. Graves’ 
disease (GD) is a relatively common (0.5% men, 3% women), late onset disorder, 
with a likely multifactorial genetic background. To prevent increased severity like 
hyperthyroidism or an enlarged thyroid, GD patients are commonly treated with 
thyrostatic medication. A rare subgroup of these patients (0.1%-0.5%) develop 
agranulocytosis upon this treatment. We aimed to identify the genetic susceptibility 
for treatment-induced agranulocytosis in 5 patients from 2 families, as well as 6 
sporadic cases. WES analysis of the familial cases indicated missense variants in the 
gene encoding for the NADPH Oxidase 3 (NOX3) as a risk factor for agranulocytosis 
in these patients. Further functional and variant analyses supported an altered NOX3 
function in these patients.  
During many of the previously described studies we encountered a need for robust 
systematic characterization of phenotypic differences amongst patients. In most 
biomedical institutes the immunophenotyping is currently limited to quantification 
of peripheral blood cell populations and immunoglobulin levels. We aimed to find 
a cost-effective method to determine transcriptional defects in pathogen-induced 
immune responses. In chapter 7, we altered the existing design and protocol for 
single molecule molecular inversion probes (sm)MIPs to capture cDNA instead of 
genomic DNA. The targets of these (sm)MIPs were regions of mRNA, some of which 
span exon-exon boundaries. Stimulation of peripheral blood cells with heat-killed 
candida albicans resulted in expression profiling of an immune response against 
this type of fungi. In addition, the specificity of the method was assessed based on 
artificial transcripts with known fold changes. Overall cDNA smMIPs showed to be a 
reliable and affordable method to perform targeted expression analyses in hundreds 
of genes for thousands of samples. 
In chapter 8, we aimed to find a genetic cause of severe recurrent mucocutaneous 
infections with herpes simplex virus in 3 patients. After performing exome sequencing 
and co-segregation analysis in available relatives, we were unable to fully determine 
the genetic defect in this small cohort. In addition to the genetic experiments, we 
tried to find the functional defect in these patients by stimulating peripheral blood 
mononuclear cells from patients in vitro with the viral TLR3 ligand PolyI:C. ELISA 
measurements on the blood serum of these patients revealed a defect in IFN-γ 
production compared to control samples. Despite the absence of genetic evidence 
for the disease in these patients, their symptoms responded well to treatment with 
recombinant IFN-γ. 
The relevance of the research described in this thesis is discussed in chapter 9. Next 
to reflecting on the earlier chapters, this chapter provides insight into how technical 
innovations can further improve genetic testing and determine immunological 
defects. Ultimately, these combined tests have the potential to indicate the optimal 
targets for therapy.
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Samenvatting
Patiënten met primaire immuundeficiënties (PIDs) hebben last van ongewone infecties 
door aangeboren afwijkingen in het immuunsysteem. PIDs worden veroorzaakt door 
een defect immuunsysteem, dat niet in staat is om ziekteverwekkers als bacteriën, 
virussen of schimmels te elimineren. De genetische achtergrond van een individu 
beïnvloedt de capaciteit om ziekteverwekkers aan te vallen, waarbij een genetisch 
defect kan leiden tot een verhoogd infectierisico. 
Een van de voordelen van het bestuderen van PIDs is de beschikbaarheid van het 
aangedane weefsel; perifeer bloed kan worden afgenomen, en de cellen kunnen 
in vitro gestimuleerd worden met liganden die infecties met de ziekteverwekker 
nabootsen. Vervolgens kunnen de verschillen in cytokine productie worden 
gemeten, wat kan aangeven welk onderdeel van het immuunsysteem minder goed 
functioneert, met als doel een behandeling aan te bieden die invloed heeft op dat 
specifieke onderdeel. 
In dit proefschrift hebben we: 1) Onderzoek gedaan naar genetische factoren die 
immunologische defecten veroorzaken bij patiënten met immuundeficiënties; 
2) In vitro stimulatie testen gebruikt om te bepalen welk onderdeel van het 
immuunsysteem niet goed functioneert; 3) Deze kennis gebruikt om te bepalen 
welke medicatie het meest geschikt zou kunnen zijn om de klinische symptomen van 
de patiënt te verbeteren. 
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Hoofdstuk 1 geeft een uitgebreide introductie, waarin het belang van een functioneel 
immuunsysteem wordt uitgelegd, en besproken wordt hoe genetische variatie kan 
leiden tot primaire immuundeficiënties. Om deze genetische oorzaken te vinden 
hebben we whole exome sequencing (WES) toegepast. Deze techniek gaf ons de 
mogelijkheid om het gehele coderende deel van het DNA in één enkele test te 
analyseren. 
In hoofdstuk 2 hebben we de toepassing van WES in de diagnostiek geëvalueerd voor 
een grote (N=254) heterogene groep van patiënten met een defect immuunsysteem. 
Bij dit onderzoek heeft WES een genetische diagnose opgeleverd voor 23% van alle 
families, doordat een pathogene mutatie in een bekend PID gen is aangetoond. 
Een extra “exome-wide” analyse voor mutaties in recentelijk gepubliceerde PID 
genen alsmede in genen betrokken bij specifieke immunologische reacties, heeft 
geresulteerd in een additionele diagnose voor 4% van alle families. We vonden 
een hogere diagnostische opbrengst bij patiënten die zijn ingestuurd vanuit Saoedi 
Arabië (56%), in vergelijking tot de Europese patiënten (14%). Daarnaast hebben we 
aangetoond dat ernstig aangedane patiënten, met meerdere infecties of functionele 
defecten, een (2x) grotere kans hebben om een genetische diagnose te krijgen, in 
verhouding tot milder aangedane individuen. 
Naast het toepassen van WES in de diagnostiek hebben we WES ook toegepast in het 
onderzoek om nieuwe genetische defecten te vinden die leiden tot immunologische 
aandoeningen. 
In hoofdstuk 3 beschrijven we een erg zeldzame genetische missense variant in 
het gen dat codeert voor de Suppressor of Cytokine Signaling 4 (SOCS4), leidend 
tot verschillende auto-immuun problemen in een familie. De index patiënt was het 
ernstigst aangedaan; op jonge leeftijd leed zij aan hypothyreoïdie, haaruitval en 
nageldystrofie. Haar moeder en broer hadden mildere vormen van auto-immuniteit, 
respectievelijk hypothyreoïdie en vitiligo. Co-segregatieanalyse liet zien dat de 
SOCS4 variant aanwezig was bij alle drie aangedane familieleden. Functionele testen 
resulteerden in verhoogde waarden van de cytokines IL-1β en Il-6, na stimulatie van 
Perifeer Bloed Mononucleaire Cellen (PBMCs) met EGF. Deze hoge waarden uit de 
cytokinemetingen bevestigde de diagnose van een auto-immuunaandoening en gaf 
aan welke medicatie toegepast zou kunnen worden. 
Progressieve multifocale leukoencefalopathie (PML) is een zeldzame herseninfectie 
met het JC-virus. PML komt vaker voor bij patiënten met immunosuppressie, 
bijvoorbeeld wanneer zij HIV seropositief zijn. De patiënt die beschreven is in 
hoofdstuk 4 is één van de weinige immunocompetente personen die PML ontwikkeld 
heeft. Cytokinemetingen bij deze patiënt lieten een defect zien in IFN-γ productie en 
de WES analyse resulteerde in twee heterozygote varianten in het gen dat codeert 
voor BCL2 Associated Athanogene 3 (BAG3). Interessant genoeg zijn voor deze 
beide factoren (IFN-γ en BAG3) eerder interacties beschreven met het T-antigeen 
van het JC-virus. Vergelijkbaar met andere ziektebeelden zou vervangingstherapie 
met recombinant IFN-γ een goede optie kunnen zijn voor behandeling van de 
aandoeningen van deze patiënt. Helaas was de patiënt die beschreven is in deze 
studie al overleden voordat de behandeling kon worden gestart. 
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In hoofdstuk 5 hebben we een homogene groep van elf patiënten met mycobacteriële 
longinfecties, pectus excavatum en scoliose genetisch onderzocht. Dit klinisch beeld 
is ook bekend als Lady Windermere syndroom. In vier van deze patiënten hebben 
we met behulp van WES een zeldzame genetische variant gevonden in het gen wat 
codeert voor de Macrophage Stimulating 1 Receptor (MST1R). In vitro stimulatie van 
PBMCs met Mycobacterium avium intracellulare liet een verlaagde productie van het 
cytokine IFN-γ zien in de patiënten ten opzichte van controles. Daarnaast heeft MST1R 
een belangrijke rol in de mucociliaire functie van epitheelcellen. Een disfunctionele 
vorm van MST1R kan ervoor zorgen dat de mycobacteriën onvoldoende verwijderd 
kunnen worden, waardoor de patiënten meer last krijgen van longinfecties. 
We hebben de genetica van een farmacogenomische complicatie geëvalueerd in 
hoofdstuk 6. De ziekte van Graves’ is een redelijk vaak voorkomende aandoening 
(0.5% mannen en 3% vrouwen) die zich pas op latere leeftijd ontwikkelt, met 
een nog onbekende multifactoriële oorzaak. Om verergering van de ziekte, zoals 
hyperthyroïdie en een vergrote schildklier te voorkomen, worden Graves’ patiënten 
behandeld met thyrostatica. Een kleine minderheid van de patiënten (0.1-0.5%) 
ontwikkelt agranulocytose door deze medicatie. Wij hebben met behulp van WES 
geprobeerd de genetische risicofactoren voor het ontwikkelen van behandeling-
geïnduceerde agranulocytose te vinden in 5 patiënten van 2 families, en in 6 
sporadische patiënten. Co-segregatieanalyse in de families liet zien dat genetische 
missense varianten in het gen dat codeert voor het NADPH Oxidase 3 (NOX3) een 
risicofactor zijn voor het ontwikkelen van agranulocytose. Additionele analyses van 
zowel de genetische variant als het NOX3 enzym ondersteunde deze bevindingen. 
Bij veel van de eerdere studies hadden we opgemerkt dat er een methode nodig was 
om de functionele verschillen tussen patiënten specifieker te kunnen karakteriseren. 
Bij de meeste biomedische instituten is de huidige immunofenotypering beperkt 
tot de kwantificatie van bloed cel populaties en immunoglobuline niveaus. Wij 
hebben geprobeerd een betrouwbare en betaalbare manier te ontwikkelen om 
defecten in RNA-transcriptie te bepalen bij in vitro gestimuleerde immuunreacties. 
In hoofdstuk 7 hebben we het bestaande design en protocol voor single molecule 
molecular inversion probes (sm)MIPs aangepast om cDNA in plaats van genomisch 
DNA te kunnen verrijken. De moleculaire regio’s waarvoor deze (sm)MIPs verrijken 
zijn gebaseerd op mRNA, waarvan enkele over de grens van het ene naar het 
andere exon heen gaan. Stimulatie van perifere bloedcellen met door hitte gedode 
Candida albicans resulteerde in een RNA-expressie profiel van een immuunreactie 
tegen dit type schimmel. Daarnaast is de specificiteit van de techniek geëvalueerd 
door de methode te gebruiken voor de kwantificatie van bekende hoeveelheden 
artificiële transcripten. We toonden aan dat de cDNA smMIP assay een betrouwbare 
en betaalbare test is om de expressie te bepalen voor een honderdtal genen in 
duizenden samples. 
In hoofdstuk 8 hebben we onderzoek gedaan naar de genetische en functionele 
defecten bij drie patiënten met herhaaldelijke mucocutane infecties met herpes 
simplex virus. In deze studie hebben exoom sequencing en co-segregatieanalyse in 
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de families geen eenduidige oorzaak voor de ziekte opgeleverd. De drie patiënten 
hadden wel eenzelfde in vitro defect in cytokineproductie na stimulatie van PBMCs 
met de TLR3 ligand polyI:C. De ELISA bepalingen op het serum van de cellen van 
deze patiënten lieten een defect zien in IFN-γ productie in verhouding tot controles. 
Ondanks de afwezigheid van een genetische diagnose voor deze patiënten, zijn de 
klinische symptomen succesvol behandeld met recombinant IFN-γ.
De relevantie van het onderzoek beschreven in dit proefschrift wordt bediscussieerd 
in hoofdstuk 9. Naast een terugblik op eerdere hoofdstukken, geef ik in dit hoofdstuk 
ook aan hoe genetische en functionele testen verder kunnen worden verbeterd 
met behulp van technologische innovatie. Uiteindelijk heeft een combinatie van 
genetische en functionele testen het potentieel om de meest optimale behandeling 
te bepalen voor patiënten met aangeboren immuunstoornissen. 
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